NewMedicalBooks.net

Mosby's Radiation Therapy Study Guide & Exam Review

2011-12-08T08:08:00.000-08:00

1. Developing Good Study Habits in the Health Professions.
2. An Overview of Cancer and Management Modalities.
3. Radiation Therapy Physics.
4. Radiation Biology.
5. Radiation Protection and Safety.
6. Radiation Therapy Treatment Delivery Equipment and Quality Assurance.
7. Radiation Therapy Treatment Planning.
8. Oncology Patient Care.
9. Clinical Applications in Radiation Therapy.

Reinforce your understanding of radiation therapy and prepare for the Registry exam!

Mosby's Radiation Therapy Study Guide and Exam Review is both a study companion for Principles and Practice of Radiation Therapy, by Charles Washington and Dennis Leaver, and a superior review for the certification exam offered by the American Registry for Radiologic Technology (ARRT). An easy-to-read format simplifies study by presenting information in concise bullets and tables. Over 1,000 review questions are included in the book, with an additional 1,000 questions available online on the companion Evolve website.

Written by radiation therapy expert Leia Levy, with contributions by other radiation therapy educators and clinicians, this study tool provides everything you need to prepare for the ARRT Radiation Therapy Certification Exam.

Key Features

Over 2,000 multiple-choice questions in Registry format are provided in the text and online, allowing you to both study and simulate the actual exam experience.
Focus questions and key information in tables make it easy to find and remember information for the exam.
Review exercises reinforce learning with a variety of question formats to fit different learning styles.
Online mock exams add over 1,000 questions to those included in the book.
Questions are organized by ARRT content categories and are available in study mode with immediate feedback after each question, or in exam mode, which simulates the test-taking experience in a timed environment with ARRT exam-style questions.

About the Author

Leia Levy, MAdEd (Masters in Adult Education), RT(T), Program Director, Radiation Therapy Program, Swedish American Health System, Rockford, IL.

Book Details

Paperback: 328 pages
Publisher: Mosby; 1 Pap/Psc edition (October 20, 2011)
Language: English
ISBN-10: 0323069347
ISBN-13: 978-0323069342
Product Dimensions: 10.7 x 8.4 x 0.5 inches

List Price: $99.95

Gunderson: Clinical Radiation Oncology, 3rd Edition (Expert Consult Series)

2011-12-06T07:42:00.001-08:00

SECTION I. SCIENTIFIC FOUNDATIONS OF RADIATION ONCOLOGY
Part A. RADIOBIOLOGY

Chapter 1. Biological Basis of Radiation Oncology
Chapter 2. Molecular and Cellular Biology
Chapter 3. Dose Response Modifiers in Radiation Oncology
Chapter 4. Interaction of Chemotherapy and Radiation
Chapter 5. Biologics and Interactions with Radiation

Part B. PHYSICS

Chapter 6. Radiation Oncology Physics

Part C. RELATED CANCER DISCIPLINES

Chapter 7. Surgical Principles
Chapter 8. Principles of Chemotherapy
Chapter 9. Imaging in Oncology
Chapter 10. Nuclear Medicine
Chapter 11. Health Services Research in Radiation Oncology: Toward Achieving the Achievable for Patients with Cancer
Chapter 12. Statistics and Clinical Trials

SECTION II. TECHNIQUES AND MODALITIES

Chapter 13. Brachytherapy
Chapter 14. Conformal Therapy: Treatment Planning, Treatment Delivery, and Clinical Results
Chapter 15. Intraoperative Irradiation
Chapter 16. Stereotactic Irradiation: Linear Accelerator and Gamma Knife
Chapter 17. Total Body Irradiation
Chapter 18. Charged Particle Radiotherapy
Chapter 19. Neutron Radiotherapy
Chapter 20. Hyperthermia
Chapter 21. Targeted Radionuclide Therapy
Chapter 22. Palliation of Metastases: Bone, Spinal Cord, Brain, Liver

SECTION III. DISEASE SITES
Part A. CENTRAL NERVOUS SYSTEM TUMORS OVERVIEW

Chapter 23. Low-Grade Gliomas
Chapter 24. High-Grade Gliomas
Chapter 25. Meningioma, Ependymoma and Other Adult Brain Tumors
Chapter 26. Pituitary Tumors
Chapter 27. Spinal Tumors
Chapter 28. Orbital, Ocular, and Optic Nerve Tumors

Part B. HEAD AND NECK TUMORS OVERVIEW

Chapter 29. Oral Cavity
Chapter 30. Oropharyngeal Cancer
Chapter 31. Nasopharyngeal Carcinoma
Chapter 32. Larynx and Hypopharnyx Cancer
Chapter 33. Sinonasal Cancer
Chapter 34. Salivary Gland Cancer
Chapter 35. Thyroid Cancer
Chapter 36. Squamous Cell Carcinoma Metastatic to the Neck from an Unknown Head and Neck Primary Site
Chapter 37. Management of the Neck
Chapter 38. Cutaneous Carcinoma
Chapter 39. Melanoma

Part C. THORACIC NEOPLASMS OVERVIEW

Chapter 40. Small Cell Lung Cancer
Chapter 41. Non-Small-Cell Lung Cancer
Chapter 42. Cancer of the Esophagus
Chapter 43. Uncommon Thoracic Malignancies

Part D. GASTROINTESTINAL TUMORS OVERVIEW

Chapter 44. Stomach Cancer
Chapter 45. Pancreatic Cancer
Chapter 46. Hepatobiliary Tumors
Chapter 47. Colon Cancer
Chapter 48. Rectal Cancer
Chapter 49. Anal Carcinoma

Part E. GENITOURINARY TUMORS OVERVIEW

Chapter 50. Prostate Cancer
Chapter 51. Bladder Cancer
Chapter 52. Testicular Cancer
Chapter 53. Kidney and Ureteral Carcinoma
Chapter 54. Penile Cancer

Part F. GYNECOLOGIC TUMORS OVERVIEW

Chapter 55. Cervical Cancer
Chapter 56. Endometrial Cancer
Chapter 57. Vulvar and Vaginal Carcinoma
Chapter 58. Ovarian Cancer

Part G. BREAST CANCER OVERVIEW

Chapter 59. Noninvasive Breast Cancer
Chapter 60. Breast Cancer: Stages I and II
Chapter 61. Breast Cancer: Stages T3 and T4 Locally Advanced and Inflammatory Breast Cancer and Postmastectomy Radiation Therapy

Part H. SARCOMA and BENIGN DISEASE

Chapter 62. Soft Tissue Sarcoma
Chapter 63. Radiotherapy of Non-malignant Diseases

Part I. CHILDHOOD CANCERS OVERVIEW

Chapter 64. Central Nervous System Tumors in Childhood
Chapter 65. Pediatric Soft Tissue Sarcomas
Chapter 66. Pediatric Sarcomas of Bone
Chapter 67. Wilm's Tumor
Chapter 68. Retinoblastoma
Chapter 69. Neuroblastoma
Chapter 70. Leukemias and Lymphomas in Children
Chapter 71. Hodgkins
Chapter 72. Rare Tumors in Children

Part J. LYMPHOMA AND HEMATOLOGIC MALIGNANCIES OVERVIEW

Chapter 73. Hodgkin's Disease
Chapter 74. Non-Hodgkin's Disease
Chapter 75. Multiple Myeloma and other Plasma Cell Neoplasms
Chapter 76. Mycosis Fungoides

INDEX

With thorough updates throughout, Clinical Radiation Oncology provides the most comprehensive, authoritative, and up-to-date information available for treating patients with cancer. From a multidisciplinary perspective, this new edition, edited by Drs. Leonard L. Gunderson and Joel E. Tepper, examines the therapeutic management of specific disease sites based on both single-modality and combined-modality approaches - providing you with the well-rounded, cutting-edge guidance you need to offer the most effective treatments. A consistent chapter format, full-color design, and access to the full text at www.expertconsult.com make reference fast and easy. It is an ideal resource for mastering the latest, most effective techniques and modalities!

Key Features

Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities.
Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons.
Broaden your understanding of the basic biology of the disease processes.
Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches.
Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques.

New to This Edition

Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors -many of whom are new to this edition - affiliated with institutions across North America and internationally
Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more!
Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy.
Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens.
Understand and comply with the latest staging guidelines.

About the Authors

Leonard L. Gunderson, MD, MS, FASTRO, Emeritus Professor and Consultant, Department of Radiation Oncology, Mayo Clinic College of Medicine and Mayo Clinic, Scottsdale, Arizona.
Joel E. Tepper, MD, Hector MacLean Distinguished Professor of Cancer Research, Department of Radiation Oncology, UNC Lineberger Comprehensive Cancer CenterUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina.

Book Details

Hardcover: 1660 pages
Publisher: Saunders; 3 edition (October 27, 2011)
Language: English
ISBN-10: 1437716377
ISBN-13: 978-1437716375
Product Dimensions: 11.1 x 8.9 x 2.4 inches
List Price: $299.00

Kindle Edition:

Clinical Radiation Oncology, 3rd Edition (Expert Consult Series) [eBook]

Dasgupta: ABC of Prostate Cancer

2011-12-01T08:20:00.000-08:00

1 Applied Anatomy of the Prostate
2 Pathology of Prostate Cancer
3 Biology of Prostate Cancer
4 Prostate Cancer Diagnosis
5 Imaging of Prostate Cancer
6 Screening for Prostate Cancer
7 Active Surveillance
8 Open Radical Prostatectomy
9 Laparoscopic Radical Prostatectomy
10 Robotic Radical Prostatectomy
11 Prostate Brachytherapy
12 HIFU
13 Cryotherapy for Prostate Cancer
14 Advances in External Beam Radiotherapy
15 Recent Advances in Hormonal Therapy
16 Management of Castration-Resistant Prostate Cancer
17 Immunology of Prostate Cancer
18 New Approaches to Prostate Cancer
Index

Prostate cancer is the most common cancer in men in the UK and US and the second most common worldwide.

The ABC of Prostate Cancer provides fully illustrated guidance on the treatment and management of prostate cancer. It covers the biology, anatomy, and pathology of prostate cancer, screening, and active surveillance and monitoring. It presents an assessment of treatment options including prostatectomy, bracytherapy, chemotherapy and immunotherapy, along with modern diagnostic tests and an overview of new approaches to prostate cancer.

With an international author team, the ABC of Prostate Cancer is ideal for general practitioners, family physicians, specialist nurses, junior doctors, medical students and others working with prostate cancer patients and their families.

About the Author

Prokar Dasgupta is Consultant Urological Surgeon, Department of Urology, King's College London, Guy’s and St Thomas’ Hospital NHS Foundation Trust, London.
Roger S. Kirby is Consultant Urologist, The Prostate Centre, London.

Book Details

Paperback: 80 pages
Publisher: BMJ Books; 1 edition (February 21, 2012)
Language: English
ISBN-10: 1444334379
ISBN-13: 978-1444334371
Product Dimensions: 10.9 x 8.6 x 0.2 inches

List Price: $35.95

Hunt: ABC of Lung Cancer

2011-11-30T08:14:00.001-08:00

1. Epidemiology, risk factors and prevention.
2. Symptoms and assessment.
3. Service organisation and guidelines for referral.
4. Diagnosis and Staging.
5. Small Cell Lung Cancer.
6. Malignant pleural Mesothelioma.
7. Surgery for non-small cell lung cancer.
8. Radiotherapy for non-small cell lung cancer.
9. Combination Therapies for NSCL Cancer.
10. Screening for lung cancer.
11. Supportive and Palliative Care.
Index.

Lung Cancer is the most common cause of cancer death and cancer symptoms. The ABC of Lung Cancer is a much needed reference for those treating and caring for patients with lung cancer such as primary care doctors, specialist cancer nurses, junior doctors, nurses, physiotherapists, radiographers and other health care professionals.

This new title in the ABC series covers the epidemiology and diagnosis of lung cancer, focusing particularly on primary care issues such as what symptoms require urgent investigation, and when to refer to a specialist. This is a practical guide for all those involved in the care of the lung cancer patient, as well as patients and their families and carers.

Key Features

A practical guide for those involved in the care of the lung cancer patient.
An up-to-date evidence-based review of one of the most common cancers in the western world.
Written by the specialists involved in the launch of the NICE UK Lung Cancer Guidelines.
Looks at the epidemiology and diagnosis of lung cancer, focusing particularly on primary care issues.

About the Authors

Ian Hunt, Specialist Registrar in Cardiothoracic Surgery and Research fellow on the Lung Cancer Guidelines, Brighton, UK.
Martin Muers, Consultant Physician, Respiratory Medicine, Leeds General Infirmary, UK.
Tom Treasure, Consultant Cardiothoracic Surgeon, Cardiothoracic Centre, Guy's Hospital, London, UK.

Book Details

Paperback: 64 pages
Publisher: BMJ Books; 1 edition (May 12, 2009)
Language: English
ISBN-10: 1405146524
ISBN-13: 978-1405146524
Product Dimensions: 8.7 x 0.2 x 10.9 inches

List Price: $39.95

Bartley: Mindfulness-Based Cognitive Therapy for Cancer

2011-10-16T08:59:00.000-07:00

Introduction

Personal Story – Trish

Part One Mindfulness and The Cancer Journey

1. Mindfulness and Cancer
2. Cancer – The Psychological Implications
3. Cancer – The Medical Implications
4. The First Circle – Cancer and the Circle of Suffering

Personal Story – Beryl

Part Two The Mindfulness-Based Cognitive Therapy for Cancer Programme

5. Starting Out

Personal Story – Sally

6. The Eight Week Course

Week One
Week Two
Week Three
Week Four
Week Five
Week Six
All Day
Week Seven
Week Eight
The Follow Up Class

7. The Second Circle: Mindful Awareness and the Circle of Practice

Personal Story – Derek

8. The Practices

The Core Practices
The Short Practices
Personal Story – Bridget

9. Mindfulness In Palliative Care
10. After The Eight Week Course
11. The Third Circle – Being and the Circle of Presence

Part Three The Practitioner Teacher

12. Introducing The Teacher
13. Embodying The Practice
14. Facilitating The Learning
15. The Three Circle Model: A Formulation of MBCT for Cancer (MBCT-Ca)

Personal Story – Geraint

Epilogue

Resources and Links

Bibliography

Sources and Permissions

Index

Mindfulness-based Cognitive Therapy for Cancer presents an eight-week course for MBCT which has been tried and tested over ten years of clinical use, and is targeted specifically for people with cancer.

Key Features

There is growing evidence of mindfulness as a successful and cost-effective intervention for reducing the negative psychological impact of cancer and treatment .
Draws upon the author’s experience of working with people with cancer, and her own recent experience of using mindfulness with cancer diagnosis and treatment.
Stories from cancer patients illustrate the learning and key themes of the course.
Includes new short practices and group processes developed by the author.

About the Author

Trish Bartley has taught MBCT to people with cancer in a regional oncology unit in Wales since 2000. She is an Honorary Lecturer in the School of Psychology, Bangor University. She was one of the founding teachers at the Centre for Mindfulness Research and Practice, Bangor University, where she co-leads programmes for health professionals, and students on the Masters programme, to train as mindfulness-based teachers. She delivers mindfulness-based training retreats internationally.

Product Details

Paperback: 424 pages
Publisher: Wiley-Blackwell; 1 edition (February 7, 2012)
Language: English
ISBN-10: 047068383X
ISBN-13: 978-0470683835

List Price: $54.95

Williams: Clinical Dilemmas in Primary Liver Cancer

2011-10-15T08:46:00.000-07:00

Part 1: Learning from a Worldwide Perspective.

1 Are patterns and prevalence changing? (Hashem B. El-Serag).
2 Why is the tumour different in Africa? (Nimzing G. Ladep).
3 Control by vaccination: Asian and Taiwan experience (Jia-Horng Kao).
4 The view from the UK (Shahid A. Khan, Mireille B. Toledano, Abigail Zabron, Mehtan Ahmed, and Simon D. Taylor-Robinson).
5 The view from the United States (Hitoshi Maruyama and Arun J. Sanyal).
6 New challenges of NAFLD and HIV epidemics (Quentin M. Anstee and Janice Main).

Part 2: Influence of Tumour Characteristics.

7 Controversies in Pathology (Tania Roskams).
8 Not to forget the unusual tumour (Bernard C. Portmann).
9 What can be learned from molecular diagnostic techniques and genetic signatures? (Tariq Moatter and Saeed Hamid).

Part 3: Complexities of Patient Assessment and Scoring Systems.

10 Looking after the liver as well as the tumour (Roger Williams).
11 Comparative performances of staging systems for hepatocellular cancer: Early HCC considerations (Peter D. Peng, Timothy M. Pawlik).
12 Rival scoring systems: Do they offer more? (Angelo Sangiovanni and Massimo Colombo).
13 Is it possible to detect early lesions effectively? (Ryota Masuzaki and Masao Omata).
14 What is the value of country based surveillance programmes? (Peter Ott).

Part 4: Choice of Radiological Diagnostic Technique.

15 Computed tomography or magnetic resonance imaging for the diagnosis of hepatocellular carcinoma (Wladyslaw Gedroyc).
16 Is Microbubble ultrasound useful? (Adrian Lim).
17 Value of PET scanning (Tara Barwick, Imene Zerizer, and Adil Al-Nahhas).

Part 5: Can Treatment be Tailored to the Patient?

18 Who could benefit from chemoembolisation? (Gisèle N'Kontchou, Olivier Seror, and Michel Beaugrand).
19 Are drug eluting beads (DEB) worth using? (C. N. Hacking and Pradesh Kumar).
20 What's the future of image-guided radiofrequency ablation for hepatocellular carcinoma? (Riccardo Lencioni).
21 Alternative ablation techniques for hepatocellular carcinoma (John Karani).
22 Justification for Sorafenib and chemotherapy (Philip J. Johnson).
23 When to consider surgery? (Emmanuel Melloul, Mickaël Lesurtel, and Pierre-Alain Clavien).
24 Transplant considerations (Myron Schwartz).

Part 6: What Does the Future Hold?

25 Dipstick markers for diagnosis: Feasible or not? (Mohamed I. F. Shariff and Simon D. Taylor-Robinson).
26 Targeted gene therapy for hepatocellular carcinoma (HCC): A reality? (Christopher Binny, Marco Della Peruta, and Amit C. Nathwani).
27 Is immune modulation a possibility? (Tim F. Greten and Firouzeh Korangy).
28 Systemic therapy for hepatocellular carcinoma: Future directions (Daniel H. Palmer, Matthew Cramp).

Clinical Dilemmas in Liver Cancer follows the successful format of the other books in the Clinical Dilemmas series, with each chapter focused on a specific dilemma, or issue facing doctors in their day-to-day job, and providing them with practical clinical information and help to better assessment and treat their patients – in this case patients suffering from liver cancer, the third commonest cancer in terms of mortality worldwide.

Chapters feature up-to-date information on the basic mechanisms, epidemiological risk factors, screening and surveillance strategies, diagnosis and treatment. It is an extremely practical and clinically-orientated book, and as most patients around the world present with advanced disease, a main focus is on the most recent advances allowing early diagnosis and use of locoregional and systemic therapy, surgery, transplantation and combination therapies. Each chapter is authored by an international expert in the relevant area.

Product Details

Paperback: 244 pages
Publisher: Wiley; 1 edition (February 21, 2012)
Language: English
ISBN-10: 0470657979
ISBN-13: 978-0470657973

List Price: $84.95

Skarin: Atlas of Diagnostic Oncology 4th edition (Expert Consult Series)

2011-06-26T09:36:00.000-07:00

Chapter 1 - The Role of Molecular Probes and Other Markers in the Diagnosis of Malignancy
Chapter 2 - Radiographic Evaluation of Cancer
Chapter 3 - Nuclear Medicine in Oncology
Chapter 4 - Cancer of the Head and Neck region
Chapter 5 - Lung Cancer and Tumors of the Heart and Mediastinum
Chapter 6 - Malignant Mesothelioma
Chapter 7 - Cancer of the Gastrointestinal Tract and Neuroendocrine Tumors
Chapter 8 - Cancer of the Genitourinary Tract
Chapter 9 - Gynecologic Tumors and Malignancies
Chapter 10 - Breast Cancer
Chapter 11 - Endocrine Neoplasia
Chapter 12 - Sarcomas of Soft Tissue and Bone and Gastrointestinal Stromal Tumors
Chapter 13 - Skin Cancer
Chapter 14 - Neoplasms of the Central Nervous System
Chapter 15 - Acute and Chronic Leukemias
Chapter 16 - Hodgkin Disease and Non-Hodgkin Lymphomas
Chapter 17 - Multiple Myeloma and Plasma Cell Dyscrasias
Chapter 18 - Solid Tumors in Childhood
Chapter 19 - AIDS-Associated Malignancies
Chapter 20 - Complications of Cancer
Chapter 21 - Systemic and Mucocutaneous Reactions to Chemotherapy

Atlas of Diagnostic Oncology, 4th Edition, by Arthur T. Skarin, MD, FACP, FCCP, provides the guidance you need to diagnose a full range of neoplastic conditions with greater accuracy for better patient outcomes. An unrivaled collection of more than 2,500 images and drawings-combined with succinct, clinically focused text-equips you with essential information on pathology, diagnostic studies, staging, and clinical manifestations. New discussions on modern diagnostic PET imaging of cancer, and expanded coverage on the side effects of chemotherapy, bring you up to date on the issues impacting research and treatment. Expert Consult functionality-new to this edition-further enhances your reference power with convenient online access to the complete contents of the text, along with case studies that demonstrate effective approaches to diagnosis.

Key Features

A superb collection of more than 2,500 images encompasses the full spectrum of pathologic and radiologic studies, staging, and clinical manifestations, highlighting the pathologic anatomy of common clinical entities.
A consistent chapter organization covers each disease’s incidence, epidemiology, etiology, and histopathology - as well as molecular biology, clinical features, diagnostic studies, and current clinical and pathologic staging - providing all the assistance you need to evaluate and monitor your patients effectively.
This unique pictorial resource is a superb complement to treatment handbooks and major oncological texts.

New to This Edition

Expert Consult functionality provides online access to the complete text, fully searchable, with illustrations downloadable for your personal presentations, and case studies keyed to the book, at expertconsult.com.
Completely updated chapters covering the newest genetic markers, imaging modalities, and pathologic techniques enable you to get the best results from today’s diagnostic tools.
An expanded chapter on evaluating the side effects of chemotherapy, with additional images of reactions to the newest regimens, alerts you to potential common and uncommon side effects.
Two new chapters address the complications of cancer and modern use of diagnostic PET scans, keeping you up to date on these hotly debated topics in the oncology community.
A third new chapter covers malignant mesothelioma of the lung, plus other sites.

About the Author

Arthur T. Skarin, MD, FACP, FCCP, earned his MD from the State University of New York at Buffalo in 1961, and received postgraduate training in internal medicine at the Millard Fillmore Teaching Hospital in Buffalo. After a fellowship in hematology and oncology at Boston City Hospital, he joined Brigham and Women's Hospital and Dana-Farber Cancer Institute (DFCI) in 1970.

He served as Clinical Director of the DFCI Hematology Laboratory as well as Chairman of the Laboratory Committee from 1970 to 1998. He established the multimodality thoracic oncology clinic in 1975 and has served as Medical Director since then. During that time he also was chair of the human protection committee (IRB) for 12 years and became Associate Professor of Medicine at Harvard Medical School.

He has been the Principal Investigator (PI) as well as site PI on numerous clinical research Phase I, II and III trials, both at DFCI Partners Cancer Care and the Cancer and Leukemia Group B (CALGB). He was appointed a Research Subject Advocate (RSA) in 2002 for NIH funded studies at the Brigham and Women's Hospital General Clinical Research Center (GCRC) and DFCI.

Dr. Skarin is a board member of the American Journal of Oncology Review, the Journal of Cinical Oncology, Hospital Physician and also president of the Massachusetts Society of Clinical Oncologists. He has published 150 original articles, 97 abstracts, 67 chapters in books and 4 books.

Product Details

Hardcover: 654 pages
Publisher: Mosby; 4 edition (December 23, 2009)
Language: English
ISBN-10: 0323059058
ISBN-13: 978-0323059053
Product Dimensions: 12.2 x 9.2 x 1.3 inches

List Price: $250.00

Silberman: Principles and Practice of Surgical Oncology: A Multidisciplinary Approach to Difficult Problems

2011-06-25T09:16:00.000-07:00

Principles of Molecular Biology for Cancer Surgeons
Genetic and Environmental Factors in Cancer Pathogenesis
Specialized Nutritional Support for Cancer Patients
Occult Metastases: Detection and Prognostic and Therapeutic Implications
Hematopoietic Stem Cell Transplants for Solid Tumors
Intraperitoneal Drug Therapy for Intra-abdominal Spread of Cancer
Antibodies and Their Conjugates for the Targeted Therapy of Cancer
Computerized Tomography, Magnetic Resonance Imaging, Ultrasonography, and PET Scanning in the Evaluation and Management of Cancer Patients
Role of PET and PET-CT in Oncology
Organ Transplantation and Malignancy
Minimally Invasive Surgery for Cancer
Radiation Therapy: An Overview of Recent Advances and Future Innovations
Surgical Consequences of Abdominal Irradiation
Surgical Cytoreduction: Peritoneal Carcinomatosis, Sarcomatosis and Mesothelioma
Cancer and Pregnancy
Breast: Mammography, Early Detection of Breast Cancer, Challenges, Current Standards of Care
Breast Ultrasonography: Performance and Clinical Applications
The Role of Magnetic Resonance Imaging in the Assessment and Diagnosis of Breast Cancer
Breast Cancer: Ductal Carcinoma In Situ: Treatment Controversies and Oncoplastic Surgery
Breast Cancer: Association with Lobular Neoplasia and Other Benign Lesions
Surgical Options for Stage I and II Breast Cancer
Radiation Therapy in Breast-Conserving Therapy for Invasive Breast Cancer
Adjuvant Therapy in Breast Cancer
Axillary Lymphadenectomy for Breast Cancer: Impact on Survival
Sentinel Lymph Node Analysis in Breast Cancer: Indications, Techniques and Results
Preoperative Chemotherapy for Locally Advanced and Inflammatory Breast Cancer
Evolution of Elective Lymph Node Dissection for Cutaneous Malignant Melanoma
Adjuvant Therapy for Melanoma: Review of Published Data and Studies in Progress
Melanoma: Surgical Approach to Metastatic Disease
Management of Soft Tissue Sarcomas of the Extremity
Soft Tissue Sarcomas of the Retroperitoneum
Soft Tissue Sarcomas: Experience With Cryosurgery
Diagnosis and Treatment of Malignant Tumors of Bone
Chemotherapy for Soft Tissue Sarcomas
The Pathogenesis of Esophageal Carcinoma
Surgical Management of Cancer of the Esophagus
Neoadjuvant Therapy for Esophageal Cancer
Cancer of the Stomach: Surgical Management
Gastric Cancer: Perioperative Adjunctive Therapy
Cancer of the Pancreas: Surgical Management
Cancer of the Pancreas: Adjuvant and Neoadjuvant Therapy
Non-Hematolymphoid Tumors and Tumor-Like Conditions of the Spleen
Colorectal Cancer: Laparoscopic versus Open Surgery
Sphincter-Preserving Surgery in the Management of Rectal Cancer
Colorectal Cancer: Adjuvant and Neoadjuvant Therapy
Pelvic Exenteration: Indications, Techniques and Results
Tumors of the Gastroenteropancreatic Axis
Gastrointestinal Stromal Tumors
Small Bowel Tumors
Malignant Tumors Arising in Inflammatory Bowel Disease
Surgical Management of Primary Malignant and Benign Tumors of the Liver
Surgical Management of Metastatic Liver Disease
Liver Tumors: Multimodality Treatment of Hepatic Metastases
Primary Vascular Tumors
Diagnosis and Management of Thyroid Cancer
Surgical Management of Primary Lung Cancer
Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
Surgical Management of Metastic Lung Disease
Urologic Cancers: Surgical Management of Kidney, Bladder, Prostate, and Testis Cancers
Adjuvant and Neoadjuvant Treatment for Genitourinary Cancers
Surgical Management of Ovarian Cancer
Cancers of the Biliary Tract: Surgical Management of Cancer of the Gallbladder and Bile Ducts
Radiological Intervention in Malignant Biliary Obstruction
Management of Pain in Cancer and Cancer Treatment

Principles and Practice of Surgical Oncology uniquely emphasizes a multidisciplinary, integrated approach to the treatment of solid tumors. It presents treatment strategies that combine surgery with preoperative or postoperative adjunctive chemotherapy, hormonal therapy, and/or radiation therapy to achieve optimal outcome.

The book features contributions from surgeons, basic scientists, pathologists, radiologists, radiation therapists, and medical oncologists and offers a comprehensive presentation of genetics, molecular biology, pathogenesis, and multimodal therapeutic approaches. A unique feature of the book is a commentary following each chapter, which describes alternative approaches and discusses controversial areas of current therapy.

Book Features

Emphasizes a multidisciplinary, integrated approach to the treatment of solid tumors, combining surgery with preoperative or postoperative adjunctive chemotherapy, hormonal therapy, and/or radiation therapy to achieve optimal outcome
Contributions not only from surgeons but also from basic scientists, pathologists, radiologists, radiation therapists, and medical oncologists
Comprehensive presentation of genetics, molecular biology, pathogenesis, and multimodal therapeutic approaches
Each chapter is followed by a commentary which presents alternative approaches and discusses controversial areas of current therapy

Book Details

Hardcover: 1200 pages
Publisher: Lippincott Williams & Wilkins; 1 Har/Psc edition (September 23, 2009)
Language: English
ISBN-10: 0781765463
ISBN-13: 978-0781765466
Product Dimensions: 11.1 x 8.6 x 1.8 inches

List Price: $239.00

Bombardieri: Advances in Nuclear Oncology: Diagnosis and Therapy

2011-06-10T04:06:00.000-07:00

There has been enormous progress in nuclear medicine in recent years, and the impact of this progress has been particularly noticeable in oncology. Research into molecular imaging has led to the development of radiopharmaceuticals that can explore the cellular metabolism, and visualize at molecular and subcellular levels the pathological processes specific to cancer. Equipment development has produced high-technology instruments such as those used in positron emission tomography (PET), able to produce high-quality images that have become indispensable in the diagnostic work-up of cancer patients, because they often reveal alterations and lesions not demonstrated by conventional morphologically oriented techniques such as X-ray imaging, ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). Research in the area of image fusion techniques has led to the design of software programs able to merge in a single image the molecular, functional, and metabolic information of nuclear medicine with the morphological information provided by radiology. Hybrid instruments (PET/CT, SPECT/CT) are now available which allow the fusion of images of a patient in just one diagnostic session. Intensive research is ongoing to obtain detectors, hardware, and software able to perform whole-body scans faster and with increasing spatial resolution, so that it may become possible to detect lesions on a submillimeter level. Nuclear medicine has made the step from bench to bedside, to a significant extent.
All of these achievements have had a great impact on not only the diagnosis but also the treatment of cancer. Improved, individually tailored therapy is now on the horizon. Radiopharmaceuticals developed specifically to target and visualize malignant tumors can also be used, at high doses, for therapeutic purposes. Nuclear medicine therapeutics thus takes advantage of selective radiopharmaceuticals that have demonstrated marked anticancer efficacy in many types of tumors. For example, in recent years, these techniques have been used and shown greatest efficacy in the treatment of lymphomas and neuroendocrine tumors.
The diagnostic and therapeutic achievements in nuclear medicine are the result of the interdisciplinary research efforts of cell biologists, chemists, pharmacologists, physicists, computer scientists, engineers, nuclear medicine physicians, and oncologists. The clinical implications of these achievements have made nuclear medicine indispensable in the management of cancer.
This textbook on modern nuclear medicine applications in the diagnosis and treatment of cancer describes the state of the art and the current position of nuclear medicine in the light of these recent developments. It is intended as a valuable update also for non-nuclear medicine specialists working in oncology. Nuclear medicine as part of molecular imaging and therapy has changed radically in the past decade. The growing importance and clinical impact of these changes for the near future has impelled the authors to record them in this book.

Contents
I: Biology of cancer
1. What is cancer?
2. Targets
II: Diagnostic applications
3. Primary brain tumors
4. Head and neck cancer
5. Lung cancer
6. Esophageal cancer
7. Colorectal cancer
8. Prostate cancer
9. Ovarian cancer
10. Breast cancer
11. Thyroid cancer
12. Adrenal tumors
13. Neuroendocrine gastroenteropancreatic tumors
14. Lymphoma
15. Bone and soft tissue tumors
16. Malignant melanoma
17. Cancer of unknown primary
9. Ovarian cancer
10. Breast cancer
11. Thyroid cancer
12. Adrenal tumors
13. Neuroendocrine gastroenteropancreatic tumors
14. Lymphoma
15. Bone and soft tissue tumors
16. Malignant melanoma
17. Cancer of unknown primary
III: Therapeutic applications
18. Therapy of differentiated thyroid cancer
19. Therapy of medullary thyroid cancer
20. Therapy of lymphoma
21. Therapy of neuroendocrine tumors
22. Therapy of bone metastases
23. Therapy of liver tumors
24. Therapy of colorectal cancer
25. Therapy of brain tumors
26. Therapy of ovarian cancer
IV:Methods and technology
27. New instrumentation
28. New radiopharmaceuticals for cancer diagnosis
29. Radiopharmaceuticals for therapy
30. New concepts in dosimetry and radiation protection
31. Advances in nuclear medicine imaging in oncology
32. Nuclear medicine-guided radiotherapy
Index

Book Details

Hardcover: 544 pages
Publisher: INFRMA-HC; 1 edition (November 5, 2007)
Language: English
ISBN-10: 1841846147
ISBN-13: 978-1841846149
Product Dimensions: 11.5 x 8.7 x 1.4 inches

List Price: $339.95

Smith: Atlas of Gynecologic Oncology 2nd Edition

2011-05-21T03:11:00.000-07:00

Fully updated and revised, the second edition of An Atlas of Gynecologic Oncology presents a full description of the investigative and surgical procedures carried out by the gynecologic oncologist.
Key features of this important text include:

a practical guide to a range of operative and investigative procedures
contributions from international opinion leaders
over 450 colour illustrations

All chapters have been reviewed by both the editors and their authors, some chapters have been replaced and we have added some new chapters. Amongst the new chapters there are included surgical simulation with its impact on training, palliative care, ovarian tissue preservation/transplantation and sentinel lymph node biopsy.
This book follows the ‘cookbook’ formula of the first edition, that is, nobody is telling you which operation to do, but rather telling you how to do the operation you have decided upon.

Contents
1 Introduction
2 Anatomy
3 Tumor markers
4 Cross-sectional imaging
5 Sigmoidoscopy, cytoscopy and stenting
6 Ovarian tissue preservation and transplantation techniques
7 Sentinel lymph node biopsy
8 Cone biopsy
9 Radical abdominal hysterectomy
10 Radical vaginal hysterectomy
11 Radical vaginal trachelectomy
12 Radical abdominal trachelectomy
13 Central recurrent cervical cancer: the role of exenterative surgery
14 Pelvic side-wall recurrence of cervical cancer: the LEER and CORT procedures
15 Surgical management of trophoblastic disease
16 Epithelial ovarian cancer
17 Radical vulvar surgery
18 Laparoscopy
19 Vascular access and implantable vascular and peritoneal access devices
20 Gastrointestinal surgery
21 Urologic procedures
22 Fistula repair
23 Treatment of vascular defects and injuries
24 Plastic reconstructive procedures
25 Objective assessment of technical surgical skill
26 Pain management
27 Palliative care
28 Doctor-patient communication
Index

Book Details

Hardcover: 344 pages
Publisher: Informa Healthcare; 2 edition
Language: English
ISBN-10: 1841843687
ISBN-13: 978-1841843681
Product Dimensions: 11.4 x 8.7 x 1.1 inches

List Price: $299.95

Intracranial Metastases: Current Management Strategies

2011-05-20T03:09:00.000-07:00

The current incidence of tumors metastasizing to the brain is high, and brain metastases are now the most common type of intracranial tumor. Current estimates indicate that, in the USA alone, more than 200,000 patients per year are developing brain metastases. Treatment of patients who have these intracranial metastases involves many different medical specialties. Therefore, there is a need for a better integration of these specialties in the orchestration of patient care.
This volume represents the first up-to-date comprehensive textbook devoted to the subject of human brain metastases in more than 20 years (since 1980).
There are four main areas of emphasis in the present work:
1 It provides an overview of the topic of brain metastases: their biology, diagnosis, and treatment throughout history.
2 Instead of considering brain metastases that arise from tumors in different tissues collectively in a single chapter, each tumor type that metastasizes to the brain is presented in a separate chapter written by an expert on the subject.
Special categories not previously covered have been included, such as the epidemiology of brain metastases and the quality of life in patients who have them, tumor metastasis to the skull base, and strategies that may help prevent metastasis of cancer to the brain.
4 The latest state-of-the-art technology for treatment of brain metastases is reviewed, including surgery, stereotactic radiosurgery, and whole-brain radiation therapy.
With such advances in neurosurgical techniques since the mid-1990s, even patients who had traditionally been excluded as surgical candidates, such as some of those with multiple or recurrent brain metastases, have been shown to survive longer after surgical treatment. Nevertheless, in the future, more work on the treatment of brain metastases needs to take place. More prospective randomized studies are required on issues such as:
1 The relative roles of surgery and stereotactic radiosurgery in the treatment of brain metastases. One should note that data on radiosurgery for treatment of brain metastases were not available in 1980 when the last text focusing on brain metastasis was published.
2 Determination of the best balance between treatment of intracranial metastases with whole-brain radiation therapy and the cognitive outcome and quality of life of the patient.
A completely understudied area that may hold promise is the role of molecularly targeted therapy for metastatic brain tumors. Scientists in the neurosur gical oncology molecular biology laboratories are working hard to translate their discoveries into therapeutic agents for such clinical use.
This book will provide valuable insight into the nature and current treatment of brain metastases to all those in the many medical specialties and subspecialties who are likely to encounter these tumors. It should be a real time saver to be able to look to this single volume for information on brain metastases from tumors of diverse histological origins.

Contents
Part I General
1 Management of intracranial metastases: history
2 The epidemiology of brain metastasis
3 The biology of brain metastasis
4 Brain metastases: histopathological evaluation and diagnostic pitfalls
5 Imaging of metastatic tumors of the brain
Part II Principles of Therapy
6 Intracranial metastases: medical management and prognostic factors
7 Surgical management and techniques
8 Whole-brain radiation therapy
9 Radiosurgery for single and multiple brain metastases
10 Stereotactic radiation of intracranial metastases
11 Chemotherapy for brain metastases
Part III Specific Tumor Sites
12 Metastatic lung cancer
13 Current management strategies in intracranial breast cancer metastasis
14 Management of brain metastasis in malignant melanoma patients
15 Brain metastases from renal cell carcinoma
16 Metastatic colorectal carcinoma
17 Brain metastasis from cancer of an unknown primary site
18 Leptomeningeal carcinomatosis: diagnosis and management
19 Brain metastases from gynecologic cancers
20 Brain metastases from genitourinary cancer: germ cell, testicular, prostate and bladder cancer
21 Brain metastasis from upper gastrointestinal tract cancers: esophageal, gastric, hepatic, gallbladder, and pancreatic
22 Brain metastases from thyroid carcinoma and other endocrine malignancies
23 Brain metastasis from sarcomas
Part IV Special Considerations
24 Metastatic tumors of the skull base
25 Neuropsychological impact of brain metastasis and its treatment
26 Adjuvant approaches for preventing brain metastases
27 Intracranial metastases: management guidelines and decision-making
Index

Book Details

Hardcover: 512 pages
Publisher: Wiley-Blackwell; 1 edition
Language: English
ISBN-10: 1405116463
ISBN-13: 978-1405116466
Product Dimensions: 9.2 x 6.3 x 1.4 inches

List Price: $217.95

Faigel: Endoscopic Oncology

2011-05-19T03:04:00.000-07:00

PART I: ESOPHAGUS

1 Barrett’s Esophagus: Screening, Diagnosis, and Management
2 Endoscopic Screening for Squamous Cell Carcinoma of the Esophagus
3 Image Enhancement Endoscopy
4 Staging of Esophageal Cancer
5 Endoscopic Therapy for Early Esophageal Cancer and Premalignant Lesions in Barrett’s Esophagus
6 Endoscopic Therapy for Advanced Esophageal Cancer
7 Radiological Imaging of the Upper Gastrointestinal Tract
8 Esophageal Cancer Therapy: Surgery, Radiation, and Chemotherapy

PART II: STOMACH AND SMALL BOWEL

9 Premalignant Lesions of the Stomach
10 Gastric Polyps
11 Endoscopic Ultrasound for Staging Gastric Cancer
12 Endoscopic Treatment for Gastric Cancer
13 Diagnosis and Management of Gastrointestinal Lymphoma
14 Gastrointestinal Stromal Tumors
15 Carcinoid Tumors
16 Medical and Surgical Therapy for Gastric Cancer

PART III: COLON

17 Colorectal Cancer Screening
18 Polyposis and Familial Cancer Syndromes
19 Endoscopic Colon Surveillance: Post-Polypectomy, Post-Colorectal Cancer Resection, and Inflammatory Bowel Disease
20 Endoscopic Ultrasound for Staging Rectal and Anal Cancer
21 Endoscopic Therapy of Colorectal Carcinoma
22 Radiological Imaging of the Lower Gastrointestinal Tract
23 Current Status of Colorectal Cancer Therapy

PART IV: PANCREAS, BILE DUCTS, AND MEDIASTINUM

24 Cystic Neoplasms of the Pancreas
25 Diagnosis and Evaluation of Pancreatic Ductal Adenocarcinoma
26 Adenocarcinoma of the Pancreas: Endoscopic Palliation
27 Pancreatic Neuroendocrine Tumors
28 Endoscopic Diagnosis and Management of Cholangiocarcinoma
29 Ampullary Neoplasia
30 Magnetic Resonance Imaging of Neoplasms of the Pancreatobiliary System
31 Medical and Surgical Therapy of Pancreatic Cancer
32 Endoscopic Ultrasound for Thoracic Disease

Index

Cancer is the second most common cause of death in Americans (see www.cdc.gov). Colorectal cancer kills more Americans than any other malignancy except for lung cancer. Taken as a group, the five most common GI malignancies account for more cancers and more cancer deaths than for any other site.

Flexible endoscopy has given physicians unprecedented access to the GI tract. The ability to endoscopically visualize, biopsy, and apply therapy has had implications for the management of all the major GI malignancies. Accepted applications of endoscopy range from detection of malignant and premalignant lesions (e.g., colonoscopy for colon cancer screening), prevention of cancers through removal of precursor lesions (e.g., polypectomy), surveillance of premalignant conditions (e.g., Barrett’s esophagus), palliation of symptoms (e.g., placement of stents for biliary or esophageal obstruction) or staging of cancers to allow stage directed therapy (e.g., endoscopic ultrasound), and, in selected circumstances, definitive therapy for early stage neoplasms (e.g., endoscopic mucosal resection). This partial list of applications demonstrates the central role that endoscopy plays in management for those at risk for or with a GI malignancy. The wide variety of endoscopic techniques applied suggests a new subspecialty of endoscopy: “endoscopic oncology.” This is similar to “surgical oncology,” as it concerns itself with the subset of endoscopic procedures directly applied for the management of neoplastic and precancerous conditions.

It becomes apparent that a substantial proportion of endoscopies are performed for a cancer-related indication. To determine what proportion of endoscopic procedures are done out of a concern for cancer or a premalignant condition, a large national database of endoscopic reports (Clinical Outcomes Research Initiative [CORI]) was queried. Indications related to cancer were defined by convening an expert panel.

The results demonstrated that the majority of endoscopic procedures (63.5%) in these practices were performed owing to a primary concern for cancer. In fact, only for EGD were the majority not done for a cancerrelated indication (32.7%). The great majority of colonoscopy (84.4%), ERCP (59.9%), and EUS (98.7%) procedures are done for cancer-related indications. For colonoscopy, the major cancer-related indications are surveillance of patients with prior polyps (21.3% of cancer-related indications), evaluation of hematochezia (26.2%), follow-up of a positive hemoccult test (15.6%), or surveillance in a patient with a family history of colorectal cancer (17.8%). For EGD, dysphagia was the most common cancer-related indication (62.4%) followed by anemia (23%) and Barrett’s screening/surveillance (12.2%). For ERCP, 98% of the cancer-related indications are related to bile duct obstruction. For EUS, the primary indications related to cancer are FNA of a mass (26%), stage a known cancer (23%), or evaluate a pancreas lesion (23%). With nearly two-thirds of all endoscopic procedures being done out of a primary concern for cancer, it is apparent that all of us who do endoscopy are endoscopic oncologists!

This textbook examines the interface between endoscopy and oncology. It is organized anatomically: esophagus, stomach, colorectum, and pancreaticobiliary. For each site, the relevant cancers and premalignant conditions are addressed and the use of endoscopy in their diagnosis, management, and treatment discussed in detail. Additionally, the reader will find chapters summarizing the state of the art for nonendoscopic medical and surgical cancer treatment.

Book Details

Hardcover: 400 pages
Publisher: Humana Press; 1 edition
Language: English
ISBN-10: 158829532X
ISBN-13: 978-1588295323
Product Dimensions: 11.2 x 8.3 x 0.8 inches
List Price: $225.00

Women's Cancers: Pathways to Healing: A Patient's Guide to Dealing with Ovarian and Breast Cancer 2nd edition

2011-05-18T03:00:00.000-07:00

This book is designed, as the title “Pathways to healing” suggests, to allow you and your family ready access to all the information you require about your cancer to allow you to understand the different directions your disease may take. It should allow you to realize the breadth of possible outcome from where you stand at the particular point in time when you buy the book, or as your disease progresses or not. This book has been written for you wherever you are in the disease, ranging from cured, to those that spend many years living with their cancer, to those who sadly die of their cancer. One of the greatest privileges working in the field of cancer care is meeting many wonderful people, some of who have very kindly written sections of this book. We do hope that by reading this book things may be a little clearer for you and at least some worries made lighter.

About the Author
My name is Richard Smith and I am a Consultant Gynaecological Surgeon who specializes in treating women with cancer. I was born and educated in Scotland, graduating from Glasgow University (MB, ChB). I subsequently underwent postgraduate training in the West of Scotland and London. In the late 1980s, I worked at St. Mary’s Hospital in London and did my thesis on the interaction of infections with cervical cancer (MD, Glasgow).
I have worked for many years the Chelsea and Westminster Hospital and have recently joined the new West London Gynaecological Centre at the Hammersmith Hospital in West London. In terms of Teaching, I am a Senior Lecturer at Imperial College School of Medicine, London, UK, and Adjunct Associate Professor at New York University School of Medicine.
I have had a long running interest in doctor–patient communication and have edited two series of books (The “Guide to …” series and another series, “Patient Pictures”), which were designed to help doctors and nurses explain surgical operations to their patients. These books have sold well (approximately 240,000 copies), suggesting that colleagues, both nursing and medical, are very much interested in this area, not what you would think from looking in the press!
I have always been keen on the synthesis of “standard” or orthodox medicine with “complementary” medicine. This started with being taught hypnosis, practicing it, and has subsequently widened out to include referring my patients for hypnotherapy, homeopathy, acupuncture, counseling, and psychotherapy. Over the last decade I have also become convinced that although I believe that people with some form of religious belief do not survive longer, I am sure they cope better with their cancer. For those with no religious sentiment there are other ways of helping them to find the inner self. The synthesis of these factors allows for a truly holistic approach.
My co-author, Giuseppe Del Priore is also a gynecologist specializing in cancer treatment. He works at New York Downtown Hospital, Weill-Cornell School of Medicine in New York City and has a long-standing interest in doctor–patient communication. He has been a pioneer in the field of fertility sparing surgery.
The artist for the book is Ms. Dee MacLean, who is one of the foremost medical artists in the world today. She has an outstanding ability to make complex anatomy look comprehensible to both doctors and patients and has a long running interest in illustrating medical problems for patients. The Rev. Gary Bradley is the Vicar of the Churches of Little Venice, London, and Founder and Chairman of the Westminster Bereavement Council.
Mrs. Mira Dharamshi, Mrs. Patricia Walker, Mrs. Gallina Dean, and her husband John kindly wrote pieces as to their feelings about living with their cancer, or in John’s case, his wife’s cancer.

Contents
General Information
1. General Introduction
2. Anatomy Overview
3. The 4-cusp Approach to Cancer Care
4. General Concepts of Surgical Management
5. Sex, Cancer, and Surgery

Specific Cancers
6. Cervical Cancer and Precancer (Cervical Intraepithelial Neoplasia)
7. Ovarian Cancer (Including Cancer of the Fallopian Tube)
8. Endometrial Cancer
9. Vulval Cancer
10. Breast Cancer
11. Choriocarcinoma: Gestational Trophoblastic Neoplasia

General Treatments and Care
12. General Concepts of Chemotherapy and Radiotherapy
13. Pain Management
14. Complementary Therapies
15. Bereavement/Grief
16. Spiritual Approaches to Living with Cancer
17. Conclusion
Suggested Further Reading
Glossary
Index

Book Details

Paperback: 154 pages
Publisher: Springer; 2nd Printing edition
Language: English
ISBN-10: 1846284376
ISBN-13: 978-1846284373
Product Dimensions: 8 x 5 x 0.5 inches

List Price: $19.95

Blackburn: Nutritional Oncology 2nd Edition

2011-05-17T02:58:00.000-07:00

Nutritional oncology is an interdisciplinary field that bridges two areas of metabolic homeostasis—nutrition and cancer. Increasingly there are critical links being found between normal metabolic control, normal inflammation, normal genetic and epigenetic homeostasis, DNA repair, and the abnormal processes leading to the multistep process of carcinogenesis. The sequencing of the human genome and the rapidly expanding areas of molecular epidemiology, molecular endocrinology, and cellular signaling have provided new pathways for the study of the abnormal regulatory steps involved in initiating and maintaining carcinogenesis and the steps involved in the progression to metastatic spread.

From these insights it is clear that there are many genetic predispositions that can interact with a Western dietary pattern in experimental models and in human populations to lead to common forms of cancer. The Western dietary pattern does not exist in isolation but is found nested within a sedentary lifestyle and an excess of dietary fats, starches, and refined carbohydrates often combined with excess use of tobacco and alcohol. In the past few decades, the ability to modify environmental factors through nutritional counseling and exercise instruction has been refined, but the ability to modify the behavior of populations through public health measures and dietary guidelines remains a major challenge.
Medical oncologists, nurses, and dietitians will have an increasing opportunity to enhance their care of patients with cancer and those at risk by using the principles and information in this text. Basic scientists moving from a focus on molecular biology, genetics, and metabolism will have an opportunity to integrate basic science with questions important in clinical medicine. In these ways, the field of nutritional oncology aims to modify the environmental factors influencing the genetic changes and their expression at every stage of carcinogenesis, from the initiation of the cancer cell to its metastatic spread to other areas of the body.

This text is divided into the following sections:

First, the biology of nutrition and cancer including fundamentals of human nutrition, nutrigenomics and nutrigenetics, genetics and epigenetics, metabolic networks, and energy balance in cancer are described.
Second, the evidence from the nutritional epidemiology of cancer is explored, including fruit and vegetable consumption, whole grains, obesity, tobaccorelated cancers, alcohol, and environmental toxins.
Third, biological approaches to investigating cancer are described, including endocrine and paracrine factors, oxidants and antioxidants, thiols, tumor immunology, and animal models of cancer.
Fourth, gene–nutrient interaction in cancer is explored, including an overview of the challenges facing the field, methodological issues in dietary assessment, and the evidence for specific cancers, including prostate cancer, breast cancer, skin cancer, colon cancer, gastric cancer, pancreatic cancer, bladder cancer, leukemia, and lymphoma.
Fifth, bioactive food components are examined in detail, including dietary supplements, fiber and carbohydrates, dietary lipids, calcium and vitamin D, soy isoflavones, selenium, glucosinolates, green tea, garlic, berries, and isoprenoids.
The sixth section deals with the nutritional assessment and support of the patient with cancer, including cancer anorexia and cachexia, weight management of the breast cancer survivor, nutritional support of the adult patient with cancer, endocrine effects of cancer and ectopic hormone syndromes, counseling the cancer survivor, and nutritional support in quality of life. Finally, the seventh section tackles the problem of implementing nutrition in guidelines and clinical practice, including an analysis of modern statistical methods, evidence-based practice management in prevention and treatment, dietary guidelines in cancer prevention, dietary interventions for cancer prevention, and the future of nutritional oncology with a detailed analysis of the prospects for personalized medicine based on gene–nutrient interaction.

Book Details

Hardcover: 848 pages
Publisher: Academic Press; 2 edition
Language: English
ISBN-10: 0120883937
ISBN-13: 978-0120883936
Product Dimensions: 11 x 8.8 x 1.7 inches

List Price: $225.00

HPV and Other Infectious Agents in Cancer: Opportunities for Prevention and Public Health

2011-05-16T09:53:00.000-07:00

The role of viruses in the etiology of cancer has been a focus of scientific inquiry for much of the twentieth century; the more recent development of vaccines against the hepatitis B virus and some types of human papillomavirus has provided an important public health opportunity for preventing the development of liver and cervical cancers, respectively.
A fuller appreciation of this topic is a priority in cancer control. Thus, the National Infectious Agents Committee of the Canadian Partnership Against Cancer’s Primary Prevention Action Group, in partnership with Canadian Cancer Society, sponsored the development and publication of this volume.
Despite signifi cant improvements in cancer prevention, treatment, and survival, more and more Canadians are diagnosed with cancer. This story is repeated in many jurisdictions in the world. One driver of such trends is an aging population, but cancer is not only a disease of the elderly. For example, cancer is the leading cause of death in middleaged adults in Canada. In the 35- to 64-year age group, cancer causes more deaths than heart disease, stroke, injury, and infectious diseases combined.
Over a decade ago, facing the reality of a growing burden of cancer within Canadian society, cancer community stakeholders from across the country identifi ed a need to create a coordinated, national plan for cancer control. The Canadian Strategy for Cancer Control (CSCC) was the volunteer network that drafted such a plan and successfully advocated for its funding. With that funding in place, the work begun by the CSCC is being refi ned and driven forward by the Canadian Partnership Against Cancer (CPAC).
Networks of expert groups are leading efforts across all priority areas of cancer control, supported by CPAC since it began operations on April 1, 2007. One of these eight expert groups is the Primary Prevention Action Group, which in turn includes three subcommittees focused on advancing efforts that are central to the prevention of cancer: the National Committee on Environmental and Occupational Exposure, the National Committee on Skin Cancer Prevention, and the National Committee on Infectious Agents.
This volume was supported by the Partnership through funding by Health Canada and by the Canadian Cancer Society’s National Cancer Institute of Canada. Given the sponsorship and concerns of this book, and active cooperation in medical research across the border, there will sometimes be a Canadian or U.S. focus to the information presented.
But as also will become clear in the book, researching the infection/ cancer connection was an international project from the start, and continues to be so.
Although infectious agents have been the focus of etiological and applied research for many decades, the relative interest and the level of research investment on infectious agents in Canada, the United States, and the rest of the developed world has waxed and waned over that time frame. Above and beyond the complexity of the science to understand how viral and bacteriological agents increase the risk for developing cancer, an explanation for the uneven research investment on infectious agents and cancer in the developed world is the fact that the infectionrelated burden is disproportionately found in developing countries.
Moreover, within the developed world, many of the cancers linked to infectious agents (e.g., cervical cancer) disproportionately burden the most vulnerable populations (e.g., low income, ethnic minorities). These underserved populations often have few, if any, voices to advocate for more research investment in addressing the cancers that contribute to the cancer health disparities they experience.
Particularly in the developing world, where resources available for early detection and the treatment of disease are extremely limited, controlling a complex set of diseases like cancer must perforce focus on prevention and palliation. The relatively recent developments of clinical prevention approaches for liver cancer (vaccination against hepatitis B virus) and cervical cancer (vaccination against specifi c types of HPV) hold great promise for cancers that are a much larger public health burden for vulnerable populations worldwide. Thus, this book goes beyond an update of the biological and clinical data relevant to infections that cause cancer by focusing on prevention as a theme of the knowledge synthesis provided.
As suggested earlier, the primary prevention perspective is the particular value that the present book seeks to add to the several published reviews of infectious causes of cancer. It is important to organize the proven and potential interventions so that classic primary prevention categories are clearly delineated. In this way, health care planners worldwide can more easily see where their proposed strategies fi t on the prevention spectrum, thereby promoting comprehensive prevention approaches and clear resource allocation decisions.
This book hopefully will assist those in Canada, the United States, and around the world interested in building on the knowledge gained from research to expand cancer prevention partnership initiatives and enhance the strategies that can be put into practice to prevent cancers linked to infectious agents.

Contents
1 Introduction - Infection and Cancer: An Expanding Paradigm
2 Human Papillomavirus: Structure, Transmission, and Occurrence
3 Human Papillomavirus: Infection, Natural History, and Carcinogenesis
4 Human Papillomavirus: Associations with Cervical Cancer
5 Human Papillomavirus: Associations with Non cervical Cancer
6 Human Papillomavirus: Detection of Infection and Disease
7 Human Papillomavirus: Prevention of Infection and Disease
8 Hepatitis Viruses
9 Helicobacter pylori
10 Epstein-Barr Virus
11 Human Herpesvirus Type 8
12 Human T-cell Lymphotropic Virus Type 1
13 Conclusion - Infection and Cancer: A Paradigm Shift
Index

Book Details

Hardcover: 560 pages
Publisher: Oxford University Press, USA; 1 edition (April 12, 2010)
Language: English
ISBN-10: 0199732914
ISBN-13: 978-0199732913
Product Dimensions: 9.1 x 6.1 x 1.4 inches

List Price: $89.95

Mehta: Principles & Practice of Neuro-oncology: A Multidisciplinary Approach

2011-05-15T09:47:00.000-07:00

Neuro-oncologic (brain and spine) cancers account for 19,000 new cases and 13,000 deaths per year. The early and proper diagnosis of these virulent cancers is critical to patient outcomes and diagnosis and treatment strategies are continually evolving. The multidisciplinary team that manages these patients involves medical radiation oncology, neurosurgery, molecular biology, neuroimaging, nurses and therapists. Principles and Practices of Neuro-Oncology establishes a new gold standard in care through a comprehensive, multidisciplinary text covering all aspects of neuro-oncology. Six major sections cover all topics related to epidemiology and etiology, clinical features and supportive care, imaging, neuroanatomy and neurosurgery, medical oncology and targeted therapies, and radiation oncology for adult and pediatric cancers.

Expert contributors from multiple disciplines provide detailed and in-depth discussions of the the entire field of neuro-oncology including histopathologic harmonization, quality of life amd therapeutic changes in terms of combined modality treatments, the advent of new drugs, especially targeted agents, and the tantalizing early promise of personalized therapeutic approaches.

With contributions from over 180 authors, numerous diagrams, illustrations and tables, and a 48-page color plate section, Principles and Practice of Neuro-Oncology reflects the breadth and depth of this multi-faceted specialty.

About the Author

Minesh Mehta, MD, FASTRO, Professor, Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Susan Chang, MD, Professor, Vice Chair, Neurological Surgery, Director, Division of Neuro-Oncology, University of California San Francisco, San Francisco, California.
Herbert Newton, MD, FAAN, Professor of Neurology, Neurosurgery, and Oncology, Esther Dardinger Endowed Chair in Neuro-Oncology, Department of Neurosurgery, Dardinger Neuro-Oncology Center, The Ohio State University Medical Center, James Cancer Hospital, Columbus, Ohio.
Abhijit Guha, MSc, MD, FRCSC, FACS, Professor of Surgery (Neurosurgery), Toronto Western Hospital, Senior Scientist and Co-Director, The Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, Hudson Chair in Neuro-Oncology, Department of Surgery (Neurosurgery), University of Toronto, Toronto, Ontario, Canada.
Michael Vogelbaum, MD, PhD, FACS, Robert and Kathryn Lamborn Chair for Neuro-Oncology, Associate Director of Neurosurgical Oncology, Department of Neurosurgery, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio.

Book Details

Hardcover: 1048 pages
Publisher: Demos Medical Publishing; 1 edition (October 22, 2010)
Language: English
ISBN-10: 1933864788
ISBN-13: 978-1933864785
Product Dimensions: 11.1 x 8.5 x 1.9 inches

List Price: $245.00

Macromolecular Anticancer Therapeutics (Cancer Drug Discovery and Development Series)

2011-05-14T09:42:00.000-07:00

Cancer therapy has been a major challenge since most of the medicines currently on the market display limited efficacy and/or significant toxicity. Even if new molecules are discovered to treat cancer diseases, the clinical use and efficacy of conventional chemotherapeutics are, indeed, hampered by drug resistance at the tumor level due to physiological barriers (noncellular-based mechanisms), drug resistance at the cellular level (cellular mechanisms), and by non-specific distribution as well as by biotransformation and clearance of anticancer drugs in the body. In other words, conventional chemotherapeutics is often limited to inadequate delivery of therapeutic concentrations to the tumor target tissue or cells. It is therefore of importance to develop new approaches for safer and more efficient delivery of anticancer compounds to tumors both at the cell and tissue level, thereby improving the therapeutic index of these medicines.
In this context, “macromolecular therapeutics” represents, behind the conventional small chemical entities, a second generation of anticancer compounds holding enormous promise and making use of smart approaches to fight cancer. Design and development of macromolecular anticancer therapeutics have assembled interdisciplinary efforts from scientists belonging to various fields like biochemistry, immunology, cell biology, chemistry, bioengineering, pharmaceutics, pharmacology, and oncology.
Macromolecular anticancer therapeutics represents a significant volume of research in the recent years so that a large number of macromolecular therapeutic substances are already in the market or are currently in clinical trials or in pre-clinical stage, demonstrating activity against numerous experimental cancer models. Thus, the therapeutic index of various anticancer substances may be increased by linkage with macromolecules of different nature (i.e., proteins, lipids) in order to improve pharmacokinetic and biodistribution. Other anticancer macromolecules are active per se: by mimicking Mother Nature, they are able to recognize cancer targets in a highly specific manner (i.e., antibodies or oligonucleotides). It is out of question that macromolecular anticancer therapeutics possesses improved specificity toward cancer tissues whereas in certain circumstances they also can overcome resistance which, as stated before, is an important drawback associated with many of the conventional currently available anticancer substances. Thus, macromolecular anticancer therapeutics opens new prospects in the current therapy of cancer.
This book will describe in great detail the possible ways to improve cancer treatment by using these macromolecular-based therapies which are
(1) by the selective delivery of small molecule drugs to tumors; this is the major challenge in efficient and safe cancer therapy. The capability of macromolecular substances such as polymers and lipids to alter the fate of conjugated small molecule drugs in the biological environment has prompted the development of macromolecular prodrugs. Thus, a variety of such macromolecular entities have successfully improved the biological fate of the conjugated small molecules and positively contributed toward improvement of efficacy in the treatment of drug-sensitive and drug-resistant tumors, simultaneously lowering the associated toxicity;
(2) by the employment of tumor-specific antibodies, tumors can be targeted with high molecular recognition and efficient therapy can be assured;
(3) by using synthetic fragments of DNA or RNA (i.e., antisense oligonucleotides, aptamers, or small interfering RNA), it is possible to inhibit oncogene expression.
Practically and in order to discuss these various therapeutic strategies, this book containing 17 chapters is divided into 6 parts.
In Part I, the anticancer drugs have been classified, and the various signal transduction pathways involved in the cancer growth and resistance to therapy are discussed. Different classes of anticancer therapeutics either in preclinical or in clinical phases have also been elaborated.
Parts II and III describe the different categories of macromolecular therapeutics of polymer and lipid origin, respectively, designed to improve the accumulation of anticancer agents into tumors by virtue of their physicochemical and pharmacokinetic properties. Design and development, opportunities and challenges, current status, and preclinical and clinical progress of these macromolecular prodrugs are detailed.
Part IV discusses the antibody-mediated drug targeting to cancer employing antibody–drug conjugates, radioimmunoconjugates, toxin–antibody conjugates, antibody-mediated enzyme prodrug therapeutics, and using also antibodies themselves to interfere with specific molecular targets responsible for tumor growth and progression. This part principally deals with the design, the development, the preclinical and clinical status, as well as the challenges involved in cancer therapy using various categories of antibody-based therapeutics.
Part V refers to a variety of therapeutic anticancer oligonucleotides designed and developed for specific inhibition of oncogenes. Their efficacy is discussed both at the pre-clinical and clinical state.
Part VI primarily deals with the molecular therapeutic interventions in breast cancer treatment.
On the whole, this book assembles all the major areas related to the use of macromolecular strategies for cancer therapy and it discusses the “past, present, and future” of these pharmacological approaches. This book is expected to serve as an essential reference to a broad scientific community including chemists, biologists, biomedical scientists, pharmacologists and pharmaceutical technologists, and oncologists.

Contents
Part I Classification, Opportunities and Challenges
1 Classification of Anticancer Drugs Based on Therapeutic Targets
2 Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy
Part II Polymer-Based Anticancer Prodrugs
3 HPMA-Anticancer Drug Conjugates
4 Poly-L-Glutamic Acid Anti-cancer Drug Conjugates
5 Polysaccharide-Based Anticancer Prodrugs
6 PEG–Anticancer Drugs
7 Poly(ethylene glycol)-Protein, Peptide, and Enzyme Conjugates
Part III Lipid-Based Anticancer Prodrugs
8 Lipid-Based Anticancer Prodrugs
Part IV Antibody-Directed Cancer Therapy
9 Antibody–Cytotoxic Compound Conjugates for Oncology
10 Immunoconjugate Anticancer Therapeutics
11 Antibody-Directed Enzyme Prodrug Therapy (ADEPT) for Cancer
12 EGFR-Directed Monoclonal Antibodies
13 The Biology of the HER Family and Her2/neu Directed-Antibody Therapy
14 Anti-Vascular Endothelial Growth Factor Monoclonal Antibodies
15 Monoclonal Antibody Therapy for Hematologic Malignancies
Part V Anticancer Oligonucleotide Therapeutics
16 Anticancer Oligonucleotides
Part VI Miscellaneous
17 New Molecular Therapeutic Interventions: The Case of Breast Cancers
Author Index
Subject Index

Book Details

Hardcover: 500 pages
Publisher: Springer; 1st edition
Language: English
ISBN-10: 1441905065
ISBN-13: 978-1441905062
Product Dimensions: 9.5 x 6.1 x 1.8 inches

List Price: $199.00

DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology 9th edition

2011-04-25T09:16:00.000-07:00

PART ONE MOLECULAR BIOLOGY OF CANCER
1. The Cancer Genome

Cancer Genes and Their Mutations
Identification of Cancer Genes
Cancer Genome Investigation: Tools and Quality Controls
Somatic Alteration Classes Detected by Cancer Genome Analysis
Pathway-Oriented Models of Cancer Genome Analysis
Networks of Cancer Genome Projects
The Genomic Landscape of Cancers
The Cancer Genome and the New Taxonomy of Tumors
Cancer Genomics and Drug Resistance
Perspectives of Cancer Genome Analysis

2. Mechanisms of Genomic Instability

Basic Defenses Against Genomic Instability
Barriers to Genomic Instability
Mutations in Cancer
Mechanisms of Genome Destabilization in Human Tumors
What Causes Chromosomal Instability and Whole-Chromosome Aneuploidy?
Does Whole-Chromosome Aneuploidy Cause Cancer?
Perspectives and Implications for Cancer Therapeutics

3. Epigenetics of Cancer

Epigenetic Processes
Epigenomic Changes in Cancer
The Timing of Epigenetic Alterations
Epigenetic Biomarkers for Early Detection of Cancer
Epigenetic Therapies
Problems with Epigenetic Therapies

4. Telomeres, Telomerase, and Cancer

Telomeres and Telomerase
Senescence
Telomere Maintenance and Cancer

5. Receptors

Cell Signaling Growth Factors
Signal Transduction Systems
Sensory Machinery: Ligands and Receptors
Regulation of Protein Kinases
Small-Molecule Second Messengers
Efficiency and Specificity: Formation of Multiprotein Signaling Complexes
Signaling Networks

6. Cell Cycle

Cell-Cycle Engine
Induction of Cell-Cycle Phase Transitions
Ubiquitin-Mediated Proteolysis
Regulation of the Cell Cycle
Cell Cycle and Cancer
MicroRNAs, the Cell Cycle, and Cancer
The Cell Cycle and Cancer Therapy

7. Mechanisms of Cell Death

Apoptosis
Autophagy
Necrosis

8. Cancer Metabolism

Altered Metabolism in Cancer Cells
Energetics of Cell Proliferation
Imaging Cancer Metabolism in Patients
Genetic Events Important for Cancer Influence Metabolism
Targeting Metabolism to Treat Cancer

9. Angiogenesis

Introduction: Origins of the Concept of Antiangiogenic Therapy for Cancer
Sequential Steps Involved in the Formation of Blood Vessel Capillaries in Tumors
Pericytes
Dysfunctional Nature of the Tumor Vasculature
Molecular Mediators of Tumor Angiogenesis: Angiogenic Stimulators and Their Receptors
Endogenous Inhibitors of Tumor Angiogenesis
A Cooperative Regulator of Tumor Angiogenesis: The Notch Receptor- DLL4 Signaling Pathway in Endothelial Cells
Strategies for Development of Antiangiogenic Drugs
Enhancement of Chemotherapy Efficacy and Other Therapeutic Modalities by Antiangiogenic Drugs
Resistance to Antiangiogenic Drugs or Treatments
Biomarkers for Tumor Angiogenesis and Antiangiogenic Therapy
Antiangiogenic/Anti-VEGF Drug-Based Clinical Trials
Looking Ahead: New Targets, New Drugs, and New Strategies for Antiangiogenic Therapy

10. Invasion and Metastasis

The Evolution and Pathogenesis of Metastasis
An Integrated Model for Metastasis
Selective Pressures at the Primary Tumor Driving Acquisition of Metastasis Functions
Coupling Tumorigenesis with Metastasis Initiation
Coupling Tumorigenesis with Metastasis Progression
From Metastasis Progression to Macrometastatic Colonization
Micro-RNAs and Metastasis

11. Cancer Stem Cells

Tumor Heterogeneity
Leukemia Stem Cells
Cancer Stem Cells in Solid Tumors
Genetic Diversity and Clonal Evolution in Cancer
The Origins of Cancer Stem Cells
Epithelial-Mesenchymal Transition
Cancer Stem Cells: Targeted Therapy

12. Biology of Personalized Cancer Medicine

Cancer Predisposition
Familial Adenomatous Polyposis
Lynch Syndrome
Other Polyposis Syndromes
Association Studies
Breast Cancer
Early Detection
Tumor Classification and Patient Stratification
Treatment
Development of Resistance to Tyrosine Kinase Inhibitors
Alternative Mechanisms of Resistance
BRAF Inhibitors
The Future
Changing Face of Personalized Medicine
Summary

PART TWO ETIOLOGY AND EPIDEMIOLOGY OF CANCER
Section 1: Etiology of Cancer
13. Tobacco

Epidemiology of Tobacco and Cancer
Tumor Induction in Laboratory Animals by Tobacco Products
Carcinogens in Tobacco Products
Overview of Mechanisms of Tumor Induction by Tobacco Products
Tobacco Carcinogen and Toxicant Biomarkers

14. Cancer Susceptibility Syndromes

Principles of Cancer Susceptibility
Genetic Testing
Cancer Susceptibility Syndromes
Future Directions

15. DNA Viruses

History of Viral Oncology
Hepadnaviruses and Hepatocellular Carcinoma
Papillomaviruses
Epstein-Barr Virus
Kaposi's Sarcoma–Associated Herpesvirus
Human Polyomaviruses

16. RNA Viruses

Retroviruses: Background, Replication Cycle, and Molecular Genetics
Human T-Lymphotropic Virus Type 1
Human T-Lymphotropic Virus Type 2
Human Immunodeficiency Virus
Hepatitis C Virus

17. Inflammation

Tumor Immune Surveillance
Inflammation and Tumorigenesis
Mechanisms of Cell Transformation and Cancer Initiation in the Inflammatory Environment 196 Inflammatory Cells and Stromal Cells in the Initiation of Neoplasia and in the Tumor Microenvironment

18. Chemical Factors

The Nature of Chemical Carcinogens: Chemistry and Metabolism
Animal Model Systems and Chemical Carcinogenesis
DNA Repair Protects the Host from Chemical Carcinogens
Genetic Susceptibility to Chemical Carcinogenesis
Molecular Epidemiology, Chemical Carcinogenesis, and Cancer Risk in Human Populations
Polyclic Aromatic Hydrocarbons as a Model for Gene-Environment Interaction

19. Physical Factors

Ionizing Radiation
Ultraviolet Light
Radiofrequency and Microwave Radiation
Electromagnetic Fields
Asbestos
Nanoparticles

20. Dietary Factors

Methodologic Challenges
The Role of Individual Food and Nutrients in Cancer Etiology
Other Foods and Nutrients
Dietary Patterns
Diet During Early Phases of Life
Summary
Limitations

DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology has been acclaimed by the worldwide medical community as the standard-setting oncology reference. Its primary goal is to present the practicing oncologist with the practical as well as cutting-edge information needed to ensure the best possible care for each individual patient. The hallmark of this book from its inception and a major reason it has gained worldwide acceptance as the definitive source of cancer information has been its approach to the treatment of cancer patients by stage of presentation with a tightly coordinated description of the role of each treatment modality in the care of individual patients.

To ensure a balance multidisciplinary approach, a surgeon, a medical oncologist, and a radiation oncologist author each of the major treatment chapters. Each of the major treatment sections is preceded by an updated, brief chapter describing the molecular biology of that cancer and the prospects this new information holds for the improved management of cancer patients. Greater emphasis has been given in recent editions to the increasing importance of molecular biology and cancer screening and prevention, as well as palliative care, supportive oncology and quality of life issues.

Book Features

Cutting edge information on the science and practice of oncology
Discusses in detail the growing importance of prevention, early screening, and quality of life issues for cancer patients
Exhaustive coverage of combined modality cancer treatment
Greater emphasis on the increasing role of biologic therapy in the treatment of cancer
Over 300 1st rate contributors
The single, most comprehensive oncology reference ever published

New in this edition

NEW 11 new chapters
NEW 25% new 4-color illustrations
NEW completely revamped art program with new/redrawn pieces of art
NEW updates to book posted quarterly (available with purchase of print book)
NEW single volume text for greater portability

Book Details

Hardcover: 2800 pages
Publisher: Lippincott Williams and Wilkins; Ninth, North American Edition (April 25, 2011)
Language: English
ISBN-10: 1451105452
ISBN-13: 978-1451105452
Product Dimensions: 11.4 x 9.4 x 4.2 inches

List Price: $399.00

Bernier: Head and Neck Cancer: Multimodality Management

2011-04-21T06:49:00.000-07:00

Chapter 1 Epidemiology and Aetiology of Head and Neck Cancers
Chapter 2 Head and Neck Cancer Prevention
Chapter 3 Cellular and Molecular Pathology of Head and Neck Tumors
Chapter 4 Oncogenomics/Proteomics of Head and Neck Cancers
Chapter 5 Genetics and Epigenetics of Head and Neck Cancer
Chapter 6 Immunology of Head and Neck Cancer
Chapter 7 HPV and EBV in Head and Neck Cancer
Chapter 8 Head and Neck Cancer Staging and Prognosis: Perspectives of the UICC and the AJCC
Chapter 9 Biomarkers in Head and Neck Cancer
Chapter 10 Hypoxia in Head and Neck cancers: Clinical Relevance and Treatment
Chapter 11 Translational Research in Head and Neck Oncology
Chapter 12 Preclinical Models of Head and Neck Squamous Cell Carcinoma
Chapter 13 Morphologic Investigations in Head and Neck Cancer
Chapter 14 Ultrasound Investigations in Head and Neck Cancer Patients
Chapter 15 Functional Imaging
Chapter 16 Sentinel Node Biopsy for Head and Neck Cancer
Chapter 17 Approaches to Supportive Care
Chapter 18 Intensity-Modulated Radiation Therapy for Head and Neck Cancer
Chapter 19 Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer
Chapter 20 Molecular Targeted Therapies in Head and Neck Cancer
Chapter 21 Phase I Study Methodology in Head and Neck Oncology
Chapter 22 Evidence-Based Head and Neck Oncology: Principles and Pitfalls
Chapter 23 Programs of Organ and Function Preservation
Chapter 24 Multidisciplinary Approach of Unresectable Disease
Chapter 25 Laser Endoscopic Treatment
Chapter 26 Multidisciplinary Management of Skull Base and Superstructure Tumors
Chapter 27 Multidisciplinary Management of Oral Cavity and Maxillary Sinus Cancers
Chapter 28 Management of Nasopharyngeal Carcinoma
Chapter 29 Multidisciplinary Management of Oropharynx Carcinomas
Chapter 30 Multidisciplinary Management of Hypopharyngeal Carcinoma
Chapter 31 Cancers of the Larynx: Tis, T1, T2: Evaluation and Management
Chapter 32 Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers
Chapter 33 Principles and New Approaches in Surgical Reconstruction
Chapter 34 Multidisciplinary Treatment of the Neck
Chapter 35 Postoperative Management of High-Risk Resectable Head & Neck Cancer
Chapter 36 Management of Salivary Gland Cancer
Chapter 37 Head and Neck Melanoma
Chapter 38 Cervical Lymph Node Metastases of Squamous Cell Carcinoma from an Unknown Primary Site
Chapter 39 The Management of Thyroid and Parathyroid Cancers
Chapter 40 Head and Neck Paragangliomas
Chapter 41 Treatment of the Elderly Head and Neck Cancer Patient
Chapter 42 Interstitial Radiation Therapy in Cancer of the Oropharynx and Oral Cavity
Chapter 43 Proton Beam Therapy for Head and Neck Cancer
Chapter 44 Normal Tissue Complications and Protection in Head and Neck Cancer Patients
Chapter 45 Rehabilitation of Heavily Treated Head and Neck Cancer Patients
Chapter 46 Salvage Therapy in Head and Neck Cancer Patients
Chapter 47 Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Chapter 48 Best Supportive Care for Palliative Treatment
Chapter 49 Quality of Life in Head and Neck Cancer Patients
Chapter 50 Quality Assurance of Clinical Trials in the Management of Cancer in the Head and Neck

In recent years, great advances in translational research have led to new paradigms in the treatment of cancers of the head and neck. Written by leading international physicians and investigators, this innovative multi-disciplinary book presents the most up-to-date research and clinical approaches. Coverage is given to progress in a variety of clinical settings, including programs of organ and function preservation, curative treatments, unresectable disease, adjuvant treatments in high-risk patients, and recurrent/metastatic disease.

Complementary to the techniques of surgery, radiotherapy, and systemic treatments, the authors present data on epidemiology, molecular pathology, normal tissue complications, rehabilitation, palliative care, and treatment in the elderly.

State-of-the-art functional imaging is elucidated; and the latest developments in high precision techniques in irradiation, sequencing of chemo- and radiotherapy, as well as the integration of biomolecular therapies into cytotoxic treatments are explored.

Book Details

Hardcover: 685 pages
Publisher: Springer; 1st edition (June 1, 2011)
Language: English
ISBN-10: 1441994637
ISBN-13: 978-1441994639
Product Dimensions: 10.8 x 8.4 x 1.6 inches

List Price: $239.00

Rare Hematological Malignancies (Cancer Treatment and Research Series)

2011-04-20T08:15:00.000-07:00

Advances in diagnostic techniques and therapeutic modalities have brought about significant progress in the management of many hematologic malignancies. For the practicing clinician these changes are occurring at a rapid rate and it is difficult to keep informed of all the new information. Therefore, most physicians focus on the major diagnostic and therapeutic changes in common cancers, and it is often a challenge to stay up to date on the advances in the less common malignancies. Furthermore, it is difficult to find the new information in a timely fashion when seeing patients with an uncommon or unusual hematologic malignancy. In this book, data on rare hematologic malignancies have been assembled to provide a concise resource for practicing oncologists.
Each chapter provides information on the biology of the various rare hematologic diseases but also focuses on the latest therapeutic advances. Because of the paucity of clinical trials in most of these diseases, the authors have not only summarized the literature but also provided their own expertise regarding management of patients.

This book will be helpful to physicians seeing patients with uncommon hematologic malignancies, and will also be of benefit to patients by providing the treating physicians with recommendations concerning the optimal management of diseases that are uncommonly seen in their practice.

Contents
1 Polycythemia Vera and Other Polycythemia Syndromes
2 Primary Myelofi brosis
3 Essential Thrombocythemia
4 Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome
5 Chronic Myelomonocytic Leukemia
6 The 5q– Syndrome
7 Rare Acute Leukemias
8 Hairy Cell Leukemia
9 Waldenstrom’s Macrogloblinemia/ Lymphoplasmacytic Lymphoma
10 Rare B-cell Lymphomas: Primary Mediastinal, Intravascular, and Primary Effusion Lymphoma
11 Lymphomatoid Granulomatosis
12 Posttransplant Lymphoproliferative Disorders
13 Castleman Disease
14 Rare T-Cell Lymphomas
15 CD30+ Diseases: Anaplastic Large-Cell Lymphoma and Lymphomatoid Papulosis
16 Nodular Lymphocyte Predominant Hodgkin’s Lymphoma
17 Langerhans Cell Histiocytosis
18 Systemic Mastocytosis
Index

Product Details

Hardcover: 443 pages
Publisher: Springer; 1 edition (December 10, 2007)
Language: English
ISBN-10: 038773743X
ISBN-13: 978-0387737430
ASIN: 038773743X

List Price: $159.00

Cell-Extracellular Matrix Interactions in Cancer

2011-04-19T08:06:00.000-07:00

Cancer is a term used for diseases that affect any organ in the body, in which abnormal cells divide in an uncontrolled manner and in some instances are able to invade other tissues. Cancer is not just one disease, but many diseases with origins in multiple different organ systems. The defining abnormality in cancer is an imbalance between cell proliferation and death and is caused by mutations in DNA that code for proteins that regulate these cellular processes. Genes that promote cell growth in tumors are called proto-oncogenes, while tumor suppressor genes code for proteins that mediate antiproliferation signals and suppress mitosis and cell growth. Upregulation of proto-oncogenes and/or downregulation of tumor suppressor genes are a common event in cancer.
Cells do not exist in isolation and require interactions with extracellular matrix (ECM) components in order to undergo normal morphogenesis with respect to organogenesis. ECM, which is composed of large macromolecules (e.g., collagens, fibronectin, laminins) and polysaccharides (e.g., glycosaminoglycans such as hyaluronan), plays a significant role in regulating numerous cellular functions including cell shape, adhesion, migration, proliferation, polarity, differentiation, and apoptosis.

In physiological conditions, ECM levels are tightly regulated by a fine balance between synthesis and degradation. However, in pathological conditions, such as cancer, both increased synthesis of certain ECM components (i.e., collagens, fibronectin, and laminins) and/or increased breakdown with consequent generation of ECM cleavage products (i.e., laminin- or collagen-cleavage products) can contribute to cancer growth and progression. Finally, the observation that many growth factors (i.e., FGF, VEGF) are stored in the ECM milieu and released upon protease-dependent cleavage further confirms the importance of ECM in regulating cell functions.
Cells interact with ECM via a family of transmembrane receptors, known as integrins. These receptors are not only important for cells to adhere on ECM, but are also important regulators of cell signaling that controls cell processes such as proliferation, apoptosis, and migration. These signals are either transduced via the integrins upon binding to ECM components or by a crosstalk between integrins and growth factor receptors. Both integrins and growth factor receptors have been shown to bind either directly and/or indirectly with numerous signaling and scaffolding molecules that have been linked to oncogenesis.
The overall goal of this book is to describe how ECM creates a niche for tumor formation and the contribution of ECM components and their respective receptors in the development and spread of cancer.

Contents
1 The Extracellular Matrix: An Overview
2 Integrin Structure and Function
3 Cancer in Context: Importance of the Tumor Microenvironment
4 Basement Membrane Collagens and Cancer
5 Laminins and Cancer Progression
6 Fibronectins and Their Receptors in Cancer
7 Vitronectin-Binding Integrins in Cancer
8 The Function of SPARC in Tumor Cell Biology: SPARC as a Modulator of Cell-Extracellular Matrix Interaction
9 Proteoglycans and Cancer
10 Tetraspanins in Cancer
11 The Role of Integrin-Linked Kinase in Cancer Development and Progression
12 Focal Adhesion Kinase with the Interacting Proteins and Signaling in Cancer
Index

Product Details

Hardcover: 314 pages
Publisher: Springer; 1st edition (December 14, 2009)
Language: English
ISBN-10: 1441908137
ISBN-13: 978-1441908131

List Price: $159.00

ESMO Handbook of Cancer in the Senior Patient

2011-04-18T08:11:00.000-07:00

The European Society for Medical Oncology (ESMO) is to be complimented for having decided to dedicate an issue of its “Handbook” series to geriatric oncology. The International Society for Geriatric Oncology (SIOG) has been happy to help in the task of developing this volume, which was initiated by Dirk Schrijvers, Branko Zakotnik, Riccardo Audisio, Hendrik van Halteren, Arti Hurria, and the undersigned. This handbook is not only for Europeans. Cancer is a disease related to ageing, and the proportion of senior patients increases worldwide. While the proportion of persons beyond age 70 is still small in developing countries, their numerous population means that there are more “elderlies” in India than in Europe.
The authors have done a major effort in providing in record time chapters that truly reflect the state of the art in the management of senior adults with cancer. Many questions in this advancing field need considerable work before adequate guidelines can be provided. Nevertheless, progress is being made and is reflected by the contributions.
Some diseases have not been discussed and interesting topics have not been addressed. This gap is filled by more comprehensive books, and today’s electronic communications allow one to explore any area of interest easily.
The treatment of any patient requires a careful evaluation of the person who is in need of such treatment. This is even truer for the seniors, who have less reserves to cope with cancer and its treatment. Therefore, this handbook leaves ample space for chapters that help in the delicate decisionmaking process, which should lead to the best therapy, adapted not only to the disease but also to the person who suffers from it. Annals of Oncology, the official journal of ESMO, and the soon-to-belaunched Journal of Geriatric Oncology, official journal of SIOG, will keep us updated, as will all major medical journals.

Contents
Chapter 1 Introduction
Defining the Elderly
Biology of Aging and Changes in Organ Function
Changes in Cognition
Cancer and Aging
Clinical Aspects
Chapter 2 Cancer Epidemiology
Introduction
Population Demographics
Cancer Demographics
Society-Related Problems
Chapter 3 Evaluation of the Senior Cancer Patient: Comprehensive Geriatric Assessment and Screening Tools for the Elderly
Introduction
Short Screening Tools
The Vulnerable Elders Survey
MGA Packages
Chapter 4 Frailty in the Elderly
Frailty in the Elderly
The Impact of Frailty on Cancer
Assessment of Frailty
Conclusion
Further Reading
Chapter 5 Surgical Treatment
Introduction
Indications for Surgery
Patients Selection
Outcomes
Survival
Palliation
Side Effects
Chapter 6 Radiotherapy in the Elderly Cancer Patient
Indications for Radiotherapy in the Elderly
Side Effects of Radiotherapy in the Elderly (Acute and Late)
Efficacy and Outcome of Radiotherapy in the Aging
Palliative Setting: Toxicity and Efficacy Ratio
Curative Setting: Combinations of Chemotherapy and Radiotherapy
Selection Criteria for Radiotherapy in the Elderly
Chapter 7 Hormonal Anticancer Treatment in the Senior Cancer Patient
Introduction
Breast Cancer
Prostate Cancer
Chapter 8 Cytotoxic and Targeted Anticancer Treatment in the Senior Cancer Patient
Introduction
Chemotherapy in Senior Adults
Targeted Therapies in Senior Adults
Further Reading
Chapter 9 Treatment of Lymphoma in the Elderly Population
Introduction
Diagnosis and Prognosis
Treatment
Chapter 10 Management of Myeloproliferative Diseases in Senior Patients
Diagnosis and Classification of Myeloproliferative Disorders
Treatment Strategies of MPD in the Senior Patient
Chapter 11 Myelodysplastic Syndromes in the Senior Patient
The Relevance of Myelodysplastic Syndromes in the Elderly
Classification and Risk Scoring in MDS
Age-Adjusted Models and Assessment in Elderly MDS Patients
Treatment Options in Elderly MDS Patients
Future Perspectives
Chapter 12 Breast Cancer in the Senior Patient
Introduction
Early Breast Cancer
Metastatic Breast Cancer
Chapter 13 Lung Cancer in the Elderly
Introduction
Early Non–Small Cell Lung Cancer in the Elderly
Advanced Non–Small Cell Lung Cancer in the Elderly
Small Cell Lung Cancer in the Elderly
Palliative Treatment in Elderly Lung Cancer Patients
Chapter 14 Colorectal Cancer
Introduction
Adjuvant Chemotherapy
Metastatic Disease
Chapter 15 Prostate Cancer
Introduction and General Background
Treatment of Localized Prostate Cancer in Senior Adult Patients
Treatment of Metastatic Prostate Cancer in Senior Adult Patients
Chapter 16 Bladder Cancer
Incidence and Mortality
Etiology and Risk Factors
Pathology
Natural History and Tumor Biology
Signs and Symptoms
Imaging, Cystoscopy, and Urinary Cytopathology
Staging
Treatment of NMIBC
Surgical Treatment
Radiotherapy
Organ-Sparing Treatments
Systemic Chemotherapy
Prognosis of BC
Follow-Up
Chapter 17 Gynecological Cancer in the Senior Patient
Introduction
Cervical Cancer
Uterine Cancer
Special Types of Endometrial Malignancy
Vaginal Cancer
Vulvar Cancer
Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Chapter 18 Head and Neck Cancer in the Elderly
Introduction
Surgery
Radiotherapy
Chemotherapy
Targeted Therapies
Chapter 19 Renal Cell Cancer
Introduction
Surgery in the Senior Cancer Patient
Systemic Therapy of Metastatic Renal Cell Carcinoma in the Senior Cancer Patient
Patient-Focused Approach
Conclusion
Further Reading
Chapter 20 Psychological Problems in Older Cancer Patients
Introduction
Depression
Anxiety
Chapter 21 Social and Ethical Aspects
Introduction
Respect
Admiration
Attention
Information
Protection
Diagnosis
Care
Time
Caution
Freedom
Further Reading
Chapter 22 The Role of the Multidisciplinary Team
Introduction
The Assessment of Age
Polypharmacy
Management of the Caregiver
Function of the Team
Index

Product Details

Authors: Dirk Schrijvers, Matti Aapro, Branko Zakotnik and Riccardo Audisio
Paperback: 168 pages
Publisher: Informa Healthcare; 1 edition (May 15, 2010)
Language: English
ISBN-10: 1841847097
ISBN-13: 978-1841847092
Product Dimensions: 7.2 x 4.8 x 0.5 inches

List Price: $100.00

Suba: Estrogen Versus Cancer

2011-04-17T05:50:00.000-07:00

Oral Cancer is a neoplasm with a fairly large male to female ration in most populations. Moreover, it develops in older age in females in comparison with males, and the ration of non-smokers, non-drinkers among elderly female oral cnacer cases if suprisingly high. The conspicuously lower incidence of this tumor among women than men is suggestive of certain endocrine involvement in its development. There are no available literary data as yet which would give an explantion to this gender specific incidence of oral cancer. Oral cancer is a multicasual disease and there are thorough interrelationships among the etiologic factors. Till now, exogenous harmful noxae (tobacco, alcohol comsumption and energy rich diet) were overemphasized in its epidemology. However, these exogenous factors have not only local carcinogenic effect in the oral cavity, but also induce systemtic changes by means of metabolic and hormonal pathways. With full knowledge of these correlations, isolated investigations of exogenous risk factors may be misleading.
Nowadays, all anticancer agents have severe, toxic effects, killing the hemopoetic cells and thoroughly suppressing the immune system of the patient. One of our old dreams may come true with recognition of the anticancer capacity of estrogen. This new panacea is ideal for cancer cure as it has regulatory effects on cell proliferation and opposes growth factor activities. Moreover, it has beneficial effects on the altered metabolic processes and at the same time is capable of strengthening the immune system. The theory, which reveals the anticancer capacity of estrogen, may cut a small pathway in the jungle of cancer research. Hopefully, within a few years it will be widened to a highway on which many clinicians and researchers will rush to reach higher levels in prevention and cure of cancer.
This book containing the author's results on oral cancer raises a new concept concerning tumor initiation. Not estrogen, but its deficiency may provoke malignant transformation. This new theory may explain many controversial literary data concerning the associations of female sexual steroids and maliginancies.

Contents
Chapter 1 Global Trends in Oral Cancer Epidemiology in the XXth Century

Traditional Risk Factors for Oral Cancer
Controversial Changes in Oral Cancer Epidemiology
Oral Cancer: Morbus Hungaricus in the XXIst Century
Epidemiological Changes of Oral Cancer Incidence over a 20-Year
Calendar Period in Hungary
Evaluation of the Epidemiological Changes in Oral Cancer Incidence in Hungary
Necessity to Search for Further Cancer Risk Factors

Chapter 2 Insulin Resistance, Hyperinsulinemia and Cancer Risk

Correlation of Metabolic Syndrome (Insulin Resistance Syndrome) with Cancer Risk
Hyperinsulinemia and Cancer Risk
Insulin-Like Growth Factors and Cancer Risk
Hyperglycemia and Cancer Risk
Visceral Obesity and Cancer Risk
Dyslipidemia and Cancer Risk
Hypertension, Insulin Resistance and Cancer Risk
Dietary Habits, Insulin Resistance and Cancer Risk
Physical Activity, Insulin Resistance and Cancer Risk
Darkness, Melatonin, Insulin Resistance and Cancer Risk
Tobacco Use, Insulin Resistance and Cancer Risk
Alcohol Consumption, Insulin Resistance and Cancer Risk
Aging, Insulin Resistance and Cancer Risk
Importance of Associations between Insulin Resistance and Cancer Risk

Chapter 3 Hyperglycemia, Type-2 Diabetes and Cancer Risk

Hyperglycemia and cancer risk
Expression of Glucose Transporters (GLUTs) and Oral Cancer Risk
Non-enzymatic Glycation of Different Structures in type-2 Diabetes and Oral Cancer Risk
Overexpression of Matrix Metalloproteinases and Oral Cancer Risk
Altered Inflammatory Reactions in Type-2 Diabetes and Oral Cancer Risk
Altered Immunologic Reactions in type-2 Diabetes
Type-2 Diabetes and Risk for Oral Precancerous Lesions
Type-2 Diabetes and Cancer Risk
Epidemiological Associations of Diabetes Mellitus and Risk for Oral Cancer in Hungary
Correlations between Diabetes and Risk of Oral Premalignant and Malignant Lesions
Correlations of Type-2 Diabetes and Progression of Oral Cancer
Type-2 Diabetes and Prognosis of Oral Cancer

Chapter 4 The Role of Estrogen in Health and Disease

Biological Effects of Sexual Steroids
Advantageous Biological Effects of Estrogen
Cardiovascular Complications in Premenopausal Women with Type-2
Diabetes and in Postmenopausal Cases
Androgens, Cardiovascular Diseases and Cancer Risk
Female Longevity and its Sources
Hormonal Influences on Longevity and Cancer Risk
Literary Data Supporting the Carcinogenic Capacity of Estrogen
Assumed Carcinogenic Capacity of Estrogen Based on Animal Experiments
Epidemiological Data Suggesting Carcinogenic Capacity of Estrogen in Humans
Assumptions for the Mechanism of Estrogen Carcinogenicity
Controversial Associations of Hormone Replacement Therapy and Cancer Risk
Revision of Results Concerning Carcinogenic Capacity of Estrogen
Physiologically Elevated Level of Female Sexual Steroids in Humans

Chapter 5 Estrogen Deficiency as Cancer Risk Factor

Gender Related Risk Factors for Oral Cancer: Estrogen Deficiency and Elevated Fasting Glucose (Hungarian Case-Control Study)
Systemic Risk Factors for Oral Cancer
Estrogen Deficiency as Cancer Risk
Molecular Mechanisms of Estrogen Action
Estrogen Receptors and Their Actions
Actions of Estrogen and ERs on Nonclassical Target Tissues
Cross Talk between Receptor Signals of Estrogen and Growth Factors
Estrogen Receptors and Human Cancers

Chapter 6 Re-evaluation of the Epidemiological Associations of Female Sexual Steroids and Cancer Risk

Risk Factors for Highly Hormone Related Cancers
Shortcomings of Studies on Correlations of HRT Use and Cancer Risk
Selection of Patients for HRT Studies
Dynamics of Cancer Growth and Length of the Observational Period
Awareness of Estrogen Receptor Positivity of Cancers
Anticancer Capacity of HRT Use in Several Organs
Estrogen Deficiency and Cancer Risk in Postmenopausal Women
Moderate Estrogen Deficiency and Cancer Risk in Premenopausal Women
Bewildering Differences between Cancer Epidemiology of Highly and Moderately Estrogen Sensitive Organs
Extraovarian Estrogen Synthesis
Risk of Antiestrogen Therapy for Postmenopausal Women with ER-positive Breast Cancer
Estrogen Deficiency in Men

Chapter 7 Insulin Resistance, Estrogen Deficiency and Cancer Risk

Clinical Associations between Estrogen Deficiency and Insulin Resistance
Molecular Mechanism of Estrogen Effect on Glucose Metabolism
Effects of Estrogen on Lipid Metabolism
Effects of Insulin on Steroid Hormone Production and on their Signals at Receptor Level
Increased Cancer Risk of Insulin Resistance among Women as Compared with Men
Increased Cancer Risk of Insulin Resistance among Postmenopausal as Compared with Premenopausal Cases
Importance of Combined Insulin Resistance and Estrogen Deficiency as Cancer Risk

Chapter 8 Hormonal and Metabolic Risk Factors for Oral Cancer among Nonsmoker, Non-drinker Women

Case-control Study of Non-smoker, Non-drinker Women with Oral Cancer in Hungary
Risk Factors for Oral Cancer other than Tobacco and Alcohol
Questions to be Answered in Oral Cancer Epidemiology
Metabolic and Hormonal Associations of Hypothyroidism
Similar Mechanisms of Genomic and Nongenomic Actions of Thyroid and Steroid Hormones

Epilogue: Conclusions for Cancer Prevention, Cure and Research
Index

Product Details

Hardcover: 180 pages
Publisher: Nova Science Pub Inc; 1 edition (October 2008)
Language: English
ISBN-10: 1604569492
ISBN-13: 978-1604569490
Product Dimensions: 10.2 x 7.2 x 0.7 inches

List Price: $89.00

Haddad: Multidisciplinary Management of Head and Neck Cancer

2011-04-16T10:10:00.000-07:00

Chapter 1 Role of HPV Infections in Head and Neck Cancer
Chapter 2 State of the Art in Radiation Oncology in the Multidisciplinary Treatment of Head and Neck Cancer
Chapter 3 Molecularly Targeted Agents in Recurrent, Metastatic Squamous Cell Carcinoma of the Head and Neck
Chapter 4 Induction Chemotherapy in Locally Advanced Head and Neck Cancer: An Evolving Concept
Chapter 5 Endoscopic Head and Neck Surgery: The Impact of Minimally Invasive Surgery Within Multidisciplinary Care
Chapter 6 Incorporating Novel Agents With Chemotherapy and Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Chapter 7 Concurrent Chemoradiotherapy in Head and Neck Cancer
Chapter 8 Multidisciplinary Management of Thyroid Cancer
Chapter 9 Evaluation and Treatment of Dysphagia and Aspiration in Head and Neck Cancer
Chapter 10 Functional Imaging of Head and Neck Cancer with Positron Emission Tomography
Chapter 11 Diagnostic and Therapeutic Advances in Multidisciplinary Care for Nasopharyngeal Cancer
Index

Head and neck cancer is a very common cancer worldwide with an estimated 500,000 individuals diagnosed each year. In the United States an average of 39,000 new cases are reported each year representing between 3 to 5% of all new cancer cases diagnosed annually. Head and neck cancers are more common in men and in individuals over the age of 50.

The treatment of head and neck cancer is extremely challenging and involves insight and expertise from multiple disciplines. Multidisciplinary Management of Head and Neck Cancer is a comprehensive textbook looking at different aspects of head and neck cancer, including the diagnosis, treatment and outcomes for patients with this disease. The chapters written by world-renowned experts cover the entire discipline of head and neck oncology and include discussion of the role of HPV infections, advances in radiotherapy, new surgical techniques, novel agents in thyroid therapy and more. The book is designed to be both practical and comprehensive for the physicians treating this complex disease.

Features of Multidisciplinary Management of Head and Neck Cancer include:

A chapter on the role of HPV infections in head and neck cancer
A chapter on new advances in radiotherapy for head and neck cancer, including review IMRT, new standards and potential pitfalls
Detailed discussion of the role of chemotherapy in head and neck cancer, including commonly used drugs and how to combine them with radiotherapy to improve patient outcomes
Detailed discussion on incorporating novel agents with radiotherapy
Detailed discussion of novel therapeutics in head and neck cancer, including new drugs and biologics.

Book Details

Hardcover: 208 pages
Publisher: Demos Medical Publishing; First edition (December 15, 2010)
Language: English
ISBN-10: 1933864559
ISBN-13: 978-1933864556
Product Dimensions: 10 x 7 x 0.6 inches

List Price: $85.00

Shaw: Nutrition and Cancer

2011-04-15T09:04:00.000-07:00

The role of nutrition in cancer treatments should not be underestimated; within a clinical setting, carefully considered nutritional options can help to control cachexia, the patient's ability to cope with treatments such as chemotherapy and the ability to recover from invasive surgery.
Edited by Dr Clare Shaw, Head of Rehabilitation Research at the Royal Marsden Hospital, Nutrition and Cancer Care takes an unrivalled look at this prevalent disease, offering the reader:

A practical guide to good nutrition and dietetic practice in cancer care
A detailed look at nutritional options for different diagnostic groups and disease states
Contributions from a wide range of cancer specialists

An excellent resource for dietitans, clinical nutritionists, doctors, nurses and other health professionals working with cancer patients this book is also a fascinating reference for students and researchers with an interest in the area.

Contents
1 Cancer in the twenty-first century
2 Cancer and nutritional status
3 Treatment of cancer
4 Effect of malnutrition on cancer patients
5 Nutrition screening
6 Nutritional requirements of patients with cancer
7 The psychosocial influences of food choices made by cancer patients
8 Nutritional support for the cancer patient
9 Late effects of cancer treatment in adult patients
10 Nutrition and palliative care
11 Head and neck cancer
12 Nutrition in upper gastrointestinal cancer
13 Cancers of the lower gastrointestinal tract 255
14 Gynaecological cancer
15 Haemato-oncology
16 Paediatric oncology
17 Nutrition and breast cancer
18 Nutritional management in prostate cancer
19 Lung cancer
Index.

Product Details

Paperback: 416 pages
Publisher: Wiley-Blackwell; 1 edition (January 4, 2011)
Language: English
ISBN-10: 1405190426
ISBN-13: 978-1405190428
Product Dimensions: 9.5 x 6.6 x 0.9 inches

List Price: $57.99

Cell Cycle Deregulation in Cancer (Contemporary Cancer Research Series)

2011-04-14T05:55:00.000-07:00

Modern studies of regulation of the cell division cycle were pioneered by Leland Hartwell, Paul Nurse, and Tim Hunt in yeast and marine invertebrates. This work identified proteins termed cyclins that fluxuate in abundance during progression through the cycle and partner with Cyclin dependent kinases (Cdks) to drive major cell cycle transitions. Much has been learned since about how these and other proteins control cell cycle progression in all eukaryotes, including man. Further research is uncovering how these controls are de-regulated in cancer, a disease of unbridled cell proliferation that is the leading cause of death in developed countries. However, there is much more to be learned, and the hard won gains are just beginning to impact cancer care. In 11 reviews by leading experts, this volume lays out the current state and directions of the field for biomedical scientists of all training levels.
The collection begins with three reviews that delineate how cells initiate the cell cycle, from growth factor stimulation to activation of key transcription programs and origins of DNA replication.

The next three reviews address issues of proliferation under duress, including how derangement of mitotic checkpoints can lead to cell death or genetic instability and how recycling of intracellular molecules (autophagy) is regulated. The next three reviews address the special context of long-term proliferation—how it is regulated in stem cells, how it can erode telomeric structures on the tips of chromosomes, and how it can culminate in senescence. The last two reviews describe how cell cycle advances are beginning to touch patients, in the characterization of pre-malignant states and in cancer therapy.

Contents
Part I Starting the Cell Division Cycle
1 Escape from Cellular Quiescence
2 Interplay Between Cyclin-Dependent Kinases and E2F-Dependent Transcription
3 Regulation of Pre-RC Assembly: A Complex Symphony Orchestrated by CDKs
Part II Proliferation Under Duress
4 Mitotic Checkpoint and Chromosome Instability in Cancer
5 Mitotic Catastrophe
6 p53, ARF, and the Control of Autophagy
Part III Long-Term Proliferation
7 Regulation of Self-Renewing Divisions in Normal and Leukaemia Stem Cells
8 Maintenance of Telomeres in Cancer
9 The Senescence Secretome and Its Impact on Tumor Suppression and Cancer
Part IV Applications in Preventing and Treating Cancer
10 Cell Cycle Deregulation in Pre-neoplasia: Case Study of Barrett’s Oesophagus
11 Targeting Cyclin-Dependent Kinases for Cancer Therapy
Index

Book Details

Hardcover: 206 pages
Publisher: Springer; 1st edition (March 22, 2010)
Language: English
ISBN-10: 1441917691
ISBN-13: 978-1441917690
Product Dimensions: 10.3 x 6.4 x 0.7 inches

List Price: $189.00

Myeloma Bone Disease (Current Clinical Oncology)

2011-04-13T09:09:00.000-07:00

This state-of-the-art book presents the forefront in the science and clinical management of myeloma bone disease. Assembling the work of the world's premier thought leaders, this book begins with sections on clinical presentation, imaging, and biochemical markers and then goes on to discuss radiation, surgical, and medical therapies.
Specific chapters are devoted to bisphosphonates and novel therapeutic agents, such as RANKL inhibitors, Wnt signaling inhibitors, and IMiDs. The mechanisms of osteoclast activation and osteoblast suppression in multiple myeloma are also explored.
Myeloma Bone Disease is a valuable resource for medical, surgical, and radiation oncologists and cancer researchers.

Contents
1. Clinical presentation of myeloma bone disease (MBD)
2. Imaging of myeloma bone disease
3. Bone Markers in MBD
4. Radiation therapy for MBD
5. Surgical treatment (kyphoplasty, vertebroplasty and standard surgery)
6. Pathophysiology of MBD
7. Osteoclast activation in MBD
8. Osteoblast Suppression in MBD
9. Animal models of MBD
10. Bisphopsphonate treatment of MBD
11. Osteonecrosis of the jaw in myeloma
12. Novel therapies for MBD (Denosumab, velcade and imids)

Book Details

Hardcover: 252 pages
Publisher: Humana Press; 1st edition (May 4, 2010)
Language: English
ISBN-10: 1607615533
ISBN-13: 978-1607615538
Product Dimensions: 9.3 x 6.3 x 0.8 inches

List Price: $219.00

Clinical Nutrition for Oncology Patients

2011-04-12T09:00:00.000-07:00

Clinical Nutrition for Oncology Patients provides clinicians with the information they need to help cancer survivors and patients make informed choices about their nutrition and improve their short-term and long-term health. This comprehensive resource outlines nutritional management recommendations for care prior to, during, and after treatment and addresses specific nutritional needs and complementary therapies that may be of help to a patient. This book is written by a variety of clinicians who not only care for cancer survivors and their caregivers but are also experts in the field of nutritional oncology.

Contents
Chapter 1 Introduction to the Nutritional Management of Oncology Patients
Chapter 2 Nutrition Screening and Assessment in Oncology
Chapter 3 Nutrition Support for Oncology Patients
Chapter 4 Medical and Radiation Oncology
Chapter 5 Surgical Oncology
Chapter 7 Esophageal and Head and Neck Cancer
Chapter 8 Breast Cancer
Chapter 9 Reproductive Cancers
Chapter 10 Prostate Cancer
Chapter 11 Lung Cancer
Chapter 12 Hematologic Malignancies
Chapter 13 Brain Tumors
Chapter 14 Palliative Care
Chapter 15 Pharmacologic Management of Cancer Cachexia-Anorexia and Other Gastrointestinal Toxicities Associated with Cancer Treatments
Chapter 16 Integrative Oncology
Index 447

Product Details

Hardcover: 475 pages
Publisher: Jones & Bartlett Publishers; 1 edition (April 1, 2009)
Language: English
ISBN-10: 0763755125
ISBN-13: 978-0763755126
Product Dimensions: 9.1 x 6.1 x 1.3 inches

List Price: $88.95

Kelsen: Principles and Practice of Gastrointestinal Oncology 2nd Edition

2011-04-11T08:55:00.000-07:00

As a group, gastrointestinal malignancies are the most common cause of cancer in the world. A recent review indicated that, of the 10.8 million people in the world each year who develop cancer, approximately 3.3 million have gastrointestinal malignancies, including esophagogastric cancer, colorectal, hepatocellular, and pancreatic malignancies. In comparison, lung cancer occurs in approximately 1.4 million people each year and breast cancer in 1.2 million women per year. Furthermore, gastrointestinal malignancies are one of the most lethal malignancies. Twenty-nine percent of cancer-related deaths are caused by gastrointestinal cancers. Particularly for esophagogastric cancer, hepatocellular, and pancreatic cancer, the annual incidence and annual mortality are very similar. Prevention, early diagnosis, and improved therapy are urgently needed in gastrointestinal malignancies.
Although the incidence of gastrointestinal cancers varies substantially between different regions of the world, there is considerable overlap in their cause and in the strategies pursued for improvement in outcome. Some gastrointestinal malignancies should be nearly totally preventable, such as hepatocellular carcinoma secondary to cirrhosis from viral hepatitis or alcohol abuse and anal canal cancer secondary to infection with human papilloma virus. In both of these diseases, the development of vaccines against the infectious agent that leads eventually to the malignancy should markedly decrease the incidence of cancer. Proof of principle has already been demonstrated for hepatocellular cancer using vaccines against hepatitis B. In the case of colorectal cancer, removal of a premalignant lesion should prevent the development of subsequent cancer.
If the tumor cannot be prevented, finding it at an earlier stage also improves outcome. This has been demonstrated for colorectal cancer as well as for upper gastrointestinal tract malignancies such as gastric cancer. On the other hand, for some tumors, including pancreatic cancer, the etiology of the disease is less clear, although some progress has been made. Screening and surveillance programs have not yet been adequately developed, and the majority of patients with gastrointestinal malignancies present with extensive and frequently metastatic cancers.
Since the publication of the first edition of this book, there have been important advances in understanding the cause and pathogenesis of gastrointestinal malignancies, a far better understanding of the molecular events leading to the development of these cancers, some improvements in surveillance and screening, and improvements in therapy. From the pathogenesis point of view, colorectal cancer is a model for understanding the neoplastic process from the development of an adenoma through increasing degrees of dysplasia and carcinoma. Better preclinical models, such as genetically engineered mouse models, hold promise for an improved understanding of gastrointestinal malignancies, including such difficult-to-access tumors as pancreatic cancer. Rapid advances in molecular biology (including the sequencing of the human genome) and the development of high through-put systems hold promise for the development of better prognostic and predictive markers in the individual patient.
This second edition of Principles and Practices of Gastrointestinal Oncology is a comprehensive, in-depth review of the commonest group of human cancers. The editors and the chapter authors represent an international group of experts who are leaders in their respective fields. They have helped develop current standards of care and direct many important research initiatives. The book features an introductory section that reviews the principles of modern oncology, including both basic and translational science points of view. The principles underlying individual disciplines—including surgery, radiation, medical oncology, diagnostic imaging, and epidemiology—are presented as they apply to gastrointestinal cancers.
The second portion of the book is an updated, in-depth review of gastrointestinal malignancies from the prospective of each individual organ. Each site-specific section features chapters that focus on epidemiology, molecular biology and pathology, prevention (including screening and surveillance), staging, and therapeutic options for that individual tumor site. The chapters are current and include the results of recent important clinical trials that may have either changed the standard of care or demonstrated that an important research initiative did not substantially change outcome. In general, the site-specific chapters dealing with clinical management are multi-authored by experts in appropriate disciplines, including medical, radiation, and surgical oncology.
This new edition of Principles and Practices of Gastrointestinal Oncology will be useful to all physicians, practitioners, and scientists who have an interest in gastrointestinal malignancies. Our understanding of gastrointestinal cancer is changing rapidly, and we hope that the book provides a readable and in-depth presentation of the most current information available to help our colleagues in the management of patients with cancer of the gastrointestinal tract.

Contents
PRINCIPLES OF GASTROINTESTINAL ONCOLOGY

Gastrointestinal Cancer: Epidemiology
Gastrointestinal Cancer: Pathology
Gastrointestinal Cancer: Cancer Genetics
Gastrointestinal Cancer: Screening and Surveillance
Gastrointestinal Cancer: Surgical Oncology
Gastrointestinal Cancer: Radiation Oncology
Gastrointestinal Cancer: Medical Oncology
Gastrointestinal Cancer: Nutritional Support
Imaging of Gastrointestinal Malignancies
Endoscopic Diagnosis, Staging, and Management of Gastrointestinal Cancers
An Overview of Outcomes Research in Gastrointestinal Cancer
Integrative Oncology: Complementary Therapies in GI Cancer Care
Pain and Symptom Control

ESOPHAGEAL CANCER

Esophageal Cancer: Epidemiology, Screening, and Prevention
Esophageal Cancer: Molecular Biology and Genetics
Esophageal Cancer: Pathology
Esophageal Cancer: Anatomy and Staging
Esophageal Cancer: Clinical Management

GASTRIC CANCER

Gastric Cancer: Epidemiology, Screening, Surveillance, and Prevention
Gastric Cancer: Molecular Biology and Genetics
Gastric Cancer: Pathology
Gastric Cancer: Staging Systems and Techniques
Gastric Cancer: Clinical Management

PANCREAS CANCER

Pancreas Cancer: Epidemiology and Risk Factors
Pancreatic Cancer: Molecular Biology and Genetics
Pancreas Cancer: Anatomy, Staging Systems and Techniques
Pathology of Pancreatic Cancer
Pancreas Cancer: Clinical Management

HEPATOCELLULAR CANCER

Hepatocellular Carcinoma: Epidemiology, Screening, and Prevention
Hepatocellular Carcinoma: Molecular Biology and Genetics
Hepatocellular Cancer: Pathology
Hepatocellular Cancer: Anatomy and Staging
Hepatocellular Cancer: Clinical Management

CANCERS OF THE BILIARY TREE

Cancer of the Gallbladder and Biliary Tree: Epidemiology
Pathology of Biliary Tract Cancer
Cancers of the Biliary Tree: Anatomy and Staging
Cancers of the Biliary Tree: Clinical Management

COLORECTAL CANCER

Environmental and Lifestyle Issues in Colorectal Cancer
Colorectal Cancer: Screening and Prevention
Colorectal Cancer: Molecular Biology and Genetics
Colorectal Cancer: Pathology
Colorectal Cancer: Anatomy and Staging
Colon Cancer: Management of Locoregional Disease
Rectal Cancer: Management of Local and Regional Disease
Systemic Therapy for Metastatic Colorectal Cancer
Colorectal Cancer: Surgery and Local Ablation of Liver Metastases

UNCOMMON CANCERS OF THE GASTROINTESTINAL TRACT

Anal Canal Cancer
Neuroendocrine Tumors of the Gastrointestinal Tract
Primary Gastric and Intestinal Lymphomas
Gastrointestinal Stromal Tumors
Small Bowel Cancers
Cancer of Unknown Primary Site
Malignant Peritoneal Mesothelioma

Product Details

Hardcover: 1008 pages
Publisher: Lippincott Williams & Wilkins; Second edition (October 29, 2007)
Language: English
ISBN-10: 0781776171
ISBN-13: 978-0781776172

List Price: $225.95

Hemangiomas and Vascular Malformations: An Atlas of Diagnosis and Treatment

2011-04-10T05:39:00.000-07:00

Hemangiomas and Vascular Malformations: An Atlas of Diagnosis and Treatment will be a practical approach to the world of vascular tumors. The complexity of this world is related to the heterogeneity of clinical manifestations, necessitating multi-disciplinary competences in order to achieve a correct diagnosis and treatment. The complexity of the clinical manifestations is approached by introducing a clear classification of hemangiomas and vascular malformations. For both issues, diagnostic imaging and therapeutic procedures are presented. Laser, interventional radiological and surgical techniques are explained according to the type of vascular tumor and its localization.
After the introduction, the book is divided in three parts on hemangiomas, vascular malformations, and treatment according to specific localizations. The chapters are extremely well done, with images and graphics of high quality. The pictures and radiographic images provide an outstanding atlas for the diagnosis of vascular malformations. The editors and contributors are leaders in the treatment of these pathologies.
The book is addressed to all professionals who meet vascular tumors in their daily clinical practice and need up-to-date references for these pathologies.

Contents
Part I Introduction
1 Angiogenesis
2 Historical Background
Part II Hemangiomas
3 Hemangiomas of Infancy: Epidemiology
4 Classification of Infantile Hemangiomas and Other Congenital Vascular Tumors
5 Diagnosis of Hemangiomas
6 Visceral Hemangiomas
7 Principles of Therapy of Infantile Hemangiomas and Other Congenital Vascular Tumors of the Newborns and Infants
8 Medical Treatment of Hemangiomas
9 Laser Therapy of Infantile Hemangiomas and Other Congenital Vascular Tumors of Newborns and Infants
10 Surgery of Hemangiomas
11 Facial Hemangiomas
12 Anogenital Hemangiomas
Part III Vascular Malformations
13 Genetic Aspects of Vascular Malformations
14 Epidemiology of Vascular Malformations
15 Classification of Vascular Malformations
16 Non Invasive Diagnostics of Congenital Vascular Malformations
17 Nuclear Medicine in Diagnostics of Vascular Malformations
18 Invasive Diagnostics of Congenital Vascular Malformations
19 Principles of Treatment of Vascular Malformations
20 Interventional Therapy in Arteriovenous Congenital Malformations
21 Diagnosis and Management of Soft Tissue Vascular Malformations with Ethanol
22 Sclerotherapy in Vascular Malformations
23 Laser Therapy of Vascular Malformations
24 The Combined Treatment of Arteriovenous Malformations
25 Multidisciplinary Surgical Treatment of Vascular Malformations
26 Treatment of Arterial Malformations
27 Treatment of Arteriovenous Malformations
28 Treatment of Venous Malformations
29 Treatment of Lymphatic Malformations
30 Treatment of Vascular Malformations in Newborns and Infants
Part IV Treatment Problems According to Specific Localizations
31 Introductory Remarks
32 Management of Head and Neck Vascular Malformations: an Overview
33 Surgical Treatment of Vascular Malformations in the Hand
34 Management of Vascular Malformations in the Thorax Wall
35 Joint Involvement in Patients with Vascular Malformations. Destructive Angiodysplastic Arthritis
36 Surgical Approach to Congenital Vascular Malformations in the Foot
37 Diagnosis and Management of Vascular Malformations of Bone
38 The Role of Syndromes
Conclusions
Subject Index

Product Details

Hardcover: 336 pages
Publisher: Springer; 1 edition (April 6, 2009)
Language: English
ISBN-10: 884700568X
ISBN-13: 978-8847005686
Product Dimensions: 10.9 x 7.9 x 0.8 inches

List Price: $169.00

Johns Hopkins Patients' Guide to Leukemia

2011-04-09T05:32:00.000-07:00

Johns Hopkins Patients' Guide to Leukemia is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining leukemia treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman s terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

About The Series
Learning that you or someone you love has cancer is devastating, and feeling lost and powerless is a common immediate response. The Johns Hopkins patients’ guides are designed to alleviate your anxiety, empower you with information, and enable you to fully understand your treatment options. Each book in this series is dedicated to a specific type of cancer. The information is there to help lighten your burden and to assist you in becoming an active participant in your care. Cancer rarely allows us to take a diversion from life, and offering guidance on how to continue to live life while.
Product Details

Paperback: 172 pages
Publisher: Jones & Bartlett Learning; 1 edition (August 6, 2010)
Language: English
ISBN-10: 0763774332
ISBN-13: 978-0763774332
Product Dimensions: 8 x 5.3 x 0.6 inches

List Price: $19.95

Atlas of Neoplastic Pulmonary Disease: Pathology, Cytology, Endoscopy and Radiology

2011-04-08T05:31:00.000-07:00

PART I Tumors of Childhood

Chapter 1 Lymphangiomatosis
Chapter 2 Pleuropulmonary Blastoma
Chapter 3 Congenital Pulmonary Myofibroblastic Tumor

PART II Benign Epithelial Tumors

Chapter 4 Alveolar Adenoma
Chapter 5 Uncommon Endobronchial Surface Tumors

PART III Salivary Gland Tumors (Benign andMalignant)

Chapter 6 Mucous Gland Adenoma
Chapter 7 Pleomorphic Adenoma
Chapter 8 Mucoepidermoid Tumor
Chapter 9 Adenoid Cystic Carcinoma 4

PART IV Mesenchymal Tumors (Benign and Malignant)

Chapter 10 Inflammatory Polyps
Chapter 11 Inflammatory Pseudotumor
Chapter 12 Pulmonary Chondroma
Chapter 13 Pulmonary Hamartoma
Chapter 14 Localized Fibrous Tumor
Chapter 15 Lipomas and Liposarcomas
Chapter 16 Cystic Lymphangioma
Chapter 17 Lymphangio-leiomyomatosis
Chapter 18 Epithelioid Hemangio-endothelioma
Chapter 19 Pulmonary Artery Sarcoma
Chapter 20 Synovial Sarcoma

PART V Lymphoid Neoplasms

Chapter 21 Marginal Zone B-Cell Lymphoma (Maltoma)
Chapter 22 Diffuse Large B-Cell Lymphoma
Chapter 23 Lymphomatoid Granulomatosis
Chapter 24 Langerhans Cell Histiocytosis

PART VI Carcinoid Tumors

Chapter 25 Typical and Atypical Carcinoids

PART VII Miscellaneous Tumors

Chapter 26 Teratoma
Chapter 27 Melanoma
Chapter 28 Thymoma
Chapter 29 Glomus Tumor of the Lung
Chapter 30 Sclerosing Hemangioma

PART VIII Preinvasive Disease

Chapter 31 Preinvasive Disease

PART IX Common Major Malignant Epithelial Tumors

Chapter 32 Squamous Cell Carcinoma
Chapter 33 Adenocarcinoma
Chapter 34 Large Cell Carcinoma
Chapter 35 Small Cell Carcinoma

PART X Less Common Malignant Epithelial Tumors

Chapter 36 Adenosquamous Carcinoma
Chapter 37 Bronchioloalveolar Carcinoma
Chapter 38 Large Cell Neuroendocrine Carcinoma
Chapter 39 Sarcomatoid Carcinoma
Chapter 40 Pulmonary Blastoma

PART XI Metastatic Tumors

Chapter 41 Metastatic Tumors

Subject Index

The diagnosis of lung cancer and benign pulmonary tumors can be challenging. This diagnosis can be facilitated by the study of images that allow recognition of patterns of disease, both at the clinical and pathologic levels. Conceptually defined, atlases are specialized books that rely heavily upon images to illustrate any subject matter.

Fitting with such a concept, this atlas was developed to fill a void in the approach to diagnosis. In contrast to previous conventional atlases, this atlas is unique in that images from four major disciplines (endoscopy, radiology, histopathology, and cytopathology) involved in the study and diagnosis of lung tumors are brought together in a single volume.

This book had two objectives:

(1) to illustrate the common while not ignoring the esoteric by recognizing the need to cover some entities that may only infrequently cross the paths of the practitioner; and
(2) to provide a quick, reliable tool that may facilitate diagnosis through recognition of images using an interdisciplinary approach. To achieve these aims, the authors have selected and put forward images that in our opinion best represent the tumor entities.

The atlas is organized into 11 parts containing 41 chapters, closely following the 2004 Classification of Lung Tumors by theWorld Health Organization (WHO).

Accordingly, the chapters represent a wide range of neoplastic lung entities. It begins with tumors of children followed by sections on benign epithelial tumors, salivary gland tumors, mesenchymal neoplasms, lymphoproliferative disorders, cardcinoid tumors, and a section of miscellaneous tumors. The atlas further includes a chapter on WHO-recognized variants of pre-invasive lung disease, major epithelial malignancies, and concludes with a chapter on metastatic lung tumors.

This book is a useful, state-of-theart work that will educate trainees and guide and support the best efforts of practitioners managing lung tumors.

Book Details

Hardcover: 176 pages
Publisher: Springer; 1st edition (January 11, 2010)
Language: English
ISBN-10: 0387898387
ISBN-13: 978-0387898384
Product Dimensions: 11 x 8.4 x 0.6 inches

List Price: $229.00

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care

2011-04-05T03:10:00.000-07:00

Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide. This tumor, which is a major health problem worldwide, has stimulated the energy of several disciplines. The liver is a massive and complex organ requiring an excellent knowledge of its anatomy and physiology, with an exquisite comprehension of its impact on cardiovascular, pulmonary, and renal function. Because early detection is rare, the overall prognosis is generally poor. Understanding of the etiology, epidemiology, pathophysiology, molecular biology, and clinical features of HCC is important in providing optimal patient care. In addition, understanding of the limitations of our current knowledge and therapeutic capabilities is essential in order to guide future research efforts. Management of patients with HCC is necessarily a multidisciplinary effort which involves the skill of radiologists, pathologists, gastroenterologists, anesthesiologists, surgeons, medical oncologists, radiation oncologists, nurses, and other health professionals.
Initially, the treatment of HCC was limited to surgical approaches with liver resection being the only option with curative intent. The development of HCC in chronic liver disease was associated with a high risk of technical difficulties and a high morbidity/mortality rate. This has challenged liver surgeons to improve their knowledge regarding liver anatomy, assessment of liver function, use of intraoperative imaging, tolerance of vascular clamping, and better anticipation of postoperative liver recovery. As shown in several chapters of this book, progress in liver surgery for HCC has expanded its development, yielding a true specialty. Imaging of liver parenchyma was motivated by two different goals including an efficient screening along with an accurate evaluation of the tumor in a background of abnormal parenchyma.

Interventional radiology was initially focused on the treatment of this tumor with substantial technical advances allowing an efficient destruction of larger tumors. In parallel, radiologists developed transarterial chemoembolization and radioembolization. Those two locoregional approaches can stabilize the tumors, allowing in some cases for subsequent resection or transplantation. These multiple therapeutic approaches have contributed to expand the indications for liver transplantation, which remains the best curative treatment for limited HCC in patients with advanced chronic liver disease. However, this luxury treatment is restricted to very few countries, with a discrepancy between the increasing number of candidates and the limited number of grafts. Therefore, there is a considerable need for alternative treatments which are extensively developed in this textbook. There is no efficient treatment without an accurate comprehension of the development of HCC. Beyond viral infections of the liver, the role of other potential causes is emphasized in an important chapter. There is no doubt that etiologies of HCC will not be considered similarly in the future, given more attention to both environmental and chronic medical conditions. These emerging factors, such as metabolic syndrome, will probably highlight future targets relevant to the screening of high-risk patients.
The chapter on staging of HCC is very comprehensive. As such, J.N. Vauthey dedicated a great part of his initial studies to the stratification of patients with similar prognostic factors. The ongoing debate on transplant candidates confirms that stratification of patients is a prerequisite before considering any therapeutic modalities.
Indeed, our clinical experience shows that HCC is often a heterogeneous disease with variable outcomes. The chapter on pathologic considerations confirms that HCC has multiple histological components which will be clarified in the future by molecular classifications.
The last chapters of this remarkable book highlight that management of patients with HCC relies necessarily upon multidisciplinary effort involving the skills of radiologists, pathologists, oncologists, gastroenterologists, hepatologists, anesthesiologists, hepatobiliary, and transplant surgeons. In addition, these specific areas of knowledge and experience are guided by the important innovations from Asian countries and efficiency of medical treatment to an increasing degree. Of note in this book, supervised by eminent US authors, an entire chapter is devoted to the guidelines for treatment in Japan. Sorafenib has been approved as a standard of care for advanced HCC. Several studies evaluating other antiangiogenic agents and multi-target inhibitors are at various phases of their development with promising results. However, the most fascinating forthcoming issue will be the appropriate combination of medical treatment with surgical and radiological procedures.
The improvement of resectability and survival observed in patients with colorectal liver metastasis treated by novel active chemotherapy was a major therapeutic step. Recent results in HCC strongly support that similar expectations might be achieved to improve outcome by including neoadjuvant or adjuvant therapy.
This book is dedicated to the researchers, clinicians, and support staff involved in the fight against HCC, with admiration and appreciation for the work that is done every day to prevent, detect, and treat this disease.

Contents
1 Epidemiology and Pathogenesis of Hepatocellular Carcinoma
2 Biology of Hepatocellular Carcinoma
3 Hepatocellular Cancer: Pathologic Considerations
4 Screening Program in High-Risk Populations
5 Staging of Hepatocellular Carcinoma
6 Multidisciplinary Care of the Hepatocellular Carcinoma Patient
7 Evidence-Based Guidelines for Treatment of Hepatocellular Carcinoma in Japan
8 Hepatocellular Carcinoma Arising in the Non-viral, Non-alcoholic Liver
9 Liver Resection for Hepatocellular Carcinoma
10 Ultrasound-Guided Liver Resection for Hepatocellular Carcinoma 11 Portal Vein Embolization Prior to Resection
12 Laparoscopic Liver Resection for HCC: A European Perspective
13 Laparoscopic Liver Surgery for the Management of Hepatocellular Carcinoma: The American Perspective
14 Liver Transplant for Hepatocellular Carcinoma
15 Vascular Resection for Hepatocellular Carcinoma
16 Radiofrequency Ablation for Hepatocellular Carcinoma
17 Microwave Ablation and Hepatocellular Carcinoma
18 Transarterial Chemoembolization
19 Chemoembolization with Drug-Eluting Beads
20 Yttrium-90 Radioembolotherapy for Hepatocellular Cancer
21 Cytotoxic Chemotherapy and Endocrine Therapy for Hepatocellular Carcinoma
22 Targeted Therapies for Hepatocellular Carcinoma
23 The Future: Combination Systemic Therapy for Hepatocellular Carcinoma
24 Follow-Up and Salvage Therapy for Recurrent Hepatocellular Carcinoma
Index

Product Details

Hardcover: 415 pages
Publisher: Springer; 1st edition (December 2, 2010)
Language: English
ISBN-10: 1603275215
ISBN-13: 978-1603275217
Product Dimensions: 9.1 x 6.1 x 1.1 inches

List Price: $219.00

Hammer: Adrenocortical Carcinoma: Basic Science and Clinical Concepts

2011-04-01T16:02:00.000-07:00

Adrenocortical carcinoma (ACC) is a disease that most physicians, including many endocrinologists, will rarely, if ever, diagnose or let alone treat during the course of their medical practice. Medical textbooks of endocrinology and oncology rarely dedicate an entire chapter to this disease entity. The pursuit of research and clinical excellence in uncommon diseases is extremely challenging because of a lack of research prioritization, nonexistent treatment guidelines and overall paucity of coordination between researchers and physicians. ACC is one such disease where no infrastructure for a unified research agenda and no consensus treatment guidelines had been developed.
While a number of international meetings over the past two decades have indeed focused on adrenal tumors in the context of hormone excess (Cushing’s syndrome, hyperaldosteronism, and pheochromocytoma), few have exclusively catered to the science and clinical care of ACC and those afflicted with the disease. With only a single FDA-approved drug for ACC (mitotane – a derivative of the pesticide DDT), institutional experiences varied widely until recently when historic biases have slowly yielded to data-driven treatment strategies. A large part of the impetus for this push has come from Europe, where the availability of country-wide integrated networks for treatment has allowed a small number of centers in Italy, France, and Germany (among others) to develop specific expertise and specific treatment protocols for this rare disease.
In an attempt to facilitate coordination of global efforts, a consensus conference was organized and held at the University of Michigan in September 2003. At that meeting, an international group of physicians and scientists with research interest and clinical expertise in ACC set up initial guidelines for the diagnosis and treatment of ACC. Three principles emerged. Successful treatment of ACC demands coordinated care in the context of a multidisciplinary team dedicated to the disease. Future therapies for ACC need to be predicated on hypothesis-driven research based on a thorough analysis of tumor biology. Lastly, major advancement in the field demands national and international collaborative networks to facilitate analysis of large datasets and coordinate future clinical trials. The FIRM-ACT (First International Randomized Trial in locally advanced and Metastatic Adrenocortical Cancer Treatment) that coordinated over 35 ACC centers in a single multinational trial set precedence for the actualization of these principles. The Second International Adrenal Cancer Symposium: Clinical and Basic Science held at the University of Michigan in March 2008 built upon the momentum of the 2003 consensus meeting and the successful development of a large international ACC network through the FIRM-ACT trial.
As opposed to a solitary review article, a textbook with multiple chapters dedicated to discrete topics in the field provides contributors the opportunity to objectively review historic data and detail the current state of clinical care and research accomplishments. While this is a major advantage of a textbook, it is also a major challenge for a book that focuses solely on a rare cancer where data are scant. Each individual chapter covers well established knowledge in the area, but also allows room for expert opinion. Lastly, because ACC has been linked to several genetic disorders that usually escape discussion in a focused review of adrenal tumors, the various syndromes will be discussed in their entirety in separate chapters. The 32 Chapters of the 9 Sections are authored by the scientific and clinical leaders in the field. The overall goal of this book is therefore to provide definitive reference material for scientists and clinicians, to introduce trainees to concepts of ACC management, and to stimulate further research, future collaborations, and networking.

Contents
Part I History of Adrenocortical Carcinoma Research and Clinical Care
1 The History of Adrenocortical Carcinoma Treatment – A Medical Perspective
2 The History of Adrenocortical Carcinoma Treatment – A Surgical Perspective
Part II Epidemiology, Presentation and Diagnosis
3 Epidemiology of Adrenocortical Carcinoma
4 Clinical Presentation and Initial Diagnosis
5 Diagnostic Approach to Incidentaloma
Part III Imaging
6 Computed Tomography/Magnetic Resonance Imaging of Adrenocortical Carcinoma
7 Functional Imaging of Adrenocortical Carcinoma
Part IV Pathology
8 Classical Histopathology and Immunohistochemistry
9 Cellular and Molecular Pathology of Adrenocortical Carcinoma
Part V Genetic and Molecular Aspects
10 Overview of Genetic Syndromes Associated with Adrenocortical Cancer
11 Li–Fraumeni Syndrome
12 TP53 Molecular Genetics
13 Telomeres and Telomerase in Adrenocortical Carcinoma
14 Beckwith–Wiedemann Syndrome
15 The Insulin-Like Growth Factor System in Adrenocortical Growth Control and Carcinogenesis
16 WNT/ß-Catenin Signaling in Adrenocortical Carcinoma
Part VI Models of Adrenocortical Cancer
17 Adrenocortical Stem and Progenitor Cells: Implications for Cancer
18 Adrenocortical Cell Lines
19 Mouse Models of Adrenal Tumorigenesis
Part VII Therapies
20 Overview of Treatment Options for Adrenocortical Carcinoma
21 Chemotherapy
22 Mitotane
23 Pharmacotherapy for Hormone Excess in Adrenocortical Carcinoma
24 Surgery for Adrenocortical Carcinoma
25 Radiation Therapy for Adrenocortical Carcinoma
26 Follow-Up and Monitoring of Adrenocortical Carcinoma
Part VIII Unique Cohorts and Future Perspectives
27 Aldosterone-Producing Adrenocortical Carcinoma
28 Adrenocortical Cancer in Children
29 Genome-Wide Studies in Adrenocortical Neoplasia
30 New Strategies for the Treatment of Adrenocortical Carcinoma
Part IX Adrenal Cancer Networks and Registries
31 The Dutch Adrenal Network
32 The ENS@T Initiative
Index

Product Details

Hardcover: 546 pages
Publisher: Springer; 1st edition (November 24, 2010)
Language: English
ISBN-10: 0387772359
ISBN-13: 978-0387772356
Product Dimensions: 9.2 x 6.2 x 1.5 inches

List Price: $209.00

Chabner: Cancer Chemotherapy and Biotherapy: Principles and Practice 5th Edition

2011-03-24T01:01:00.000-07:00

Section 1: BASIC PRINCIPLES OF CANCER TREATMENT

1: Clinical Strategies for Cancer Treatment: The Role of Drugs
2: Target Identification and Drug Discovery
3: Clinical Drug Development and Approval for Marketing
4: Principles of Pharmacokinetics
5: Special Aspects of Brain Tumor Chemotherapy
6: Pharmacogenetics
7: Barriers to Drug Delivery

Section 2: CYTOTOXIC AGENTS

8: Antifolates
9: Fluoro-pyrimidines
10: Cytidine Analogues
11: Purine Analogues
12: Hydroxyurea
13: Antimitotic Drugs
14: Alkylating Agents (Including Methylating Agents)
15: Platinum Analogues
16: Antitumor Antibiotics (Including Bleomycin)
17: Topoisomerase I Inhibitors
18: Topoisomerase II Inhibitors: Anthracyclines
19: Topoisomerase II Inhibitors: Etoposide, Teniposide
20: L-Asparaginase

Section 3: MOLECULARLY TARGETED THERAPIES

21: Proteosome Inhibitors
22: HDAC Inhibitors
23: Differentiating Agents (Retinoids)
24: Arsenic Trioxide
25: Monoclonal Antibodies: Discovery & Development
26: Anti-angiogenic Agents (Including MonAB)
27: Anti-EGFR Therapies (Including MonAB)
28: Anti-her 2 Therapies
29: Intracellular Signal Inhibitors (bcr-abl)
30: Signal Transduction Inhibitors in Development
31: Inhibitors of the PI3k Pathway & Mitotic Kinase

Section 4: IMMUNOLOGIC AGENTS

32: Interferon and Cytokines
33: Vaccines
34: Adoptive Cellular Therapies
35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)

Section 5: HORMONAL THERAPY

36: Hormonal Therapy of Breast Cancer
37: GNRH Agonists and Anti-Androgens

Section 6: SUPPORTIVE CARE

38: Pain Management in Cancer Patients
39: Colony Stimulating Factors
40: Anti-nausea Medications
41: Bone Loss Modulators
42: Intravenous Access and Catheter Management

Section 7: SURVIVORSHIP

43: Monitoring for Late Side Effects of Chemotherapy

Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents.

Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance.

Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.

This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.

A companion website includes the fully searchable text and an image bank.

Book Details

Hardcover: 848 pages
Publisher: Lippincott Williams & Wilkins; Fifth edition (December 31, 2010)
Language: English
ISBN-10: 1605474312
ISBN-13: 978-1605474311
Product Dimensions: 11.1 x 8.7 x 1.5 inches

List Price: $225.00

Gullatte: Clinical Guide to Antineoplastic Therapy 2nd edition: A Chemotherapy Handbook

2011-03-21T00:55:00.000-07:00

Newly updated and expanded to reflect new research and clinical advances in oncology, this resource provides you with detailed information on all facets of chemotherapy administration. New to this edition are chapters on targeted therapy, chemotherapy regimens, complementary and alternative therapy, botanicals, and reimbursement issues. Also included are more than 100 detailed drug monographs on current chemotherapeutic, biotherapeutic, and hormonal agents based on current guidelines from the manufacturers and the U.S. Food and Drug Administration. Whether in the classroom or clinical setting, this new edition is a must-have!

About the Author
Mary Magee Gullatte comes with more than 29 years of oncology nursing experience and is currently the associate chief nursing officer of the Oncology Ambulatory Treatment Centers for the Emory Crawford Long Hospital of Emory Healthcare in midtown Atlanta. She is an accomplished author and is editor of Nursing Management: Principles and Practice, a 2005 American Journal of Nursing Book of the Year winner in the leadership and management category.

Contents

Chapter 1.	Cellular Mechanisms of Chemotherapy	1
	Overview	1
	Normal and Malignant Cell Growth	1
	Immunology: Host Defense	3
	Histology of Cancer	6
	Cancer Physiology	7
	Goals of Chemotherapy	7
	Cell Phase Specificity	8
	Tumor Response Criteria	9
	Factors Affecting Chemotherapy Response	9
Chapter 2.	Pharmacologic Principles of Chemotherapy	13
	Overview	13
	Treatment Goals	21
	Cell-Cycle Response of Chemotherapy	21
	Alkylating Agents	22
	Toxicity of Alkylating Agents	23
	Antimetabolities	23
	Antitumor Antibiotics	25
	Biologic Agents	25
	Hormones	26
	Plant Alkaloids	27
Chapter 3.	Principles and Standards of Chemotherapy Administration	31
	Introduction	31
	Preparation and Administration	34
	Chemotherapy Protective Agents	35
	Routes of Chemotherapy Administration	35
	Safe Handling and Disposal	40
	Latex Sensitivity	41
	Patient and Significant Other Education and Support	42
Chapter 4.	Vascular Access Devices	47
	Introduction	47
	Brief History of Vascular Access Devices	47
	Central Venous Catheters	48
	Implanted Ports and Reservoirs	52
	Peripherally Inserted Central Catheters	54
	Alternative Administration Devices	55
	Ambulatory Infusion Pumps	64
	Pertinent Documentation for All Vascular Access Devices	65
	Patient/Family Education Regarding Vascular Access Devices	67
	Liability Issues and the Role of the Oncology Nurse	67
	Research Questions	67
Chapter 5.	Antineoplastic Agents	71
	History	71
	Principles of Chemotherapy	71
	Classification	71
	Chemotherapy (A-Z)	72
	Abbreviations used in Chapter 5	74
	Chemotherapeutic Agents	75
	Hormonal Therapies	227
	Biotherapeutics	255
Chapter 6.	Legal Issues in Chemotherapy Administration	281
	Source of Laws	281
	Nursing Liability	283
	Liability Issues for Nurses	285
	Clinical Trials	288
	Liability Regarding Chemotherapy Administration	289
Chapter 7.	Symptom Management	297
	Nausea and Vomiting	297
	Mucositis	304
	Taste Changes	307
	Fatigue	307
	Pain	311
	Bone Marrow Suppression	313
Chapter 8.	Clinical Trials	321
	Institutional Review Boards	322
	Drug Development Process	322
	Informed Consent	325
	Educational Resources	326
Chapter 9.	Psychosocial Support of the Patient Receiving Chemotherapy	329
	Social Support Theory	329
	Support of Patient and Caregivers	331
	Systems Theory for Support Group Development	334
	Support Groups	335
	Cancer Survivorship Issues	337
Chapter 10.	Public and Professional Cancer Resources	351
	Public Resources	351
	Professional Resources and Organizations	355
	Funding Sources	358
	Patient and Professional Information Resources on the World Wide Web	359
	Cancer Statistics	361
	Index	363

Product Details

Paperback: 688 pages
Publisher: Oncology Nursing Society; 2nd edition (July 2, 2007)
Language: English
ISBN-10: 1890504688
ISBN-13: 978-1890504687
Product Dimensions: 9.1 x 5.9 x 1.7 inches

List Price: $108.00

Chemotherapy and Biotherapy Guidelines and Recommendations for Practice 3rd Edition

2011-03-20T00:54:00.000-07:00

Order your copy of the third edition of the best-selling resource used by more than 72,000 healthcare professional. Edited by Martha Polovich, Julie M. Whitford, and MiKaela Olsen, this new edition has been revised and updated to reflect the current procedures and practices in your specialty.

Featured are sections detailing principles of :

antineoplastic therapy,
cancer therapy goals and response,
fundamentals of administration,
pretreatment, treatment and post-treatment care,
side effects of cancer therapy,
immediate complications of cytotoxic therapy,
and more.

Also included are :

treatment schedules, including dose category and determination, as well as nursing and chemotherapy flow charts,
information on safe management of chemotherapy in the home,
clinical practicum and evaluations,
and much, much more.

Product Details

Spiral-bound: 376 pages
Publisher: Oncology Nursing Society; 3 Spi edition (April 2009)
Language: English
ISBN-10: 1890504815
ISBN-13: 978-1890504816
Product Dimensions: 11.2 x 9.5 x 1.2 inches
Editor: Martha Polovich, Julie M. Whitford, MiKaela Olsen

List Price: $80.00

Khan: The Physics of Radiation Therapy

2011-03-19T07:00:00.000-07:00

Dr. Khan's classic textbook on radiation oncology physics is now in its thoroughly revised and updated Fourth Edition. It provides the entire radiation therapy team—radiation oncologists, medical physicists, dosimetrists, and radiation therapists—with a thorough understanding of the physics and practical clinical applications of advanced radiation therapy technologies, including 3D-CRT, stereotactic radiotherapy, HDR, IMRT, IGRT, and proton beam therapy. These technologies are discussed along with the physical concepts underlying treatment planning, treatment delivery, and dosimetry.
This Fourth Edition includes brand-new chapters on image-guided radiation therapy (IGRT) and proton beam therapy. Other chapters have been revised to incorporate the most recent developments in the field. This edition also features more than 100 full-color illustrations throughout.
A companion Website will offer the fully searchable text and an image bank.

Contents
PART I: Basic Physics
1 Structure of Matter Chapter
2 Nuclear Transformations Chapter
3 Production of X-rays Chapter 4 Clinical Radiation Generators
5 Interactions of Ionizing Radiation
6 Measurement of Ionizing Radiation
7 Quality of X-ray Beams
8 Measurement of Absorbed Dose
PART II: Classical Radiation Therapy
9 Dose Distribution and Scatter Analysis
10 A System of Dosimetric Calculations
11 Treatment Planning I: Isodose Distributions
12 Treatment Planning II: Patient Data, Corrections, and Setup
13 Treatment Planning III: Field Shaping, Skin Dose, and Field Separation
14 Electron Beam Therapy Chapter 15 Brachytherapy
16 Radiation Protection
17 Quality Assurance
18 Total Body Irradiation
PART III: Modern Radiation Therapy
19 Three-Dimensional Conformal Radiation Therapy
20 Intensity-Modulated Radiation Therapy
21 Stereotactic Radiosurgery
22 High-Dose-Rate Brachytherapy
23 Prostate Implants
24 Intravascular Brachytherapy
25 Image-Guided Radiation Therapy
26 Proton Beam Therapy
Appendix
Index

Product Details

Hardcover: 592 pages
Publisher: Lippincott Williams & Wilkins; Fourth edition (May 15, 2009)
Language: English
ISBN-10: 0781788560
ISBN-13: 978-0781788564
Product Dimensions: 11.1 x 8.5 x 1 inches

List Price: $210.00

Radiotherapy in Practice - Imaging

2011-03-18T07:20:00.000-07:00

Imaging is a critical component in the delivery of radiotherapy to patients with malignancy, and this book teaches the principles and practice of imaging specific to radiotherapy. Introductory chapters outline the basic principles of the available imaging modalities including x-rays, ultrasound, CT, MR, nuclear medicine, and PET. Site specific chapters then cover the main tumor sites, reviewing optimal imaging techniques for diagnosis, staging, radiotherapy planning, and follow-up for each site. Chapters are co-authored by oncologists and radiologists specializing in a specific area to provide an authoritative view on the role of imaging in the patient's journey and examples of relevant images are provided throughout. The important areas of radiation protection, exposure justification, and risks, are also comprehensively covered, exploring issues such as balancing radiation exposure with long-term risks of radiation effects, such as second cancer induction.

Contents

1 Introduction
2 Principles of imaging
3 Breast
4 Lung and thorax
5 Lymphoma
6 Oesophageal tumours
7 Gastric tumours
8 Hepatic and biliary tumours
9 Pancreatic tumours
10 Gastrointestinal stromal tumours
11 Rectal cancer
12 Anal cancer
13 Urological cancers
14 Gynaecological cancers
15 Head and neck cancers
16 Central nervous system
17 Connective tissue (soft tissue sarcoma)
18 Endocrine tumours
19 Skeletal tumours
20 Paediatrics
21 Imaging for common complications
22 Radiation protection issues when imaging patients for radiotherapy
Index

About the Author

Peter Hoskin qualified at the Royal Free Hospital and, after junior posts in general medicine in London, trained in clinical oncology at the Royal Marsden Hospital. He currently has a busy clinical practice focusing on urological and gynaecological malignancies and lymphomas. He also directs a research programme through UCL developing and evaluating functional imaging in oncological practice. Professor Hoskin is series editor of the OUP series, Radiotherapy in Practice. Vicky Goh qualified in medicine at Cambridge and, after junior posts in general medicine, went on to train in radiology in London, and completed a fellowship in cross-sectional imaging in Toronto, Canada. She has a busy clinical practice with a special interest in imaging gastrointestinal and thoracic malignancies. Her area of research is on developing and evaluating functional imaging techniques.

Product Details

Paperback: 336 pages
Publisher: Oxford University Press, USA; 1 edition (March 19, 2010)
Language: English
ISBN-10: 019923132X
ISBN-13: 978-0199231324
Product Dimensions: 9.1 x 6.1 x 0.8 inches

List Price: $79.95

Radiologic Science for Technologists: Physics, Biology, and Protection 9th Edition

2011-03-17T07:15:00.000-07:00

Develop the skills and knowledge to make informed decisions regarding technical factors and diagnostic imaging quality with this highly detailed, vibrantly illustrated, full-color resource. Updated with the latest advances in radiologic science, this new edition addresses a broad range of radiologic disciplines, providing a strong foundation in the study and practice of radiologic physics, imaging, radiobiology, radiation protection, and more. Unique learning tools strengthen your understanding of key concepts, and challenging review exercises help you prepare for success on the ARRT certification exam and in the workplace.

Book Features

Quick-reference guides printed on colored end sheets provide easy access to frequently used formulas, conversion tables, abbreviations, and more.
Special Math Formulas boxes and Important Concepts boxes emphasize key chapter content.
A full-color design highlights important information and clarifies concepts.
Objectives, key terms, outlines, introductions, and summaries for every chapter help you organize material and identify vital information.
Challenge Questions at the end of each chapter test your understanding of terms, concepts, and formulas with a variety of definition exercises, short answer questions, and calculations.

New in this edition

Significant chapter updates help you ensure success on the ARRT exam and keep you current with the latest practices in mammography, interventional radiology, multislice spiral computed tomography, and radiation protection.
A new chapter on The Digital Image identifies the benefits and challenges of working with digital imaging and familiarizes you with technology you'll encounter in the clinical setting.
A new Viewing the Digital Image chapter guides you through the most up-to-date viewing practices to ensure an accurate understanding.
An expanded glossary introduces important new terms common to today's practice settings.

Contents
Pt. I Radiologic Physics
1 Concepts of Radiologic Science 2
2 Fundamentals of Radiologic Science 16
3 The Structure of Matter 37
4 Electromagnetic Energy 56
5 Electricity, Magnetism, and Electromagnetism 72
Pt. II The X-Ray Beam
6 The X-ray Imaging System 100
7 The X-ray Tube 119
8 X-ray Production 138
9 X-ray Emission 151
10 X-ray Interaction With Matter 162
Pt. III The Radiograph
11 Radiographic Film 180
12 Processing the Latent Image 193
13 Radiographic Intensifying Screens 207
14 Control of Scatter Radiation 223
15 Radiographic Technique 244
16 Image Quality 272
17 Image Artifacts 297
18 Quality Control 304
Pt. IV Advanced X-Ray Imaging
19 Mammography 318
20 Mammography Quality Control 331
21 Fluoroscopy 346
22 Interventional Radiology 360
23 Multislice Spiral Computed Tomography 367
Pt. V Digital Imaging
24 Computer Science 396
25 Computed Radiography 412
26 Digital Radiography 426
27 Digital Fluoroscopy 436
28 The Digital Image 449
29 Viewing the Digital Image 466
30 Digital Display Quality Control 478
31 Digital Image Artifacts 486
Pt. VI Radiobiology
32 Human Biology 500
33 Fundamental Principles of Radiobiology 512
34 Molecular and Cellular Radiobiology 520
35 Early Effects of Radiation 534
36 Late Effects of Radiation 549
Pt. VII Radiation Protection
37 Health Physics 570
38 Designing for Radiation Protection 580
39 Patient Radiation Dose Management 597
40 Occupational Radiation Dose Management 613
Glossary 631
Illustration Credits 651

Product Details

Hardcover: 704 pages
Publisher: Mosby; 9 edition (March 4, 2008)
Language: English
ISBN-10: 0323048374
ISBN-13: 978-0323048378
Product Dimensions: 11 x 8.4 x 1.3 inches
Author: Stewart C. Bushong
List Price: $102.00

Washington: Principles & Practice of Radiation Therapy 3rd edition

2011-03-16T07:04:00.000-07:00

Unit I: Introduction

1. Cancer: An Overview
2. The Ethics and Legal Considerations of Cancer Management
3. Principles of Pathology
4. Overview of Radiobiology
5. Detection and Diagnosis
6. Radiographic Imaging
7. Treatment Delivery Equipment
8. Treatment Procedures
9. Education
10. Infection Control in Radiation Oncology
11. Assessment
12. Pharmacology and Drug Administration

Unit II: Physics, Simulation and Treatment

13. Applied Mathematics Review
14. Introduction to Radiation Therapy Physics
15. Aspects of Brachytherapy
16. Image Guided Radiation Therapy NEW!
17. Intensity Modulated Radiation Therapy NEW!
18. Radiation Safety and Protection
19. Quality Improvement in Radiation Oncology
20. Surface and Sectional Anatomy
21. Simulator Design
22. Conventional Simulation
23. CT Simulation NEW!
24. Photon Dosimetry Concepts and Calculations
25. Dose Distributions
26. Electron Beams in Radiation Therapy
27. Electronic Charting and Image Management

Unit III: Practical Applications

28. Bone, Cartilage and Soft Tissue Sarcomas
29. Lymphoreticular System
30. Leukemia
31. Endocrine System
32. Respiratory System
33. Head and Neck Cancers
34. Central Nervous System
35. Digestive System
36. Gynecological Tumors
37. Male Reproductive and Genitourinary
38. Breast Cancer
39. Pediatric Solid Tumors
40. Skin and Melanoma

App. A: Glossary
App. B: Answers to Review Questions
Index

Learn everything you need to know about radiation therapy with the only comprehensive text written for radiation therapy students by radiation therapists. Principles and Practice of Radiation Therapy is designed to help you understand cancer management, improve clinical techniques for delivering doses of radiation, and apply complex concepts to treatment planning and delivery.

This edition features enhanced learning tools and thoroughly updated content, including three new chapters to inform you of increasingly important technologies and practices. The up-to-date and authoritative coverage of this text make it a resource you'll want to consult throughout your radiation therapy courses and beyond.

Book Features

Complete coverage of radiation therapy provides all introductory content plus the full scope of information on physics, simulation, and treatment planning.
This popular and well-reviewed text continues to be regarded by many radiation therapy professionals as a strong, comprehensive, and authoritative source.
Contributions from a broad range of practitioners bring you the expertise of radiation therapists, physicians, nurses, administrators, and educators who are part of cancer management teams.

New in this edition

Chapters on image guided radiation therapy, intensity modulated radiation therapy, and CT simulation keep you up-to-date with emerging technologies.
Objectives, bulleted summaries, and spotlights join an already impressive list of pedagogical features including chapter outlines, key terms, review questions with answers, critical thinking questions, and a complete, updated glossary.
Color inserts show significant procedures and imaging technologies clearly.

About the Authors

Charles M. Washington, MBA, RT(T), FASRT, Director, Clinical Services and Operations, The University of Texas, M. D. Anderson Cancer Center, Houston, TX.
Dennis T. Leaver, MS, RT(R)(T), FASRT, Professor and Chair, Radiation Therapy Department, Southern Maine Community College, S. Portland, ME.

Book Details

Hardcover: 1008 pages
Publisher: Mosby; 3rd edition (February 2, 2010)
Language: English
ISBN-10: 0323053629
ISBN-13: 978-0323053624
Product Dimensions: 11.2 x 8.8 x 1.7 inches

List Price: $184.00

Quality and Safety in Radiotherapy (Imaging in Medical Diagnosis and Therapy)

2011-03-15T19:10:00.000-07:00

The first text to focus solely on quality and safety in radiotherapy, this work encompasses not only traditional, more technically oriented, quality assurance activities, but also general approaches of quality and safety. It includes contributions from experts both inside and outside the field to present a global view. The task of assuring quality is no longer viewed solely as a technical, equipment-dependent endeavor. Instead, it is now recognized as depending on both the processes and the people delivering the service. Divided into seven broad categories, the text covers:

Quality Management and Improvement includes discussions about lean thinking, process control, and access to services.
Patient Safety and Managing Error looks at reactive and prospective error management techniques.
Methods to Assure and Improve Quality deals broadly with techniques to monitor, assure, and improve quality.
People and Quality focuses on human factors, changing roles, staffing, and training.
Quality Assurance in Radiotherapy addresses the general issues of quality assurance with descriptions of the key systems used to plan and treat patients and includes specific recommendations on the types and frequencies of certain tests.
Quality Control: Equipment and Quality Control: Patient-Specific provides explicit details of quality control relating to equipment and patient-specific issues.

Recently, a transformation of quality and safety in radiotherapy has begun to take place. Among the key drivers of this transformation have been new industrial and systems engineering approaches that have come to the forefront in recent years following revelations of system failures. This book provides an approach to quality that is long needed, one that deals with both human and technical aspects that must be the part of any overall quality improvement program.

Contents
Part I Quality Management and Improvement

A Perspective on Quality and Safety in Radiotherapy
Quality as Viewed and Lived by the Patient
Quality Management: An Overview
Quality Management: Radiotherapy
Development and Operation of a Quality Management Program: Case Study
Methodologies for Quality Improvement
Lean Thinking and Quality Improvement
Process Control and Quality Improvement
Access to Care: Perspectives from a Private Healthcare Environment
Access to Care: Perspectives from a Public Healthcare Environment
The Cost of Quality: Health Technology Assessment
The Past, Present, and Future of Quality in Radiotherapy
Past, Present, and Future of Quality in Radiotherapy Physics

Part II Patient Safety and Managing Error

Issues in Patient Safety
An Overview of Risk Management
Tools for Risk Management
Error and Near-Miss Reporting: A View from Europe
Error and Near-Miss Reporting: A View from North America
The Impact of Cultural Biases on Safety
A Primer on High Reliability Organizing
Errors in Patient Information Flow
Identifying and Reducing Risk
A New Paradigm for Quality Management in Radiation Therapy Based on Risk Analysis
Risk Analysis and Control for Brachytherapy

Part III Methods to Assure and Improve Quality

Medical Indicators of Quality: Terminology and Examples
Medical Indicators of Quality: Structure, Process, and Outcome
The Role of Quality Audits: A View from North America
The Role of Quality Audits: A View from the IAEA
Peer Review: A Physician’s View from Australia
Peer Review: A Physicist’s View from North America
An Overview of Credentialing and Certification
An Approach to Radiation Oncology Practice Accreditation
Clinical Trials: Credentialing
Clinical Trials: Quality Assurance
The Vendor’s Role in Quality Improvement

Part IV People and Quality

The Role of Leadership
Human Factors Engineering: An Overview
Human Factors Engineering: A Radiotherapy Application
Human Factors Engineering: A Case Study
The Changing Role of the Radiation Oncologist
The Changing Role of the Medical Physicist
Staffing for Quality: Overview
Staffing for Quality: Physics
The Role of Training
Practical Aspects of Training

Part V Quality Assurance in Radiotherapy

CT Simulation
MRI and MRS Simulation
Image Registration, Fusion, and Segmentation
4D Simulation
Treatment Planning Systems
External Beam Radiotherapy
Linear Accelerator: Resource Analysis for Commissioning
Linear Accelerator: Implementation and Use
Cobalt: Implementation and Use
Superficial and Orthovoltage: Implementation and Use
Computer-Controlled and Intensity-Modulated Radiotherapy
Intensity-Modulated Volumetric Arc Radiotherapy
Four-Dimensional Treatment
Combined Planning and Delivery Systems
Proton Radiotherapy
Stereotactic Radiosurgery and Stereotactic Radiation Therapy
Total Body Irradiation
High Dose Rate Brachytherapy
Electronic Brachytherapy
Technical Guidance Documents

Part VI Quality Control: Equipment

Dosimetry Equipment and Phantoms
Conventional Simulators
Computed Tomography, Positron Emission Tomography, and Magnetic Resonance Imaging
Stand-Alone External Beam Treatment Planning Systems
Conventional Linear Accelerators
Linear Accelerator–Based MV and kV Imaging Systems
Elekta Multileaf Collimator
Varian Multileaf Collimator
Siemens Multileaf Collimator
Integrated Systems: Tomotherapy
Integrated Systems: GammaKnife
Integrated Systems: CyberKnife
Stand-Alone Localization Systems: Ultrasound
Stand-Alone Localization Systems: Transponder Systems
Stand-Alone Localization: Surface Imaging Systems
Mobile Electron Beam Intraoperative Radiation Therapy
Proton Radiotherapy
High-Dose-Rate Brachytherapy

Part VII Quality Control: Patient-Specific

External Beam Plan and MU Checks
Monte Carlo
Patient Setup
Motion Management
Total Skin Electron Therapy
Total Body Irradiation and Intensity-Modulated Total Marrow Irradiation
Tomotherapy
CyberKnife
Multileaf Collimator-Based Intensity-Modulated Radiotherapy
Compensator-Based Intensity-Modulated Radiotherapy
Cranial Stereotactic Radiosurgery and Stereotactic Radiotherapy
Stereotactic Body Radiation Therapy
Proton Radiotherapy
High-Dose-Rate Brachytherapy
Low-Dose-Rate Brachytherapy
Brachytherapy with Unsealed Sources
Intravascular Brachytherapy

Product Details

Hardcover: 643 pages
Publisher: Taylor & Francis; 1 edition (December 20, 2010)
Language: English
ISBN-10: 1439804362
ISBN-13: 978-1439804360
Product Dimensions: 11 x 8.5 x 1.7 inches
Author: Todd Pawlicki, Peter Dunscombe, Arno J. Mundt and Pierre Scalliet
List Price: $129.95

Practical Radiotherapy Planning 4th edition

2011-03-14T05:31:00.000-07:00

Planning is a critical stage of radiotherapy. Careful consideration of the complex variables involved and critical assessment of the techniques available are fundamental to good and effective practice.
First published in 1985, Practical Radiotherapy Planning has, over three editions, established itself as the popular choice for the trainee radiation oncologist and radiographer, providing the 'nuts and bolts' of planning in a practical and accessible manner.
This fourth edition encompasses a wealth of new material, reflecting the radical change in the practice of radiotherapy in recent years. The information contained within the introductory chapters has been expanded and brought up to date and a new chapter on patient management has been added. CT stimulators, MLC shieldings and dose profiles, principles of IMRT, and use of MRI, PET and ultrasound are all included, amongst other new developments in this field.
The aim of this book remains unchanged. Complexity of treatment planning has increased greatly, but the fourth edition continues to emphasize underlying principles of treatment that can be applied for conventional, conformal and novel treatments, taking into account advances in imaging and treatment delivery.

Contents
1 What you need to know before planning radiotherapy treatment 1
2 Principles of radiotherapy planning 9
3 Radiobiology and treatment planning 32
4 Organs at risk and tolerance of normal tissues 44
5 Principles of brachytherapy 54
6 Emergency and palliative radiotherapy 62
7 Skin 71
8 Head and neck: general considerations 88
9 Lip, ear, nose and treatment of the neck in skin cancer 111
10 Oral cavity 122
11 Oropharynx cancer and unknown primary tumour 134
12 Hypopharynx 146
13 Nasopharynx 156
14 Larynx 165
15 Salivary glands 177
16 Sinuses: maxilla, ethmoid and nasal cavity tumours 185
17 Orbit 196
18 Central nervous system 205
19 Thyroid and thymoma 231
20 Lung 241
21 Mesothelioma 258
22 Breast 265
23 Lymphomas 283
24 Oesophagus and stomach 294
25 Pancreas and liver 303
26 Rectum 311
27 Anus 323
28 Prostate 332
29 Bladder 351
30 Testis 359
31 Penis 365
32 Cervix 370
33 Uterus 384
34 Vagina 394
35 Vulva 401
36 Sarcoma 408
37 Paediatric tumours 415
38 Systemic irradiation 426
Appendix: List of abbreviations 433
Index 435

Product Details

Paperback: 468 pages
Publisher: Oxford University Press, USA; 4th edition (September 7, 2009)
Language: English
ISBN-10: 0340927739
ISBN-13: 978-0340927731
Author: Ann, M.D. Barrette, Jane Dobbs, Stephen Morris and Tom Roques
List Price: $59.95

Almeida: Cancer: Basic Science and Clinical Aspects

2011-02-27T04:06:00.000-08:00

This forward looking cancer biology book appeals to a wide ranging audience. Introductory chapters that provide the molecular, cellular, and genetic information needed to comprehend the material of the subsequent chapters bring unprepared students up to speed for the rest of the book and serve as a useful refresher for those with previous biology background.
The second set of chapters focuses on the main cancers in terms of risk factors, diagnostic and treatment methods and relevant current research.
The final section encompasses the immune system’s role in the prevention and development of cancer and the impact that the Human Genome Project will have on future approaches to cancer care.
While best suited to non-majors cancer biology courses, the depth provided satisfies courses that combine both majors and non-majors. Also, and deliberately, the authors have incorporated relevant information on diagnosis and treatment options that lend appeal to the lay reader.

Contents
1 The basics of cancer 1
2 Cells : the fundamental unit of life 26
3 The human genome and protein function 51
4 Cell cycle, oncogenes, and tumor suppressor genes 67
5 Tumor formation, growth, and metastasis 94
6 Cancer screening, detection and diagnostic procedures and tests 115
7 Cancer treatment modalities 135
8 Breast cancer 165
9 Ovarian cancer 189
10 Cervical cancer 206
11 Prostate cancer 224
12 Testicular cancer 247
13 Skin cancer 262
14 Lung cancer 293
15 Colorectal cancer 312
16 Leukemia and lymphoma 338
Glossary 361
Index 389

About the Author
Sheila Barry and Craig Almeida have taught the cancer biology course at Stonehill College to both majors and non-majors for several years. Discouraged by the lack of accessible and current texts, they decided to write their own.

Product Details

Paperback: 424 pages
Publisher: Wiley-Blackwell; 1 edition (January 26, 2010)
Language: English
ISBN-10: 1405156066
ISBN-13: 978-1405156066
Product Dimensions: 9.5 x 6.6 x 0.9 inches
List Price: $69.95

Pecorini: Molecular Biology of Cancer 2nd edition: Mechanisms, Targets, and Therapeutics

2011-02-26T04:03:00.000-08:00

Many of the cells in our body undergo tightly regulated replication to enable growth to occur and to ensure that damaged or worn out tissues are replaced. Regulation is mediated via many different mechanisms. It is when these mechanisms fail, and regulation is lost, that cancer can result. Recent advances in molecular cell biology have greatly expanded our understanding of the processes and mechanisms which underpin the regulation of cell replication, and what is happening at the molecular level when these fail.

Now in its second edition, The Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics gives a fresh approach to the study of the molecular basis of cancer. Written with the undergraduate student in mind, Lauren Pecorino focuses on how our understanding of the defective mechanisms which drive cancer is leading to the development of new targeted therapeutic agents.

Opening with an overview of the key hallmarks of cancer as a disease state, the book then leads us through the principal components of the regulatory machinery through which cell division is controlled and corrupted with the onset of cancer. Within each chapter, students are shown how this molecular knowledge is being applied to develop new targeted therapeutic strategies.

Ideal for courses in the molecular biology of cancer and cancer biology, The Molecular Biology of Cancer, Second Edition, is an invaluable resource for any student wishing to gain insight into the molecular basis of the disease and formulate possible solutions for its effective control.

New to this Edition

Updated research
Three brand new chapters:

"The Cell Cycle": Gives extended treatment of this central aspect of cancer biology
"Infections and Inflammation": Focuses on the relationship between infectious agents and inflammation and the onset of cancer
"The Cancer Industry": Provides an overview of the process through which drugs are developed and tested

Enhanced coverage of apoptosis
Over 25 new figures plus a new color plate section
A new "How do we know that?" feature, in which experimental methods and results are discussed, thus shedding light on how our understanding of cancer biology is developed
An extended glossary
A companion website featuring additional resources for both instructors and students:

For instructors, the site offers figures from the book available to download and a testbank of multiple-choice questions with feedback linked to the book for use in formative or summative assessment.
For students, the website features a web link library as well as hyperlinks to primary literature articles cited in the text.

Book Details

Paperback: 320 pages
Publisher: Oxford University Press, USA; 2 edition (May 6, 2008)
Language: English
ISBN-10: 0199211485
ISBN-13: 978-0199211487
Product Dimensions: 9.5 x 7.4 x 0.6 inches

List Price: $59.95

Heymann: Bone Cancer: Progression and Therapeutic Approaches

2011-02-17T22:48:00.000-08:00

The epidemiological and clinical importance of bone metastasis has long been recognized, but the past decade has seen an explosion in the fields of bone biology and bone cancer research. This period of time has been marked by a number of key discoveries that have led to the opening up of entirely new areas for investigation as well as new therapies which combine surgery and biological therapeutic approaches.
Bone is a common site of cancer metastases - cancer cells commonly develop in bone and spread to other organ systems through the bloodstream. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40% in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on a patient's quality of life and are a main cause of patient mortality.
Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for the medical and cancer research communities. This book provides, all in one resource, the most recent data on bone cancer development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases.

Book Feature

Presents a comprehensive, translational source for all aspects of bone cancer in one reference work.
Bone cancer experts (from all areas of research and practice) take readers from the bench research (cellular and molecular mechanism), through genomic and proteomic analysis, all the way to clinical analysis (histopathology and imaging) and new therapeutic approaches.
Clear presentation by bone biologists of the cellular and molecular mechanisms underlying bone tumors and bone cancer metastasis as well as the genomic and proteomic assays used in detecting cancer within given organ systems.
Clear presentation by oncologists and radiologists of how histopathology, imaging, and pain monitoring can lead to new therapeutic approaches.

Book enefit

Saves researchers and clinicians time in quickly accessing the very latest details on a broad range of bone cancer issues, as opposed to searching through thousands of journal articles.
Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system.
Correct diagnosis (and therefore correct treatment) of cancer depends on a strong understanding of the molecular basis for the disease - both oncologists and radiologists will benefit.
Bone biologists will gain insight into how clinical observations and practices can feed back into the research cycle and will, therefore, be able to develop more targeted genomic and proteomic assays.

Book Details

Hardcover: 504 pages
Publisher: Academic Press; 1 edition (September 22, 2009)
Language: English
ISBN-10: 012374895X
ISBN-13: 978-0123748959
Product Dimensions: 10.9 x 8.6 x 1.2 inches

The Cancer Degradome: Proteases and Cancer Biology

2011-02-15T00:14:00.000-08:00

The Cancer Degradome: Proteases and Cancer Biology will aim to cover recent knowledge of the composition of the Degradome, how it can be studied using modern approaches such as transcriptomics and mass spectrometry; how gene knockout mice have improved our knowledge of the roles of proteases in cancer; how their activity can be imaged both in vitro and in vivo; the links that have emerged between proteolysis and cell signalling; how the degradome can be a useful source of diagnostic and prognostic markers; and finally new approaches to targeting proteolysis for therapy.

Product Details

Hardcover: 1000 pages
Publisher: Springer; 1 edition (September 19, 2008)
Language: English
ISBN-10: 0387690565
ISBN-13: 978-0387690568
Product Dimensions: 9.3 x 6.4 x 1.9 inches

Cancer Genomics and Proteomics: Methods and Protocols (Methods in Molecular Biology)

2011-02-10T00:00:00.000-08:00

Cancer Genomics and Proteomics provides a compendium of techniques and applications in gene identification and function. The approaches described in detail are state-of-the art and can be tailored to individual ongoing or planned research projects. This volume is a valuable laboratory resource for designing experiments to identify and analyze genes that are relevant to complex biological phenomena.
Cancer Genomics and Proteomics: Methods and Protocols provides a compendium of techniques and applications that will be of profound use to researchers interested in gene identification and function. The approaches described in this volume are state-of-the-art and may be tailored to ongoing individual or planned research projects.
Reviews are written by experts in specific aspects of gene identification and full-length gene cloning, gene profiling (microarrays), chromatin modification of gene regulation, bacterial artificial chromosomes, cancer cytogenetic analyses, and gene methylation. Chapters also discuss topics such as phage display, yeast and mammalian two-hybrid systems, RNA silencing, monoclonal antibody production, kinases and signal transduction, PKR, analyses of mouse embryo fibroblasts, protein microarrays, and protein crystallization.
Cancer Genomics and Proteomics: Methods and Protocols will be of interest to molecular biologists, geneticists, cell biologists, and biochemists involved in studying genes associated with and regulating important physiological processes. This volume will serve as a valuable laboratory resource for designing experiments to identify and analyze genes that are relevant to complex biological phenomena.

Product Details

Paperback: 358 pages
Publisher: Humana Press; 1st Edition (November 19, 2010)
Language: English
ISBN-10: 1617376051
ISBN-13: 978-1617376054
Product Dimensions: 9 x 6 x 0.9 inches

Cancer Nanotechnology: Methods and Protocols (Methods in Molecular Biology)

2011-02-09T00:10:00.000-08:00

Early detection of cancer at the cellular level, even before anatomic anomalies are visible, is critical to more efficacious and cost effective diagnosis and therapeutic advances. In Cancer Nanotechnology: Methods and Protocols, an international panel of experts provide the most recent, cutting-edge, "how-to" approaches developed and employed by researchers in a variety of disciplines to identify cancer specific biomarkers, construct suitable multifunctional targeted nanostructure platforms, along with enhanced imaging and therapeutic applications. Covering such topics as multifunctional and multimodal nanoparticles, nanoparticle mediated cancer theranostics, molecular targets for cancer nanotechnology, and nanoparticles for non-invasive image-guided cancer therapy, the volume addresses the key challenges of the field today, specifically targeted and localized delivery of the drugs. As a volume in the highly successful Methods in Molecular Biology™ series, the protocols chapters include brief introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls.
Authoritative and cutting-edge, Cancer Nanotechnology: Methods and Protocols integrates cancer biology, clinical oncology, molecular cancer imaging, materials science and chemical engineering, biomedical engineering, toxicology, computer science, electrical engineering, chemistry, physics, and mathematics in order to achieve the vital goals of nanotechnology-mediated early cancer detection and more efficacious and less toxic therapies for these devastating diseases.

Product Details

Hardcover: 366 pages
Publisher: Humana Press; 1st edition (March 16, 2010)
Language: English
ISBN-10: 1607616084
ISBN-13: 978-1607616085
Product Dimensions: 10 x 7.2 x 1.2 inches

MicroRNA and Cancer: Methods and Protocols (Methods in Molecular Biology)

2011-02-08T00:12:00.000-08:00

The tiny microRNAs (miRNAs) can have huge impacts on the regulation of a variety of genes and play crucial roles in the fundamental cellular processes. Recent miRNA studies change the landscape of cancer genetics by scrutinizing the alterations of genome-wide miRNA expressions in most common cancers and their regulatory functions during the development of cancer. The connections between miRNAs and cancer are widespread enough to warrant more comprehensive investigations in the systems biology perspective. In MicroRNA and Cancer: Methods and Protocols, internationally renowned experts provide the latest miRNA knowledge, the various techniques and methodologies currently available for cancer research application. Ranging from the fundamental concepts to practical applications, this book presents:
• Overview of microRNA biogenesis, computational prediction of new miRNAs in the cancer genome, and miRNA-based therapeutic approaches for cancer treatment.
• Detailed experimental protocols in miRNA detection with novel and high-throughput technology, miRNA library cloning, miRNA epigenetic regulation, and miRNA pathway study.
• Stepwise computational and bioinformatic procedures for miRNA complex networks in cancer genomes with a variety of softwares and programs.
• Cross-cited notes on troubleshooting and avoiding known pitfalls.
Authoritative and cutting-edge, MicroRNA and Cancer: Methods and Protocols serves researchers with the basic principles of experimental and computational methods for microRNA study in cancer research and provides a firm grounding for those who wish to further develop their own applications and tailor them to their own specific research needs.

Product Details

Hardcover: 273 pages
Publisher: Humana Press; 1st edition (October 21, 2010)
Language: English
ISBN-10: 1607618621
ISBN-13: 978-1607618621
Product Dimensions: 10.2 x 7.2 x 0.9 inches

mTOR Pathway and mTOR Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development)

2011-02-07T00:05:00.000-08:00

mTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines.
In this work, experts in TOR signaling have contributed in two thematic areas: mTOR Signaling and Cancer Therapy (chapters 1 - 8) and Therapeutic Targeting Downstream of mTOR (chapter 9 – 13). All chapters of mTOR Pathway and mTOR Inhibitors in Cancer Therapy are completely new or have been extensively updated by their authors; and we are indebted to all authors who have exemplified the links between these 2 thematic areas.

Product Details

Hardcover: 304 pages
Publisher: Humana Press; 1st edition (August 2, 2010)
Language: English
ISBN-10: 1603272704
ISBN-13: 978-1603272704
Product Dimensions: 9.3 x 6 x 1 inches

The Biology of Gastric Cancers

2011-02-06T00:08:00.000-08:00

There have been many impressive advances in our understanding of the pathogenesis of gastric adenocarcinoma, gastric MALT lymphoma, gastrointestinal stromal tumors of the stomach, and gastric carcinoid tumors over the years. "The Biology of Gastric Cancers," edited by Dr. Timothy Wang, Dr. James Fox and Dr. Andy Giraud, pays homage to the cutting edge concepts of cancer stem cells, tumor microenvironment, chronic inflammation, and genetic susceptibility to cancer and represents the very first volume devoted to the subject of the basic biology of gastric cancer. With an emphasis on animal models, but also considerable attention to human studies, host genetics and the role of bacterial factors and other environmental factors influencing the pathogenesis of gastric cancer, the topics presented in this book should be of interest to clinicians and investigators interested in gastrointestinal cancer, as well as basic investigators in related areas of cancer research. This body of work will hopefully stimulate clinical and translational studies that will advance early diagnosis and treatment of gastric tumors.

Product Details

Paperback: 332 pages
Publisher: Springer; 1st edition (October 29, 2010)
Language: English
ISBN-10: 1441924051
ISBN-13: 978-1441924056
Product Dimensions: 9.2 x 6.1 x 1.5 inches

Hyaluronan in Cancer Biology

2011-02-05T23:58:00.000-08:00

Hyaluronan biology is being recognized as an important regulator of cancer progression. Paradoxically, both hyaluronan (HA) and hyaluronidases, the enzymes that eliminate HA, have also been correlated with cancer progression. Hyaluronan, a long-chain polymer of the extracellular matrix, opens up tissue spaces through which cancer cells move and metastasize. It also confers motility upon cells through interactions of cell-surface HA with the cytoskeleton. Embryonic cells in the process of movement and proliferation use the same strategy. It is an example of how cancer cells have commandeered normal cellular processes for their own survival and spread. There are also parallels between cancer and wound healing, cancer occasionally being defined as a wound that does not heal.
The growing body of literature regarding this topic has recently progressed from describing the association of hyaluronan and hyaluronidase expression associated with different cancers, to understanding the mechanisms that drive tumor cell activation, proliferation, drug resistance, etc. No one source, however, discusses hyaluronan synthesis and catabolism, as well as the factors that regulate the balance. This book offers a comprehensive summary and cutting-edge insight into Hyaluronan biology, the role of the HA receptors, the hyaluronidase enzymes that degrade HA, as well as HA synthesis enzymes and their relationship to cancer.
* Offers a comprehensive summary and cutting-edge insight into Hyaluronan biology, the role of the HA receptors, the hyaluronidase enzymes that degrade HA, as well as HA synthesis enzymes and their relationship to cancer.
* Chapters are written by the leading international authorities on this subject, from laboratories that focus on the investigation of hyaluronan in cancer initiation, progression, and dissemination.
* Focuses on understanding the mechanisms that drive tumor cell activation, proliferation, and drug resistance.

About the Author

Robert Stern, MD, is Emeritus Professor, Department of Pathology, School of Medicine, University of California, San Francisco. Robert Stern left Germany in 1938 for Seattle, Washington. He graduated from Harvard College in 1957, and obtained the M.D. degree from the University of Washington (Seattle) in 1962, followed by a rotating internship at King County Hospital (Seattle). While a medical student, he worked in the laboratories of Drs. Krebs and Fisher, who became Nobel laureates. He received his resident training in Anatomic Pathology at the NCI, and was a research scientist at the NIH for 10 years. Since 1977, he has been a member of the Pathology Department at the University of California, San Francisco. He is a board-certified Anatomic Pathologist, participating in the research, teaching, administrative, and diagnostic activities of the Department. He directed the Ph.D. program in Experimental Pathology for ten years. For the past decade, his research has focused on hyaluronan and the hyaluronidases, an outgrowth of an interest in malignancies of connective tissue, stromal-epithelial interactions in cancer, and biology of the tumor extracellular matrix. His laboratory was the first to identify the family of six hyaluronidase sequences in the human genome. These enzymes were then sequenced, expressed, and characterized in his laboratory. Subsequent work has identified a catabolic pathway for hyaluronan.

Product Details

Hardcover: 468 pages
Publisher: Academic Press; 1 edition (April 6, 2009)
Language: English
ISBN-10: 0123741785
ISBN-13: 978-0123741783
Product Dimensions: 9.1 x 6.1 x 1.1 inches

The Biology and Treatment of Cancer: Understanding Cancer

2011-02-04T23:54:00.000-08:00

This book is written with the cancer patient and their families in mind. It is also useful for the trainee oncologist and allied professionals. This book provides explanations of cancer treatments and biology to interested parties, describes advances in understanding of cells, genes and molecular biology.

Book features:

Offers a broad audience a concise presentation of the most up-to-date knowledge about the biology and treatment of cancer
Full coverage of cancer prevention and control
Clear, thorough discussion of current and possible future therapies
Edited by two of the most eminent and widely recognized scholars of cancer research and therapeutics in the world, with contributions from top researchers and clinicians from across North America.

Edited by two of the most eminent and widely recognized scholars in the field, and with contributions from top researchers and clinicians from across North America, this book offers the most up-to-date knowledge on the biology and treatment of cancer-—from its molecular and cellular origins to the latest research, preventive measures, and current and future therapies. Coverage includes:

Types of tumors, their frequency, and progression
Environmental, genetic, and viral causes of cancer
Treatment of malignant disease
Clinical challenges for treatment and a cure
Understanding the biology of cancer
Mutations and cell defenses
Detection and biomarkers
Approaches, opportunities, and obstacles with cancer diagnosis and therapy
Clinical trials in oncology
Drug development and targeted therapy
Epidemiology and population-based studies
Consumer health information

This concise, carefully organized, and clearly written book is a must-have for the medical, academic, and professional communities; medical students; undergraduate and graduate students; patients, their families, and friends; and members of the general public who want to gain a deeper understanding of the research, prevention, and therapeutic responses to cancer.

Book details

Paperback: 303 pages
Publisher: Wiley-Blackwell; 1 edition (January 9, 2009)
Language: English
ISBN-10: 0470009586
ISBN-13: 978-0470009581
Product Dimensions: 9.9 x 7 x 0.2 inches

Hematologic Malignancies - Hodgkin Lymphoma - A Comprehensive Update on Diagnostics and Clinics by Andreas Engert (Springer) 2011

2011-01-30T23:31:00.000-08:00

Hodgkin lymphoma is one of the best curable malignancies both in adult and pediatric oncology. Today, more than 80% of all patients can be cured with risk-adapted treatment including chemotherapy and radiotherapy. This progress is largely due to the development of multiagent chemotherapy more than 40 years ago and the improvements in radiotherapy. Since then, this fascinating disease has been in the focus of scientific and clinical research. Major more recent achievements were the definite proof that Hodgkin lymphoma is a true malignancy despite its peculiar histology with the Hodgkin and Reed-Sternberg cells derived from “crippled” B-lymphocytes.
Establishing immortal cell lines from patients with end-stage disease initiated a variety of different research activities into the pathophysiology, immunology, and treatment. The discovery of the Ki-1 antigen that was expressed in high density on H-RS cells substantially improved the prognostic precision since nearly all malignant cells in Hodgkin lymphoma tissue are strongly expressing this antigen, which was later designated to the CD30 cluster. Monoclonal antibodies against this antigen were not only being successfully used for immunophenotyping but also exploited therapeutically. After a number of nonsuccessful clinical trials with antibody constructs or fully human monoclonal antibodies targeting CD30, this story now seems to come full circle with the advent of an anti-CD30 antibody-drug conjugate that has given remarkable responses in end-stage Hodgkin lymphoma patients.
Due to the substantially improved prognosis and the generally young age of patients affected, Hodgkin lymphoma has also become a model to study long-term effects of successful radiotherapy and chemotherapy. Today, more patients die from treatment-related long-term toxicity than from uncontrolled Hodgkin lymphoma. We must thus very carefully balance our attempts to further improve disease control with the need to keep the risk of long-term consequences as low as possible. In addition, there are also a number of relevant physical and psychosocial issues that need to be further exploited including the risk of infertility, and fatigue. Fortunately, after more than 20 years of standstill, we now experience the development of new-targeted treatment also for patients with Hodgkin lymphoma. This hopefully might result in more individualized and less toxic treatments for our patients.
This book should give you an overview on past and current achievements in the area of Hodgkin lymphoma with a special emphasis on late effects and new treatment options.

Contents
Part I From Hodgkin’s Disease to Hodgkin Lymphoma
1 Epidemiology
2 The Role of Viruses in the Genesis of Hodgkin Lymphoma
3 Pathology and Molecular Pathology of Hodgkin Lymphoma
4 Microenvironment, Cross-Talk, and Immune Escape Mechanisms
Part II Diagnosis and Treatment
5 Clinical Evaluation
6 Functional Imaging
7 Prognostic Factors
8 Principles of Radiation Techniques in Hodgkin Lymphoma
9 Principles of Chemotherapy in Hodgkin Lymphoma
10 Treatment of Early Favorable Hodgkin Lymphoma
11 Treatment of Early Unfavorable HL
12 Treatment of Advanced Stage Hodgkin Lymphoma
13 Relapsed and Refractory Hodgkin Lymphoma
14 Pediatric Hodgkin Lymphoma
Part III Special Clinical Situations
15 Lymphocyte-Predominant Hodgkin Lymphoma
16 The Management of Hodgkin Lymphoma During Pregnancy
17 The Management of HIV-Hodgkin Lymphoma
18 The Management of Elderly Patients with Hodgkin Lymphoma
19 Allogeneic Transplantation for Relapsed Hodgkin Lymphoma
20 New Agents for Patients with Hodgkin Lymphoma
Part IV Survivorship
21 Quality of Life in Hodgkin Lymphoma
22 Second Malignancy Risk After Treatment of Hodgkin Lymphoma
23 Cardiovascular and Pulmonary Late Effects
24 Gonadal Dysfunction and Fertility Preservation in Hodgkin Lymphoma Patients
Part V Future Prospects
25 What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma?
26 Personalized Medicine in Hodgkin Lymphoma?
Index

Atlas of Procedures in Gynecologic Oncology 2nd Edition

2011-01-28T11:03:00.000-08:00

Covering the latest developments in both open and minimally invasive surgery, Atlas of Procedures in Gynecologic Oncology, Second Edition has been massively updated to keep abreast with the latest developments in the field.
Updated topics include:

surgical staging
surgical cytoreduction
central venous catheter placement
retroperitoneal lymph node dissection
vaginal radical trachelectomy
SLN mapping for cervical cancer

This Atlas is filled with over one third new updated graphic content containing high definition, true-color photographs. Each chapter is presented in great detail and explained step-by-step, giving the reader a complete working knowledge of each procedure. An accompanying DVD provides video clips and commentary for a more thorough understanding of the procedures.

NEW TO THE SECOND EDITION:

coverage of both open and minimally invasive surgery.
new and updated graphic content, with high-definition color photographs.
latest developments and research findings from one of the top cancer centers in the world.

Product Details

Hardcover: 360 pages
Publisher: Informa Healthcare; 2 edition (July 4, 2008)
Language: English
ISBN-10: 1841844985
ISBN-13: 978-1841844985
Product Dimensions: 11.4 x 8.7 x 1 inches

Non-Hodgkin Lymphomas 2nd edition

2011-01-27T11:14:00.000-08:00

Thoroughly updated for its Second Edition, Non-Hodgkin Lymphomas is the definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin lymphomas. With backgrounds in medical and radiation oncology, molecular biology, and pathology, the editors and contributors provide an international, multidisciplinary approach to the topic.
This edition is the first text using the new World Health Organization classification of non-Hodgkin lymphomas. The book offers complete coverage of the most current techniques for diagnosis, staging, and treatment, the approach to specific types of lymphoma, and special problems common to the management of patients with these disorders.
A companion Website includes the fully searchable text and downloadable images.

Contents
Section I: HISTORICAL ASPECTS
1: The History of Chemotherapy of Lymphomas
2: The History of Radiation Therapy of Lymphoma
Section II: ETIOLOGY, EPIDEMIOLOGY, AND BIOLOGY
3: Developmental and Functional Biology of B Lymphocytes
4: Developmental and Functional Biology of T Lymphocytes
5: Epidemiology
6: Infectious Etiology of Lymphoma
7: Non-Hodgkin Lymphoma in Immunodeficient Hosts
8: Molecular Genetics of Lymphoma
Section III: DIAGNOSIS, STAGING, AND RESPONSE CRITERIA
9: Diagnosis: Diagnostic Procedures, Histopathologic Problems, Immunophenotyping, Applied Genetics
10: Staging and Prognostic Factors
11: Restaging and Response Criteria
Section IV: MANAGEMENT OF SPECIFIC NON-HODGKIN LYMPHOMAS
12: Lymphoblastic Lymphoma: Precursor Cell Lymphomas of B and T Cells
Lymphomas of B-Cells
13: Small B-Cell Lymphocytic Lymphoma/Lymphocytic Leukemia
14: Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia
15: Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
16: Splenic Marginal Zone Lymphoma
17: Nodal Marginal Zone B-Cell Lymphoma
18: Follicular Lymphoma
19: Mantle Cell Lymphoma
20: Diffuse Large B-Cell Lymphoma
21: Primary Mediastinal Large B-Cell Lymphoma
22: Burkitt Lymphoma
23: Plasma Cell Neoplasms: Multiple Myeloma and Plasmacytoma
24: Primary Cutaneous B-Cell Lymphoma
Lymphomas of T-Cells
25: Mycosis Funoides and Sezary Syndrome
26: T-Cell Chronic Lymphocytic Leukemia
27: Human T-Cell Leukemia Virus Type I-Associated Adult T-Cell Leukemia-Lymphoma
28: Anaplastic Large Cell Lymphoma
29: Mature Nodal and Extranodal T-Cell and NK-Cell Lymphoma
30: Primary Cutaneous CD30+ Lymphoproliferative Disorders
Section V: LATE EFFECTS
31: Second Tumors
32: Late Effects of Treatment after Lymphoma
Section VI: SPECIAL CLINICAL SITUATIONS
33: Lymphomas in Children
34: The Management of Non-Hodgkin Lymphoma during Pregnancy
35: Management of Acquired Immunodeficiency Syndrome-Related Lymphoma
36: Management of Central Nervous System Lymphoma
37: Unique Aspects of Primary Extranodal Lymphomas
38: Diagnosis and Management of Lymphoproliferative Disorders That Can Mimic Lymphoma

Product Details

Hardcover: 672 pages
Publisher: Lippincott Williams & Wilkins; Second edition (November 5, 2009)
Language: English
ISBN-10: 0781791162
ISBN-13: 978-0781791168
Product Dimensions: 11.1 x 8.6 x 1.3 inches

List Price: $219.00

Emerging Therapeutic Targets in Ovarian Cancer by Stan Kaye (Springer) 2011

2011-01-26T23:38:00.000-08:00

Clinicians caring for advanced ovarian cancer patients are well aware of the challenges in dealing with the disease. Although it is frequently responsive to a range of conventional cytotoxic agents, it generally recurs and proves to be fatal. In facing the major obstacles to improvements in outlook – non-selectivity and drug resistance – the expectation today is that a better appreciation of the underlying biology and molecular pathology of the disease will translate into genuine progress in therapy. While there is still much to be understood about the different histological types of ovarian cancer, we are already seeing progress in linking the biology of ovarian cancer with novel targets and innovative therapies entering clinical trials.
The purpose of this book is to provide an up-to-date perspective, in essence a progress report to date on efforts to meet these challenges. The basis of successful therapeutic developments is a partnership between laboratory-based and clinical-based research scientists, and this is exemplified in the co-authorship of the 13 articles.
Each author has provided a background review of the biology behind his/her emerging target for therapy, followed by a comprehensive and up-to-date summary of treatment results. A theme which runs throughout the book is the importance of predictive biomarkers and the message of patient selection for novel-targeted therapy is now a familiar one in modern cancer therapy.
The 13 chapters are prefaced by two introductory general contributions, describing existing treatments and the discovery of novel targets. A point sometimes made is that no sooner is a book such as this published than it is ‘out of date’. Clearly new information continues to emerge on a monthly basis, and this of course is to be applauded. But we believe that there is a role for a concise overall picture, especially in 2010, which is a particularly eventful year for treatment developments in ovarian cancer. As final touches to the book are made, we are learning of the positive results in GOG 218 and ICON-7, which incorporated bevacizumab into first line treatment, and of the first clinical evidence of response in sporadic ovarian cancer to single agent PARP inhibitor treatment (see Chapters 3 and 6). These, and other positive trial data, provide real hope for improvements in treatment outcome in the near future. The book will prove useful to both clinicians and non-clinicians with interests in the field of new drug development in ovarian cancer and welcome any constructive comments and criticisms.

Contents
1 Systemic Therapy for Ovarian Cancer, Current Treatment, Recent Advances, and Unmet Needs
2 Discovery of Novel Targets
3 Novel Anti-angiogenic Therapies in Ovarian Cancer
4 Targeting the AKT Pathway in Ovarian Cancer
5 Inhibition of the Src Oncogene: Therapeutic Potential in Ovarian Carcinoma
6 Tumour-Specific Synthetic Lethality: Targeting BRCA Dysfunction in Ovarian Cancer
7 Targeting Inflammatory Pathways in Epithelial Ovarian Cancer
8 Epithelial-to-Mesenchymal Transition and Cellular Membrane Receptors in Ovarian Cancer: Moving
Forward in the Era of Molecularly Targeted Therapy
9 Epigenetic Therapies
10 Ovarian Cancer Immunology and Immunotherapy
11 Ovarian Cancer Progenitor/Stem Cells: Therapeutic Potential
12 Potential for a-Folate Receptor-Targeted Treatment for Ovarian Cancer
13 New Insights into Tubulin Binders
Index

Asbestos: Selected Cancers

2011-01-25T11:08:00.000-08:00

In conjunction with drafting comprehensive legislation concerning compensation for health effects related to asbestos exposure (the Fairness in Asbestos Injury Act), the Senate Committee on the Judiciary directed the Institute of Medicine to assemble the Committee on Asbestos: Selected Health Effects. This committee was charged with addressing whether asbestos exposure is causally related to adverse health consequences in addition to asbestosis, mesothelioma, and lung cancer.
Asbestos: Selected Cancers presents the committee's comprehensive distillation of the peer-reviewed scientific and medical literature regarding association between asbestos and colorectal, laryngeal, esophageal, pharyngeal, and stomach cancers.

Product Details

Paperback: 340 pages
Publisher: National Academies Press; 1 edition (August 31, 2006)
Language: English
ISBN-10: 0309101697
ISBN-13: 978-0309101691
Product Dimensions: 8.9 x 6 x 0.8 inches

Gastrointestinal Oncology - A Practical Guide by Charles D. Blanke (Springer) 2011

2011-01-24T05:24:00.000-08:00

Gastrointestinal oncology practitioners aim to establish effective prevention and treatment strategies for patients with malignancies involving the GI tract, ultimately leading to a reduction in morbidity and mortality from GI cancers. GI tumours arise from a number of distinct anatomic sites and may or may not share underlying biologic similarities; however, they differ in their required radiotherapeutic or surgical approaches for limited, curable disease, as well as their chemosensitivity and treatment patterns in the advanced or metastatic settings. The best therapeutic approach to these cancers is usually multidisciplinary, involving medical, surgical, and radiation oncologists, with strong input from pathologists, gastroenterologists, and specialists in diagnostic imaging. Making major strides in future GI cancer control will certainly involve both expert clinicians and researchers, specializing in areas including new drug development, clinical trial design, biostatistics, experimental and molecular therapeutics, and molecular pathology.
This edition of Gastrointestinal Oncology: A Practical Guide features chapters devoted to each of the major GI anatomic sites, as well as sections on diagnostic imaging, interventional GI oncology, practical correlative science, and non-site specific tumours such as neuroendocrine cancers and gastrointestinal stromal tumours. The emphasis of this text is to furnish useful, evidence-based clinical advice, highlighting the multidisciplinary nature of GI oncology practice. This remains an incredibly exciting time in medicine. The knowledge leaps in molecular oncology in general and characterization and treatment of GI malignancies specifically have been prodigious. We hope you find the information in this text useful, guiding your everyday practice and stimulating thought regarding potential future advances.

Contents
1 Imaging in Gastrointestinal Cancer
2 Interventional Gastrointestinal Oncology
3 Practical Gastrointestinal Oncology Correlative Science
4 Esophageal Cancer
5 Gastric Cancer
6 Gastrointestinal Stromal Tumors
7 Multimodality Management of Localized and Borderline Resectable Pancreatic Adenocarcinoma
8 Unresectable Pancreatic Cancer
9 Liver Cancer
10 Carcinoma of the Biliary Tract
11 Neuroendocrine Cancers
12 Colon Cancer
13 Rectal Cancer
14 Anal Cancer
Index

Leukemias: Principles and Practice of Therapy

2011-01-23T11:15:00.000-08:00

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.
Topics include:

Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)
Ras inhibitors
Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors)
Lenalidomide analogs
New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine
Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)
New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)
Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease.
Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area.

Product Details

Hardcover: 456 pages
Publisher: Wiley-Blackwell; 1 edition (December 21, 2010)
Language: English
ISBN-10: 1405182350
ISBN-13: 978-1405182355
Product Dimensions: 10.9 x 8.8 x 1.1 inches

Rare and Uncommon Gynecological Cancers - A Clinical Guide (Springer) 2011

2011-01-22T05:20:00.000-08:00

Rare and Uncommon Gynecological Cancers - A Clinical Guide review most of the relatively uncommon and rare gynaecological cancers. It is not easy to find this kind of information in the standard textbooks. Rare conditions generally attract a disproportionate amount of interest compared to their rarity.
Perhaps this is because unusual cases generate additional interest and also reflects the fact that for many of us, this presents a distraction from the humdrum of routine care where we are forced to think and seek out information. Rare editions of books, art or music attract collectors, perhaps for the same reasons. Nevertheless it is important when we are dealing with rare and uncommon disorders that we apply the highest standards.
Many would argue that because of their rarity these conditions should be looked after by specialist teams. This allows a smaller number of expert teams to develop real expertise in this field. Furthermore, it would seem sensible to propose that there is a degree of centralisation of care for these conditions. Protocols for shared care may be developed in parallel and there are good examples available to follow such as in gestational trophoblastic tumours.
Why is there a need for such a book as this? The main rationale for the book is to provide the reader with some guidance on how best to manage these patients with rare and uncommon cancers. Access to information on these rare cancers can be difficult even in our modern age of rapid electronic communications and electronic repositories of information. Standard textbooks often contain little information apart from descriptive pathology. One can often find a wealth of information on the histopathology as pathologists usually cross-refer to each other and the main centres may develop an expertise in reviewing and reporting these cancers. However, for many of these conditions, modern and constructive management advice is hard to find. Surgeons and oncologists are not so good as pathologists in networking traditionally, although informal networks and “phone-a friend” may be carried out. Modern medical practice is breaking down these barriers. A book like this cannot be too proscriptive as there is often not the information available to allow such an approach, but our expert authors are recognised specialists in their field and have produced authoritative guidance on how to interpret the available literature. We cannot produce specific protocols for most situations but can guide the readers through the published literature and hopefully allow them to draw the right conclusions and apply them to their practice. Of course the greatest weakness is that virtually from the moment the author completes the chapter, it is in danger of obsolescence as a new paper is published. However, with rare conditions this may be less of a risk and developments tend to occur more slowly as cases are so few, but occasional dramatic breakthroughs are seen such as the treatment of GIST with imatinib.

Contents
Part I General Principles
1 Introduction
2 Epidemiology and Databases
3 Rare and Uncommon Gynaecological Cancers: A Clinical Guide
4 The Contribution of Diagnostic Imaging in Rare Gynaecological Malignancies
Part II Ovarian Rare Cancers
5 Mucinous Cancers: Ovary
6 Pseudomyxoma Peritonei
7 Ovarian Clear Cell Carcinoma
8 Clear Cell Carcinoma of the Ovary
9 The Continuum of Serous Ovarian Tumors of Low Malignant Potential and Low-Grade Serous Carcinoma of the Ovary
10 Sex Cord-Stromal Tumors
11 Squamous Cell Carcinomas Arising From Dermoids
12 Ovarian Carcinosarcomas
13 Small Cell and Neuroendocrine Cancers of the Ovary
14 Primary Ovarian Carcinoids and Neuro-Endocrine Tumours Including Struma Ovarii
Part III Uterine Rare Cancers
15 Reed Uterine Carcinosarcomas
16 Leiomyosarcomas of Uterus
17 Mucinous Tumours of the Uterine Corpus
18 Clear Cell Cancers of Uterus
Part IV Cervix and Vulval Cancers
19 Small Cell and Neuroendocrine Cancers of the Cervix
20 Primary Malignant Melanoma of the Vulva and Vagina
21 Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting
Index

Understanding Leukemias, Lymphomas and Myelomas 2nd Edition

2011-01-21T11:11:00.000-08:00

A brand-new edition of the bestselling guide to hematologic malignancies. An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.
Following on the successful steps of the first edition, this Second Edition covers:

various types of leukemias, lymphomas, and myelomas
utilizing stem cell transplantation
side-effects of various treatments
future prospects for leukemia, lymphoma, and myeloma
targeted therapies and history of the cancers
information and support sources for patients

Product Details

Hardcover: 200 pages
Publisher: Informa Healthcare; 2 edition (August 11, 2010)
Language: English
ISBN-10: 1841846945
ISBN-13: 978-1841846941
Product Dimensions: 9.6 x 7.4 x 0.6 inches

Atlas of Staging in Gynecological Cancer

2011-01-20T11:00:00.000-08:00

Atlas of Staging in Gynecological Cancer gives a practical approach to the topic and is designed to be used in conjunction with diagnostic procedures between the surgeon and the radiologist. This book describes the two common staging regimes used by all units across the world, namely, the FIGO and TNM systems.
The landscape format allows each chapter to open on the left hand side and read across the double page, enabling the reader to see FIGO and AJCC staging together at the same time. Each chapter also has a separate section on Epidemiology, Diagnosis, Management, and a Summary section highlighting key points.
The content of Atlas of Staging in Gynecological Cancer takes the reader through each gynecological cancer with a short text accompanying clear radiographic images with explanatory legends. Staging is also shown in pictorial form to aid clarity, with many tables further explaining suggested approach and workflow.
The book will be of particular interest to the multi-disciplinary team that looks after this group of patients namely, clinical and radiation oncologists, surgeons, pathologists, radiologists and specialist nurses, all with their respective trainees.

About the Author

J Richard Smith MD FRCOG, is Consultant Gynecological Surgeon at Chelsea & Westminster Hospital, London, UK & Adjunct Associate Professor, New York University School of Medicine, New York, USA.
Dr Guiseppe Del Priore, MD is Director and Chief, Department of Gynecologic Oncology, New York University Medical Center, New York, USA.
Dr Jeremiah Healy FRCR is Consultant Radiologist, Department of Radiology, Chelsea & Westminster Hospital, London, UK.

Product Details

Hardcover: 30 pages
Publisher: Springer; 1st Edition (December 11, 2007)
Language: English
ISBN-10: 1846284333
ISBN-13: 978-1846284335
Product Dimensions: 11.9 x 8.4 x 0.5 inches

Pediatric and Adolescent Osteosarcoma (Cancer Treatment and Research)

2011-01-19T10:58:00.000-08:00

Pediatric and Adolescent Osteosarcoma provides a historical review of the nature of osteosarcoma and the conflict that accompanied the introduction of adjuvant therapy for osteosarcoma culminating in accepted and prevailing methods of current therapy. It outlines concepts in Epidemiology and Etiology, and provides chapters on pathology and radiologic characteristics of osteosarcoma, surgical therapy tailored specifically for treatment of primary tumors in pediatric/adolescent age group, treatment of pulmonary and extra pulmonary metastases and complications, as well as the role of radiation therapy. The volume concludes with a review of differences and similarities in the management of osteosarcoma in adults as compared to pediatrics / adolescents and new laboratory and animal investigations currently in progress to develop effective diagnostic and therapeutic approaches to improve the outcome.
In essence the scope and intensive coverage of the book provides a historical perspective of the advances made over the past 30 years and emerging concepts and prospects for new diagnostic and therapeutic approaches. This is based upon past experiences and new discoveries. It also provides a unique opportunity for pediatric and adult medical oncologists, physicians in training, orthopedic surgeons, pathologists, radiologists, radiotherapists, oncology nurses and allied professionals involved in the care of pediatric/adolescent patients with osteosarcoma to become acquainted with prevailing methods of treatment and new and evolving concepts and developments.

Product Details

Hardcover: 591 pages
Publisher: Springer; 1st Edition (October 26, 2009)
Language: English
ISBN-10: 144190283X
ISBN-13: 978-1441902832
Product Dimensions: 9.2 x 6.2 x 1.2 inches

Asbestos: Medical and Legal Aspects 5th Edition

2011-01-18T10:56:00.000-08:00

Written by one of the leading asbestos experts for both plaintiff and defense attorneys, occupational and environmental health professionals, as well as others in the field of toxic substances control, Asbestos: Medical and Legal Aspects has become the definitive resource on the medical and legal aspects of asbestos.

Asbestos: Medical and Legal Aspects provides a comprehensive examination of the public health history of asbestos, from the origins of industrial use to the present. It includes in-depth coverage of prior and ongoing litigation; extensive evaluation of the legal arguments put forth by plaintiff and defense counsel; and provides crucial information, materials and resources on the evolving corporate knowledge of asbestos hazards. The book covers in detail: asbestosis and cancer; compensability of asbestosis and cancer as occupational diseases; thresholds and standards used to determine safe or acceptable levels of asbestos exposure in the workplace; and company knowledge of asbestos hazards, gleaned from countless depositions, company records, industry consultants and trade associations.

Some items new to the Fifth Edition include:

extensive discussion of corporate knowledge and responsibility for asbestos hazards .
extensive examination of the international struggle over asbestos, whereby some countries have banned asbestos while others have continued to expand their usage of asbestos in building materials.
detailed discussion of alternatives to asbestos.

Product Details

Hardcover: 940 pages
Publisher: Aspen Publishers; 5th edition (March 2005)
Language: English
ISBN-10: 0735552606
ISBN-13: 978-0735552609
Product Dimensions: 10.3 x 7.4 x 2 inches

Leukaemia Diagnosis 4th Edition by Barbara J. Bain (Wiley-Blackwell) 2010

2011-01-09T07:31:00.000-08:00

Leukaemias are a very heterogeneous group of diseases, which differ from each other in aetiology, pathogenesis, prognosis and responsiveness to treatment. Accurate diagnosis and classification are necessary for the identification of specific biological entities and underpin scientific advances in this field. The detailed characterization of haematological neoplasms is also essential for the optimal management of individual patients. Many systems for the classification of leukaemia have been proposed.
Between 1976 and 1999, a collaborative group of French, American and British haematologists (the FAB group) proposed a number of classifications, which became widely accepted throughout the world. In 2001, a quarter of a century after the first FAB proposals, a World Health Organization (WHO) expert group proposed an updated system for the classification of leukaemia and lymphoma incorporating clinical features, haematological and histological features, immunophenotyping and the results of cytogenetic and, to a lesser extent, molecular genetic analysis. In 2008 a further updating of the WHO classification incorporated new knowledge and gave a greater importance to molecular genetic features.
Leukaemia Diagnosis 4th Edition by Barbara J. Bain illustrate and explain how these many laboratory techniques are used for the diagnosis and classification of leukaemia and related disorders. This book discuss diagnosis and classification in a way that will be helpful to trainee haematologists and to laboratory scientists in haematology and related disciplines. However, this book also tried to provide a useful reference source and teaching aid for those who already have expertise in this field. In addition, cytogeneticists and molecular geneticists will find that this book enhances their understanding of the relationship of their disciplines to the diagnosis, classification and monitoring of leukaemia and related disorders.
As the diagnosis and classification of leukaemia comes to rely increasingly on sophisticated and expensive investigations there is a risk that some countries will be left behind. For the first time the author have therefore incorporated, as an appendix, some suggestions as to how leukaemia might be diagnosed in under-resourced laboratories. This may seem presumptuous from someone who has not worked in a developing country for more than 40 years but I thought that at least it should be attempted.
Since photographs have been taken of many different microscopes and exact magnifications differ slightly, magnifications of photomicrographs in this edition are given as the microscope objective used.

Contents
1 The Nature of Leukaemia, Cytology, Cytochemistry and the FAB Classification of Acute Leukaemia
2 Immunophenotyping and Cytogenetic/Molecular Genetic Analysis in Leukaemia and Related Conditions
3 Acute Leukaemia: Integration of Morphological, Immunophenotypic and Genetic Information and the WHO Classification
4 The Myelodysplastic Syndromes
5 Chronic Myeloid Leukaemias
6 Lymphoid Leukaemias of Mature T, B and Natural Killer Cells
Appendix: Leukaemia Diagnosis in Resource-Poor Countries
Index

Pediatric CNS Tumors 2nd Edition (Springer) 2010

2011-01-08T07:27:00.000-08:00

Pediatric brain tumors are a tremendous challenge for the treating physician. Their diverse biological behaviors, in the unique context of the developing nervous system, require fl exible and tailored treatment plans. In the last 20 years, there has been an exponential increase in our understanding of the molecular and genetic basis of human malignancy.
The goal of Pediatric CNS Tumors 2nd Edition is to provide a current, biologically-based perspective of the management of central nervous system tumors in children. Rather than present every tumor type in an encyclopedic manner, the common tumor types encountered in clinical practice are presented in the initial chapters.
The epidemiology, pathological features, clinical presentation, diagnosis, and treatment are discussed for each tumor type. We have separated high- and lowgrade glial tumors into separate chapters, mainly because the management and outcome for these two classes of tumors are very different. In the final chapters, many of the diagnostic and treatment modalities common to all tumors are discussed with an emphasis on emerging and experimental techniques. For the second edition, new chapters have been added: Rare Tumors (Chap. 11) and Late Effects and Palliative Care (Chap. 17). A valuable resource is the WHO classification of tumors of the central nervous system; the fourth edition of which was published in 2007 (Louis et al. 2007).
It is recognized that a variety of treatment strategies are utilized by many different practitioners and institutions. For the most part, the general management principles used at the University of California, San Francisco, are presented, usually in the context of standard therapy. Although this approach may underemphasize other equally valid approaches, we believe that the reader will benefi t from a coherent approach to the management of childhood tumors.

Contents
1 Low-Grade Gliomas
2 High-Grade Gliomas
3 Brainstem Gliomas
4 Ependymoma
5 Embryonal Tumors
6 Intracranial Germ-Cell Tumors
7 Craniopharyngioma
8 Neuronal Tumors
9 Choroid Plexus Tumors
10 Intramedullary Spinal Cord Tumors
11 Rare Tumors
12 Neurocutaneous Syndromes and Associated CNS Tumors
13 Modern Neuroimaging of Pediatric Brain Tumors
14 Current Surgical Management
15 Chemotherapy
16 Advances in Radiation Therapy
17 Late Effects of Treatment and Palliative Care
Subject Index

Gynaecological Oncology (Cambridge University Press) 2010

2010-12-25T07:13:00.000-08:00

The management of gynaecological cancers has seen considerable changes over recent years. We now have a greater understanding of cancer epidemiology and significant advances have been made in genetics/screening. The approach to women with cancer has become multidisciplinary, with many professionals contributing to the excellent care and outcome that wish to see for those individuals we are privileged to look after. Women with gynaecological
cancers have general as well as specific issues and these are addressed by the various experts who have contributed to this book. The overall desire for a holistic approach should be evident in trying to address these issues.
This book is aimed at trainees in gynaecology and oncology as well as consultants with an interest in cancer care. Allied medical staff, palliative services and nurse specialists will also find it a useful adjunct to getting current information on the whole range of gynaecological oncology.
Chap ters 1 – 8 and 15 cover the broad issues in gyna ecologi cal oncology, while Chapters 9–14 discuss in some detail the issues in relation to site-specific gynaecological cancers. The further reading sections at the end of each chapter are intended to guide the interested reader wishing to seek detailed information relating to the issues covered in the chapters.

Product Details

Paperback: 248 pages
Publisher: Cambridge University Press; 2 edition (January 25, 2010)
Language: English
ISBN-10: 0521730244
ISBN-13: 978-0521730242
Product Dimensions: 9.2 x 6.2 x 0.6 inches

Tonn: Oncology of CNS Tumors 2nd Edition

2010-12-24T07:22:00.000-08:00

Knowledge about the etiology and diagnosis as well as treatment concepts of neurooncologic diseases is rapidly growing. This turnover of knowledge makes it diffi cult for the physician engaged in the treatment to keep up to date with current therapies. This book sets out to close the gap and pursues several innovative concepts.
Sooner than expected, the first edition of this book has sold out. The fact that the book was so well received shows that there is a demand for a comprehensive, practice oriented textbook of neuro-oncology. This is all the more true today as there have been many more advances in the diagnosis and treatment of patients with brain tumors than in prior decades. A number of these advancements can be attributed to the use of translational medicine for which there is now good scientifi c rationale. For this reason a comprehensive revision of the fi rst edition had become necessary.

Contents
Part I Cranial Neuro-Oncology
1 Pathology and Classifi cation of Tumors of the Nervous System
2 Targeted Therapies
3 Tumors of the Skull
4 Meningiomas and Meningeal Tumors
5 Low-Grade Astrocytomas
6 Stereotactic Brachytherapy in Low-Grade Gliomas
7 High-Grade Astrocytoma/Glioblastoma
8 Oligodendroglioma
9 Ependymomas and Ventricular Tumors
10 Medulloblastoma-PNET, Craniopharyngioma Adult Tumors of Pediatric Origin
11 Glioneuronal Tumors
12 Inactive Adenomas
13 Functioning Adenomas
14 Tumors of the Pineal Region
15 Tumors of the Cranial Nerves
16 Hemangioblastoma and Von Hippel–Lindau Disease
17 Tumors of the Skull Base
18 Orbital Tumors
19 Primary CNS Lymphoma
20 Brain Metastasis
Part II Pediatric Neuro-Oncology
21 Neurocutaneous Syndromes
22 Supratentorial Hemispheric Low-Grade Gliomas in Children
23 Optic Gliomas
24 Thalamic Gliomas
25 Midbrain Gliomas
26 Supratentorial High-Grade Gliomas
27 Ganglioglioma
28 Cerebellar Astrocytomas
29 Diffuse Intrinsic Pontine Gliomas
30 Dorsally Exophytic Brain Stem Gliomas
31 Cervicomedullary Gliomas
32 Desmoplastic Infantile Gangliogliomas
33 Pleomorphic Xanthoastrocytoma
34 Hypothalamic Hamartoma
35 Ependymomas
36 Medulloblastoma
37 Supratentorial Primitive Neuroectodermal Tumors
38 Dysembryoplastic Neuroectodermal Tumors
39 Meningiomas in Children
40 Pineal Region Tumors in Children
41 Pituitary Tumors in Children
42 Craniopharyngiomas
43 Intracranial Germ Cell Tumors
44 Choroid Plexus Tumors
45 Malignant Rhabdoid Tumors of the CNS
46 Langerhans Cell Histiocytosis
47 Tumors of the Skull Base in Children
48 Tumors of the Cranial Vault in Children
49 Epidural Spinal Tumors in Children
50 Spinal Column Tumors
51 Pediatric Spinal Intradural Extramedullary Tumors
52 Intramedullary Spinal Tumors in Children
53 Peripheral Nerve Tumors in Children
Part III Spinal Neuro-Oncology
54 Intramedullary Tumors
55 Intradural Extramedullary Tumors
56 Epidural Tumors and Metastases
57 Spinal Robotic Radiosurgery
Part IV Peripheral Nerve Tumors
58 Peripheral Nerve Tumors
Part V Systemic and General Aspects of Neuro-Oncology
59 General Care of Patients with Cancer Involving the Central Nervous System
60 Palliative Care in Neuro-Oncology
Index

Product Details

Hardcover: 793 pages
Publisher: Springer; 2nd edition (March 5, 2010)
Language: English
ISBN-10: 364202873X
ISBN-13: 978-3642028731
Product Dimensions: 10.3 x 8 x 1.6 inches

List Price: $269.00

Mechanisms of Oncogenesis: An update on Tumorigenesis (Cancer Growth and Progression Series)

2010-12-23T07:30:00.000-08:00

This volume is a continuation of the encyclopedic work entitled “Cancer Growth and Progression,” that was originally edited by Professor Hans E. Kaiser. As a tribute to the memory of Dr. Kaiser and his contributions to the field, this new edition is following his example of providing the most current information about cancer literature and comprehensive coverage of all aspects of tumor growth and progression.
This particular tome is divided into two sections: the first addressing general causes of oncogenesis such as environmental factors and tumor mechanisms; and the second addressing the oncogenic mechanisms of tumor in specific organs. This book is written and compiled by world renowned leaders in their respective fields and focuses on the most recent developments in basic oncogenesis. This definitive text will provide the practitioner, whether in research, academia or clinical practice, with a fount of easily accessible information on the most common tumors.

Contents
1 Cytokines and Stressors: Implications for Cancer Immunotherapy
2 The Role of Oncogene Activation in Tumor Progression
3 Carcinogenic Effects of Ionising Radiation
4 Chemical Carcinogenesis Role of Chloroform – Further Studies
5 Use of Organ Explant and Cell Culture in Cancer Research
6 Chromosomal Abnormalities in Selected Hematopoietic Malignancies Detected by Conventional and Molecular Cytogenetics: Diagnostic and Prognostic Significance
7 Mechanisms of Cancer Growth and Progression in Lymphoma
8 Pediatric Cancer Mechanisms of Cancer Growth and Progression
9 Carcinogenetic Pathway of Malignant Melanoma
10 Ewing Sarcoma: Molecular Characterization and Potential Molecular Therapeutic Targets
11 Molecular Mechanisms of Central Nervous System Metastasis
12 Carcinogenesis of Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
13 Postmenopausal Hormone Replacement Therapy and Breast Cancer – Clinicopathologic Associations and Molecular Mechanisms
14 Carcinogenesis of Lung Cancer
15 Genesis of Barrett’s Neoplasia: Current Concepts
16 Genesis of Pancreatic Ductal Neoplasia
17 Recent Advances in the Pathogenesis of Pancreatic Endocrine Neoplasms
18 Mechanisms of Carcinogenesis in Colorectal Cancer
19 Carcinogenetic Pathway of Superficial Low-Grade Urothelial Carcinoma
20 Carcinogenetic Pathway of Urothelial Carcinoma
21 Mechanisms of Carcinogenesis in Prostate Cancer
22 HPV in Cervical Carcinoma
Index

Product Details

Hardcover: 304 pages
Publisher: Springer; 1st edition (May 14, 2010)
Language: English
ISBN-10: 9048137241
ISBN-13: 978-9048137244
Product Dimensions: 10.3 x 7.6 x 1 inches

List Price: $229.00

New Technologies in Surgical Oncology

2010-12-22T07:28:00.000-08:00

The Italian Society of Surgery has taken the opportunity to offer its members and the medical community at large an update on new technologies in the detection and treatment of neoplastic pathologies. Progress achieved over the last few decades, especially in the field of oncology, has been unstoppable, necessitating an update on the methods used to examine patients and in turn the therapeutic protocols used in their treatment. Despite concerns over the enormous increase in the cost of healthcare, there is an irresistible drive by physicians and medical institutions to acquire state of the-art systems and to apply the most recently developed methods.
This volume is a particularly interesting scientific publication, of great significance to today’s clinical practice. Oncological surgery consists of a moment in the diagnostic-therapeutic course of the patient. The outstanding progress that has taken place in the field of oncology in the last two decades has benefited from the development of new surgical techniques, which have allowed highly specialized oncological surgery and a surgical approach more thoroughly integrated within the context of multidisciplinary oncological treatment. Indeed, it is no longer acceptable that a surgeon care for an oncology patient without having broad therapeutic and diagnostic knowledge of the opportunities offered by other fields of medicine.
Contents
01 The Evolution of Surgical Oncology
02 Minimally Invasive Techniques in Surgical Oncology
03 Radioguided Surgery in Oncological Surgery
04 Prosthetic Materials in Surgical Oncology
05 Intraoperative Radiotherapy
06 New Technologies in Oncological Endocrine Surgery
07 Robots in Oncological Surgery
08 Endoscopy and Surgical Oncology
09 Senologic Oncology and Reconstructive Surgery
10 Transplants in Surgical Oncology
11 Locoregional Therapies and Surgical Oncology
12 Hemostatic Agents in Surgical Oncology
13 Palliative Techniques and Supportive Procedures in Surgical Oncology
14 Ethical Aspects in Surgical Oncology
Subject Index

Product Details

Hardcover: 172 pages
Publisher: Springer; 1 edition (December 15, 2009)
Language: English
ISBN-10: 8847014743
ISBN-13: 978-8847014749
Product Dimensions: 9.4 x 6.2 x 0.6 inches

Berek and Hacker's Gynecologic Oncology 5th Edition

2010-12-21T07:06:00.000-08:00

Gynecologic oncology, as a subspecialty of Obstetrics and Gynecology, evolved slowly since the concept was first introduced in the United States in 1973. Canada, the United Kingdom, Australia, and New Zealand adopted the concept within the ensuing 15 years, and European countries followed later. Although gynecologic oncology was practiced by individuals in Western Europe for many years, official recognition of the subspecialty has been much more recent. Eastern Europe, India, and much of Asia have yet to officially recognize this discipline.
With subspecialization, research into gynecologic cancers flourished at both the clinical and molecular level, and accrual of knowledge expanded exponentially. The development of international collaborative groups like the Gynecologic Cancer Intergroup (GCIG) resulted in the recruitment of large numbers of patients for clinical trials within a relatively short period of time. Similarly, the multinational Human Genome Project paved the way for a better understanding of the genetic basis of cancer and facilitated the development of targeted therapies.
The first four editions of this book were titled Practical Gynecologic Oncology, and now, in recognition of its sustained utility, Lippincott Williams & Wilkins has renamed the fifth edition Berek & Hacker's Gynecologic Oncology. The previous edition was translated into Chinese and Spanish, an acknowledgment of the book's international appeal.
This edition preserves the basic format and style of the previous editions, being divided into four sections: general principles, disease sites, medical and surgical topics, and quality of life. All chapters have been thoroughly revised and incorporate a critical review of the recent literature.

Product Details

Hardcover: 912 pages
Publisher: Lippincott Williams & Wilkins; Fifth edition (October 20, 2009)
Language: English
ISBN-10: 0781795125
ISBN-13: 978-0781795128
Product Dimensions: 11.1 x 8.6 x 1.5 inches

Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology 8th Edition

2010-12-20T06:58:00.000-08:00

What's new in Cancer: Principles & Practice of Oncology, 8th edition?

First, our long-time friend and distinguished colleague Sam Hellman has retired, and the editors have welcomed Ted Lawrence, the Isadore Lampe Professor and Chair of Radiation Oncology at the University of Michigan, as his replacement. Renowned for his translational research, Dr. Lawrence brings an important perspective to the modernization of the eighth edition. And starting with this edition, the schedule of publication of the text has been accelerated, with the goal that no more than 3 years will lapse between editions to keep the book fresh.

The Lippincott Williams & Wilkins company has also acquired The Cancer Journal: The Journal of Principles & Practice of Oncology with the expressed purpose of linking it to the text as a means of updating the book on a regular basis. To do this, the format of the journal has been restructured to reflect the different divisions of the text, and both have a dedicated Web site for those so inclined. The accelerated schedule and the content-linked journal, coupled with our other products, like the Principles & Practice of Oncology Updates and the new Principles & Practice of Oncology Focus series, provide a complete package of cancer medicine in one venue that physicians so dearly need. Something else has also been added. Given the pace of discovery and the complexity of the science involved, two distinguished scientific advisors, Drs. Ronald DePinho and Robert Weinberg of Harvard and MIT, respectively, have joined the editors. They have worked with the editors to revise the first section of the book, "Molecular Biology of Cancer,"‌ so that each new chapter represents a segment in the continuum of the process a normal cell traverses to become malignant. Written with the physician in mind, this section, along with the chapters on the molecular biology of cancer that precede each of the disease oriented chapters, provides the modern science a physician needs to know to remain current in a single source.

The coupling of a text with its own journal to keep it current and the use of sophisticated scientific advisors are unique to Cancer: Principles & Practice of Oncology and continues the long list of innovations in the preparation of modern medical texts that have characterized our book.

As is usual, PARTS 2, 3 and 4, "Principles of Oncology", "Practice of Oncology", and "Newer Approaches to Cancer Treatment", have been completely revised, with chapters added and deleted and a rotation of almost half of the authors in the text to repeatedly bring a fresh perspective to the book.

So, Cancer: Principles & Practice of Oncology is all new and unique and is part of an information package that is extensive and complete. Furthermore, the text will continue to evolve as our field changes so it can continue to be a major instrument forging the declines in national incidence and mortality we are witnessing.

By Vincent T. DeVita Jr., Theodore S. Lawrence, and Steven A. Rosenber

Book Details

Hardcover: 3200 pages
Publisher: Lippincott Williams & Wilkins; Eighth edition (April 22, 2008)
Language: English
ISBN-10: 0781772079
ISBN-13: 978-0781772075
Product Dimensions: 11.7 x 9.3 x 5.7 inches

List Price: $399.00

Newer edition of this book:

DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology 9th edition

Essentials of Apoptosis 2nd Edition: A Guide for Basic & Clinical Research

2010-12-19T06:56:00.000-08:00

Part I Molecules and Pathways of Apoptosis

1 Caspases: Activation, Regulation, and Function
2 The Bcl-2 Family Proteins
3 The Mammalian IAPs: Multifaceted Inhibitors of Apoptosis
4 Structural Biology of Programmed Cell Death
5 The Death Receptor Pathway
6 The Mitochondrial Pathway: Focus on Shape Changes
7 The Endoplasmic Reticulum Pathway
8 Reactive Oxygen Species in Cell Fate Decisions
9 The Integration of Metabolism and Cell Death
10 Transcriptional Regulation of Apoptosis
11 Clearance of Apoptotic Cells – Mechanisms and Consequences
12 Systems Biology Approaches to the Study of Apoptosis

Part II Apoptosis in Model Organisms

13 Programmed Cell Death in Plants: Apoptotic but Not Quite
14 Tracing the Roots of Death: Apoptosis in Saccharomyces cerevisiae
15 Programmed Cell Death in C. elegans
16 Cell Death in Drosophila

Part III Apoptosis in Mammalian Physiology and Pathogenesis

17 Cell Death: Defining and Misshaping Mammalian Embryos
18 Matters of Life and Death in the Immune System
19 Cell Death in the Hematopoietic System
20 Cell Death in Acute Neuronal Injury
21 Apoptosis in Neurodegenerative Diseases
22 Apoptosis in Cardiovascular Pathogenesis
23 Apoptosis in Lung Injury and Disease
24 Apoptosis in Liver Injury and Liver Diseases
25 Apoptosis in Acute Kidney Injury
26 Apoptosis in Cancer Biology and Cancer Therapeutics

Part IV Alternative Cell Death Mechanisms and Pathways

27 Necrosis: Molecular Mechanisms and Physiological Roles
28 Caspase-Independent Mitotic Death
29 Lysosomal Proteases in Cell Death
30 Autophagy and Cell Death

Part V Approaches to the Study of Apoptosis

31 Analysis of Apoptosis: Basic Principles and Protocols

Index

The first edition of Essentials of Apoptosis: A Guide for Basic and Clinical Research by Xiao-Ming Yin was published in 2003. It was intended to provide the basic and essential information of apoptosis for those who were new to the field and who wanted to apply the knowledge to their own research. The book therefore focused on the concepts, the basic molecular architecture, and the pathophysiological significance of apoptosis. Since the first edition, there have been tremendous new developments in the field of apoptosis and cell death in general. The concept of various types of cell death has been further developed. The studies in both basic and clinical disciplines have been greatly expanded. In particular, notable progress has been made in extending the work into the therapeutic arena. As a result, the field has matured considerably and developed extensive cross-talk with works in other fields.

The author strive to incorporate and reflect these new developments in the second edition of this book. This book provide readers with the most updated and advanced knowledge in the field, while maintaining the fundamental information as presented in the first edition. To this end, the book has been significant expanded, not only in the page and chapter numbers but more importantly in the depth of coverage. Most of the chapters have been revised and/or rewritten, and 15 new chapters have been added to give rise to a total of 31 chapters.

In Part I, in addition to the discussion of the major apoptosis molecules, the activation and regulatory pathways, and the clearance of apoptotic cells, also present important issues that examine apoptosis from more integrated points of view. Thus, the roles of reactive oxygen species, metabolism, and transcription control in apoptosis activation and regulation are explored. A new systems biology approach to studying apoptosis is also introduced.
In Part II, discuss apoptosis and cell death in four model systems, including plant, yeast, C. elegans, and Drosophila, which together have contributed greatly to our current understanding of cell death.
In Part III, we focus on mammalian cell death under various pathophysiological situations in all major systems, including the hematopoietic and immune system, the brain, the heart, the liver, the lung, and the kidney. Two integrated chapters discussing cell death in normal development and in cancer biology have also been included.
Furthermore, a separate Part IV has been added to discuss the alternative mechanisms and pathways of cell death.
Finally, Part V discusses the technical aspect of apoptosis research.

This new edition should be valuable for both novice and seasoned investigators as a comprehensive reference as well as a practical guide.

Book Details

Hardcover: 707 pages
Publisher: Humana Press; 2nd edition (June 4, 2009)
Language: English
ISBN-10: 1603273808
ISBN-13: 978-1603273800
Product Dimensions: 9.3 x 6.2 x 1.7 inches
List Price: $149.00

Drug Discovery in Pancreatic Cancer - Models and Techniques (Springer) 2010

2010-12-10T06:26:00.000-08:00

With a median survival of 6 months and a five-year survival rate of less than 5%, pancreatic cancer is the most lethal of all cancer types. This dismal picture of pancreatic cancer is mainly due to the lack of early diagnosis and effective treatment for patients with advanced disease. To increase the survival rate of pancreatic cancer patients, improved tumor markers for diagnosis and new molecular targets for drug development are desperately needed. A lot of effort has been made in searching for genes causative to or associated with the progression of malignant behavior in pancreatic cancer. As a result, alterations in a number of cancer-related genes have been identified in pancreatic tumors. The identification and characterization of these cancer-related genes have significantly increased our understanding of pancreatic cancer tumorigenesis, progression, and metastasis. Unfortunately, the treatment of pancreatic cancer has yet to benefit from these findings as therapy has not advanced much in the past 20 years.
Over the past decade, tremendous advances have been made in the field of cancer drug discovery, particularly in the area of molecular and genetic models and technologies. Many of those advanced models and technologies have been applied to the drug discovery processes for pancreatic cancer. In this book, a team of experts describe the latest development in the application of these models and technologies in pancreatic cancer. The authors include basic scientists as well as clinicians, all who work on the front-line of the war against this disease and have first-hand experience on these cutting-edge tools and techniques. It is our hope that the knowledge presented in this book will provide a strong background for those who want to make an impact in the treatment of patients with this dreadful disease.

Contents
1 Drug Evaluations in Pancreatic Cancer Culture Systems
2 Mouse Xenograft Models for Drug Discovery in Pancreatic Cancer
3 Fluorescent Metastatic Mouse Models of Pancreatic Cancer for Drug Discovery
4 A New Preclinical Paradigm for Pancreas Cancer
5 Zebrafish as a Biological System for Identifying and Validating Therapeutic Targets and Compounds
6 Gene Expression Arrays in Pancreatic Cancer Drug Discovery Research
7 Using Array Comparative Genomic Hybridization of Pancreatic Cancer Samples to Map Interesting Regions for Target Gene Identification
8 The Application of High-Throughput RNAi in Pancreatic Cancer Target Discovery and Drug Development
9 MicroRNA Profiling and Its Application in Drug Discovery in Pancreatic Cancer
10 Methylation Detection and Epigenomics in Pancreatic Cancer
11 Tissue Microarray Applications in Drug Discovery for Pancreatic Cancer
12 Proteomic Analysis of Blood and Pancreatic Juice
13 Applications of Antibody-Lectin Sandwich Arrays (ALSA) to Pancreatic Cancer Diagnostics and Drug Discovery
14 The Development of Pharmacodynamic Endpoint Models for Evaluation of Therapeutics in Pancreatic Cancer
Index

Product Details

Hardcover: 352 pages
Publisher: Springer; 1st edition (March 18, 2010)
Language: English
ISBN-10: 1441911596
ISBN-13: 978-1441911599
Product Dimensions: 9.2 x 6.1 x 0.9 inches

Radiation Oncology: Rationale, Technique, Results 9th Edition

2010-12-09T04:01:00.000-08:00

Radiation Oncology: Rationale, Technique, Results, by James D. Cox, MD and K. Kian Ang, MD, PhD, provides you with authoritative guidance on the latest methods for using radiotherapy to treat patients with cancer. Progressing from fundamental principles through specific treatment strategies for the cancers of each organ system, it also addresses the effects of radiation on normal structures and the avoidance of complications. This 9th edition covers the most recent indications and techniques in the field, including new developments in proton therapy and intensity-modulated radiotherapy (IMRT). It also features, for the first time, full-color images throughout the text to match those that you see in practice, and uses new color-coded treatment plans to make targets, structures, and doses easier to read at a glance. Evidence from randomized clinical trials is included whenever possible to validate clinical recommendations. The state-of-the-art coverage inside this trusted resource equips you to target cancer as effectively as possible while minimizing harm to healthy tissue.

Book Features

Stands apart as the only book in the field to cover the conceptual framework for the use of radiotherapy by describing the most effective techniques for treatment planning and delivery and presenting the results of each type of therapy.
Emphasizes clinical uses of radiation therapy, providing pertinent, easy-to-understand information on state-of-the-art treatments.
Includes information useful for non-radiotherapists, making it "recommended reading" for other oncology specialists.
Offers a practical, uniform chapter structure to expedite reference.

New in this edition

Guides you through the use of the newest radiation oncology techniques, including principles of proton therapy and new developments in intensity-modulated radiotherapy (IMRT).
Incorporates evidence from randomized clinical trials whenever possible to validate clinical recommendations.
Presents full-color images throughout to match the images that you see in practice.
Uses new color-coded treatment plans to make targets, structures, and doses easier to read at a glance.
Extensive use of "combination" imaging presents a complete picture of how to more precisely locate and target the radiotherapy field.

Product Details

Hardcover: 1088 pages
Publisher: Mosby; 9 edition (October 28, 2009)
Language: English
ISBN-10: 0323049710
ISBN-13: 978-0323049719
Product Dimensions: 11.2 x 8.7 x 1.6 inches